EP3546458B1 - ((pyridin-2-yl)-amino)pyrido[3,4-d]pyrimidine and ((pyridazin-3-yl)-amino)pyrido[3,4-d]pyrimidine derivatives as cdk4/6 inhibitors for treating e.g. rheumatoid arthritis, arteriosclerosis, pulmonary fibrosis, cerebral infarction or cancer - Google Patents
((pyridin-2-yl)-amino)pyrido[3,4-d]pyrimidine and ((pyridazin-3-yl)-amino)pyrido[3,4-d]pyrimidine derivatives as cdk4/6 inhibitors for treating e.g. rheumatoid arthritis, arteriosclerosis, pulmonary fibrosis, cerebral infarction or cancer Download PDFInfo
- Publication number
- EP3546458B1 EP3546458B1 EP17874165.8A EP17874165A EP3546458B1 EP 3546458 B1 EP3546458 B1 EP 3546458B1 EP 17874165 A EP17874165 A EP 17874165A EP 3546458 B1 EP3546458 B1 EP 3546458B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- pyrimidin
- amino
- pyrido
- hydroxyethyl
- piperidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 (pyridin-2-yl)-amino Chemical group 0.000 title claims description 90
- 206010039073 rheumatoid arthritis Diseases 0.000 title claims description 12
- 206010008118 cerebral infarction Diseases 0.000 title claims description 9
- 208000026106 cerebrovascular disease Diseases 0.000 title claims description 9
- 208000005069 pulmonary fibrosis Diseases 0.000 title claims description 9
- 208000013557 cerebral hemisphere cancer Diseases 0.000 title claims description 8
- 201000008860 cerebrum cancer Diseases 0.000 title claims description 8
- 159000000016 pyrido[3,4-d]pyrimidines Chemical class 0.000 title claims description 8
- 206010003210 Arteriosclerosis Diseases 0.000 title claims description 7
- 208000011775 arteriosclerosis disease Diseases 0.000 title claims description 7
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 title description 11
- PAQYIEZTLSDLQO-UHFFFAOYSA-N pyrido[3,4-d]pyrimidine Chemical compound N1=CN=C2C=NC=CC2=C1 PAQYIEZTLSDLQO-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 318
- 125000000623 heterocyclic group Chemical group 0.000 claims description 72
- 125000001153 fluoro group Chemical group F* 0.000 claims description 69
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 46
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 44
- 125000003545 alkoxy group Chemical group 0.000 claims description 39
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 39
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims description 34
- 230000002401 inhibitory effect Effects 0.000 claims description 34
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 32
- 150000003839 salts Chemical class 0.000 claims description 31
- 125000001424 substituent group Chemical group 0.000 claims description 31
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 23
- 125000005842 heteroatom Chemical group 0.000 claims description 22
- 101000715943 Caenorhabditis elegans Cyclin-dependent kinase 4 homolog Proteins 0.000 claims description 20
- 125000004432 carbon atom Chemical group C* 0.000 claims description 19
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 18
- 125000002252 acyl group Chemical group 0.000 claims description 17
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 17
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 16
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- 229910052731 fluorine Inorganic materials 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 15
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 13
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 150000002367 halogens Chemical class 0.000 claims description 13
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- 125000006239 protecting group Chemical group 0.000 claims description 11
- 229910052717 sulfur Inorganic materials 0.000 claims description 11
- 125000002947 alkylene group Chemical group 0.000 claims description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 239000011593 sulfur Chemical group 0.000 claims description 10
- 125000005549 heteroarylene group Chemical group 0.000 claims description 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 7
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 125000006585 (C6-C10) arylene group Chemical group 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 5
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 5
- 125000001072 heteroaryl group Chemical group 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 4
- BVAFFPYTTNCAMK-MRXNPFEDSA-N (1R)-1-[2-[[6-(4-methylpiperazin-1-yl)pyridazin-3-yl]amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound C[C@@H](O)c1cc2cnc(Nc3ccc(nn3)N3CCN(C)CC3)nc2c(n1)N1CCCCC1 BVAFFPYTTNCAMK-MRXNPFEDSA-N 0.000 claims description 3
- DYJIUASZLKXDJD-GOSISDBHSA-N (1R)-1-[2-[[6-[4-(2-methylsulfonylethyl)piperazin-1-yl]pyridazin-3-yl]amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound C[C@@H](O)c1cc2cnc(Nc3ccc(nn3)N3CCN(CCS(C)(=O)=O)CC3)nc2c(n1)N1CCCCC1 DYJIUASZLKXDJD-GOSISDBHSA-N 0.000 claims description 3
- MGSQPXVIWSJLCQ-GOSISDBHSA-N (1R)-1-[8-piperidin-1-yl-2-[(6-piperidin-4-ylsulfonyl-7,8-dihydro-5H-1,6-naphthyridin-2-yl)amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound C[C@@H](O)c1cc2cnc(Nc3ccc4CN(CCc4n3)S(=O)(=O)C3CCNCC3)nc2c(n1)N1CCCCC1 MGSQPXVIWSJLCQ-GOSISDBHSA-N 0.000 claims description 3
- NALKAQZGXWYRRJ-VQTJNVASSA-N (2S)-1-[4-[[6-[[6-[(1R)-1-hydroxyethyl]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-yl]amino]pyridin-3-yl]methyl]piperazin-1-yl]propan-2-ol Chemical compound C[C@H](O)CN1CCN(Cc2ccc(Nc3ncc4cc(nc(N5CCCCC5)c4n3)[C@@H](C)O)nc2)CC1 NALKAQZGXWYRRJ-VQTJNVASSA-N 0.000 claims description 3
- 229910018828 PO3H2 Inorganic materials 0.000 claims description 3
- 229910006069 SO3H Inorganic materials 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- UTZRVQXJRVJNMM-OAHLLOKOSA-N (1R)-1-[2-[(6-piperazin-1-ylpyridazin-3-yl)amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound N1(CCNCC1)C1=CC=C(N=N1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1CCCCC1 UTZRVQXJRVJNMM-OAHLLOKOSA-N 0.000 claims description 2
- GXCLWKZUKGNQQQ-UHFFFAOYSA-N 2,2,2-trifluoro-1-[8-morpholin-4-yl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound OC(c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2c(n1)N1CCOCC1)C(F)(F)F GXCLWKZUKGNQQQ-UHFFFAOYSA-N 0.000 claims description 2
- XZYQVSYFZSADDS-MRXNPFEDSA-N 4-[6-[[6-[(1R)-1-hydroxyethyl]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-yl]amino]pyridin-3-yl]-1,4-diazepan-5-one Chemical compound C[C@@H](O)c1cc2cnc(Nc3ccc(cn3)N3CCNCCC3=O)nc2c(n1)N1CCCCC1 XZYQVSYFZSADDS-MRXNPFEDSA-N 0.000 claims description 2
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 claims 6
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 3
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 2
- DZDCGXHNUPXCLJ-QGZVFWFLSA-N (1R)-1-[2-[(6-methyl-5-piperazin-1-ylpyridin-2-yl)amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound CC1=C(C=CC(=N1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1CCCCC1)N1CCNCC1 DZDCGXHNUPXCLJ-QGZVFWFLSA-N 0.000 claims 1
- MBDGOQPDDZTFPY-MRXNPFEDSA-N (1R)-1-[2-[(6-methyl-5-piperazin-1-ylpyridin-2-yl)amino]-8-pyrrolidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound CC1=C(C=CC(=N1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1CCCC1)N1CCNCC1 MBDGOQPDDZTFPY-MRXNPFEDSA-N 0.000 claims 1
- NPKXUGPMYCJILS-QGZVFWFLSA-N (1R)-1-[2-[[5-(piperazin-1-ylmethyl)pyridin-2-yl]amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound N1(CCNCC1)CC=1C=CC(=NC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1CCCCC1 NPKXUGPMYCJILS-QGZVFWFLSA-N 0.000 claims 1
- YKBHIHAPYTVWLD-PIPMEXSNSA-N (1R)-1-[2-[[5-[(3S,4R)-3-fluoro-1-(2-hydroxyethyl)piperidin-4-yl]oxypyridin-2-yl]amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound F[C@H]1CN(CC[C@H]1OC=1C=CC(=NC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1CCCCC1)CCO YKBHIHAPYTVWLD-PIPMEXSNSA-N 0.000 claims 1
- YKBHIHAPYTVWLD-AGHHOFFYSA-N (1R)-1-[2-[[5-[(3S,4S)-3-fluoro-1-(2-hydroxyethyl)piperidin-4-yl]oxypyridin-2-yl]amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound F[C@H]1CN(CC[C@@H]1OC=1C=CC(=NC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1CCCCC1)CCO YKBHIHAPYTVWLD-AGHHOFFYSA-N 0.000 claims 1
- FWAULKJMYDQHGV-LJQANCHMSA-N (1R)-1-[2-[[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound C(C)N1CCN(CC1)CC=1C=CC(=NC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1CCCCC1 FWAULKJMYDQHGV-LJQANCHMSA-N 0.000 claims 1
- XIBFFGLOOOIDJW-GOSISDBHSA-N (1R)-1-[2-[[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-8-(1,4-oxazepan-4-yl)pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound CN1CCN(CC1)CC=1C=CC(=NC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1CCOCCC1 XIBFFGLOOOIDJW-GOSISDBHSA-N 0.000 claims 1
- JMRDRLUGAXZLCL-QZTJIDSGSA-N (1R)-1-[2-[[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-8-[(2R)-2-methylpyrrolidin-1-yl]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound CN1CCN(CC1)CC=1C=CC(=NC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1[C@@H](CCC1)C JMRDRLUGAXZLCL-QZTJIDSGSA-N 0.000 claims 1
- JMRDRLUGAXZLCL-ZWKOTPCHSA-N (1R)-1-[2-[[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-8-[(2S)-2-methylpyrrolidin-1-yl]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound CN1CCN(CC1)CC=1C=CC(=NC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1[C@H](CCC1)C JMRDRLUGAXZLCL-ZWKOTPCHSA-N 0.000 claims 1
- IMMDUHFTTYJEFK-QZTJIDSGSA-N (1R)-1-[2-[[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-8-[(3R)-3-methylpyrrolidin-1-yl]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound CN1CCN(CC1)CC=1C=CC(=NC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1C[C@@H](CC1)C IMMDUHFTTYJEFK-QZTJIDSGSA-N 0.000 claims 1
- IMMDUHFTTYJEFK-ZWKOTPCHSA-N (1R)-1-[2-[[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-8-[(3S)-3-methylpyrrolidin-1-yl]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound CN1CCN(CC1)CC=1C=CC(=NC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1C[C@H](CC1)C IMMDUHFTTYJEFK-ZWKOTPCHSA-N 0.000 claims 1
- HEOYIBPQVBDDNW-QGZVFWFLSA-N (1R)-1-[2-[[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-8-[4-(trifluoromethyl)piperidin-1-yl]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound CN1CCN(CC1)CC=1C=CC(=NC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1CCC(CC1)C(F)(F)F HEOYIBPQVBDDNW-QGZVFWFLSA-N 0.000 claims 1
- ZVAMXHLRZAPMKN-QGZVFWFLSA-N (1R)-1-[2-[[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-8-morpholin-4-ylpyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound CN1CCN(CC1)CC=1C=CC(=NC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1CCOCC1 ZVAMXHLRZAPMKN-QGZVFWFLSA-N 0.000 claims 1
- VRLMYUVJGMHRLD-GOSISDBHSA-N (1R)-1-[2-[[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound CN1CCN(CC1)CC=1C=CC(=NC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1CCCCC1 VRLMYUVJGMHRLD-GOSISDBHSA-N 0.000 claims 1
- LVKGVQSAMRBDCD-QGZVFWFLSA-N (1R)-1-[2-[[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-8-pyrrolidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound CN1CCN(CC1)CC=1C=CC(=NC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1CCCC1 LVKGVQSAMRBDCD-QGZVFWFLSA-N 0.000 claims 1
- HNRMXHSHAYIQMC-LJQANCHMSA-N (1R)-1-[2-[[5-[4-(2-hydroxyethyl)piperazin-1-yl]-6-methylpyridin-2-yl]amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound OCCN1CCN(CC1)C=1C=CC(=NC=1C)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1CCCCC1 HNRMXHSHAYIQMC-LJQANCHMSA-N 0.000 claims 1
- NIKJKOZNZPITPF-RTBURBONSA-N (1R)-1-[2-[[5-[[(2R)-2,4-dimethylpiperazin-1-yl]methyl]pyridin-2-yl]amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound C[C@H]1N(CCN(C1)C)CC=1C=CC(=NC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1CCCCC1 NIKJKOZNZPITPF-RTBURBONSA-N 0.000 claims 1
- NIKJKOZNZPITPF-RBUKOAKNSA-N (1R)-1-[2-[[5-[[(2S)-2,4-dimethylpiperazin-1-yl]methyl]pyridin-2-yl]amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound C[C@@H]1N(CCN(C1)C)CC=1C=CC(=NC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1CCCCC1 NIKJKOZNZPITPF-RBUKOAKNSA-N 0.000 claims 1
- RULATFNDLUXWNU-LJQANCHMSA-N (1R)-1-[2-[[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]pyridin-2-yl]amino]-8-(1,4-oxazepan-4-yl)pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound OCCN1CCN(CC1)CC=1C=CC(=NC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1CCOCCC1 RULATFNDLUXWNU-LJQANCHMSA-N 0.000 claims 1
- VEWOMBPJYRBROW-LJQANCHMSA-N (1R)-1-[2-[[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]pyridin-2-yl]amino]-8-(4-methylpiperazin-1-yl)pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound OCCN1CCN(CC1)CC=1C=CC(=NC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1CCN(CC1)C VEWOMBPJYRBROW-LJQANCHMSA-N 0.000 claims 1
- VHEVGWKEVFSYIG-RTBURBONSA-N (1R)-1-[2-[[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]pyridin-2-yl]amino]-8-[(2R)-2-methylpyrrolidin-1-yl]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound OCCN1CCN(CC1)CC=1C=CC(=NC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1[C@@H](CCC1)C VHEVGWKEVFSYIG-RTBURBONSA-N 0.000 claims 1
- VHEVGWKEVFSYIG-RBUKOAKNSA-N (1R)-1-[2-[[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]pyridin-2-yl]amino]-8-[(2S)-2-methylpyrrolidin-1-yl]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound OCCN1CCN(CC1)CC=1C=CC(=NC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1[C@H](CCC1)C VHEVGWKEVFSYIG-RBUKOAKNSA-N 0.000 claims 1
- DFJIURLUIMBGRR-RTBURBONSA-N (1R)-1-[2-[[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]pyridin-2-yl]amino]-8-[(3R)-3-methylpyrrolidin-1-yl]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound OCCN1CCN(CC1)CC=1C=CC(=NC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1C[C@@H](CC1)C DFJIURLUIMBGRR-RTBURBONSA-N 0.000 claims 1
- DFJIURLUIMBGRR-RBUKOAKNSA-N (1R)-1-[2-[[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]pyridin-2-yl]amino]-8-[(3S)-3-methylpyrrolidin-1-yl]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound OCCN1CCN(CC1)CC=1C=CC(=NC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1C[C@H](CC1)C DFJIURLUIMBGRR-RBUKOAKNSA-N 0.000 claims 1
- ZQINGRQDLQLEKU-GOSISDBHSA-N (1R)-1-[2-[[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]pyridin-2-yl]amino]-8-[4-(trifluoromethyl)piperidin-1-yl]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound OCCN1CCN(CC1)CC=1C=CC(=NC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1CCC(CC1)C(F)(F)F ZQINGRQDLQLEKU-GOSISDBHSA-N 0.000 claims 1
- XIXCAICIRUDBNW-GOSISDBHSA-N (1R)-1-[2-[[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]pyridin-2-yl]amino]-8-morpholin-4-ylpyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound OCCN1CCN(CC1)CC=1C=CC(=NC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1CCOCC1 XIXCAICIRUDBNW-GOSISDBHSA-N 0.000 claims 1
- KYFVFQKMSVYSFJ-LJQANCHMSA-N (1R)-1-[2-[[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]pyridin-2-yl]amino]-8-phenylpyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound OCCN1CCN(CC1)CC=1C=CC(=NC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)C1=CC=CC=C1 KYFVFQKMSVYSFJ-LJQANCHMSA-N 0.000 claims 1
- BFPBMNSRAUDNSP-LJQANCHMSA-N (1R)-1-[2-[[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]pyridin-2-yl]amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound OCCN1CCN(CC1)CC=1C=CC(=NC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1CCCCC1 BFPBMNSRAUDNSP-LJQANCHMSA-N 0.000 claims 1
- MZNICJZIAXPYLZ-HSZRJFAPSA-N (1R)-1-[2-[[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]pyridin-2-yl]amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]propan-1-ol Chemical compound OCCN1CCN(CC1)CC=1C=CC(=NC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](CC)O)N1CCCCC1 MZNICJZIAXPYLZ-HSZRJFAPSA-N 0.000 claims 1
- IPJVWLRWGLQIHJ-GOSISDBHSA-N (1R)-1-[2-[[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]pyridin-2-yl]amino]-8-pyrrolidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound OCCN1CCN(CC1)CC=1C=CC(=NC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1CCCC1 IPJVWLRWGLQIHJ-GOSISDBHSA-N 0.000 claims 1
- FDIKXLXUWHSDMC-QGZVFWFLSA-N (1R)-1-[2-[[5-[[4-(hydroxymethyl)piperidin-1-yl]methyl]pyridin-2-yl]amino]-8-morpholin-4-ylpyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound OCC1CCN(CC1)CC=1C=CC(=NC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1CCOCC1 FDIKXLXUWHSDMC-QGZVFWFLSA-N 0.000 claims 1
- NFIPREIBEBZCGS-GOSISDBHSA-N (1R)-1-[2-[[5-[[4-(hydroxymethyl)piperidin-1-yl]methyl]pyridin-2-yl]amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound OCC1CCN(CC1)CC=1C=CC(=NC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1CCCCC1 NFIPREIBEBZCGS-GOSISDBHSA-N 0.000 claims 1
- HZTFNFPEFBAPBH-QGZVFWFLSA-N (1R)-1-[2-[[5-[[4-(hydroxymethyl)piperidin-1-yl]methyl]pyridin-2-yl]amino]-8-pyrrolidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound OCC1CCN(CC1)CC=1C=CC(=NC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1CCCC1 HZTFNFPEFBAPBH-QGZVFWFLSA-N 0.000 claims 1
- JPMCCVDXOFMIPI-QGZVFWFLSA-N (1R)-1-[2-[[6-(1-methylazetidin-3-yl)-7,8-dihydro-5H-1,6-naphthyridin-2-yl]amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound CN1CC(C1)N1CC=2C=CC(=NC=2CC1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1CCCCC1 JPMCCVDXOFMIPI-QGZVFWFLSA-N 0.000 claims 1
- FUBULJCBLSOIJE-MRXNPFEDSA-N (1R)-1-[2-[[6-(2-aminoethyl)-7,8-dihydro-5H-1,6-naphthyridin-2-yl]amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound NCCN1CC=2C=CC(=NC=2CC1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1CCCCC1 FUBULJCBLSOIJE-MRXNPFEDSA-N 0.000 claims 1
- RXZOAQPCBFKFPW-OAHLLOKOSA-N (1R)-1-[2-[[6-(2-hydroxyethyl)-5,7-dihydropyrrolo[3,4-b]pyridin-2-yl]amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound OCCN1CC2=NC(=CC=C2C1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1CCCCC1 RXZOAQPCBFKFPW-OAHLLOKOSA-N 0.000 claims 1
- LGHLCBCECHKGOQ-HXUWFJFHSA-N (1R)-1-[2-[[6-(2-morpholin-4-ylethyl)-7,8-dihydro-5H-1,6-naphthyridin-2-yl]amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound N1(CCOCC1)CCN1CC=2C=CC(=NC=2CC1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1CCCCC1 LGHLCBCECHKGOQ-HXUWFJFHSA-N 0.000 claims 1
- NDKCMNJHYYRNFF-MRXNPFEDSA-N (1R)-1-[2-[[6-(azetidin-3-yl)-7,8-dihydro-5H-1,6-naphthyridin-2-yl]amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound N1CC(C1)N1CC=2C=CC(=NC=2CC1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1CCCCC1 NDKCMNJHYYRNFF-MRXNPFEDSA-N 0.000 claims 1
- KIUKATWVYLASGI-MRXNPFEDSA-N (1R)-1-[2-[[6-(oxetan-3-yl)-7,8-dihydro-5H-1,6-naphthyridin-2-yl]amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound O1CC(C1)N1CC=2C=CC(=NC=2CC1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1CCCCC1 KIUKATWVYLASGI-MRXNPFEDSA-N 0.000 claims 1
- LVZRBLWQISJGDD-QGZVFWFLSA-N (1R)-1-[2-[[6-(oxetan-3-ylmethyl)-7,8-dihydro-5H-1,6-naphthyridin-2-yl]amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound O1CC(C1)CN1CC=2C=CC(=NC=2CC1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1CCCCC1 LVZRBLWQISJGDD-QGZVFWFLSA-N 0.000 claims 1
- OYXVZBBRUTWJAG-GOSISDBHSA-N (1R)-1-[2-[[6-[1-(2-hydroxyethyl)azetidin-3-yl]-7,8-dihydro-5H-1,6-naphthyridin-2-yl]amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound OCCN1CC(C1)N1CC=2C=CC(=NC=2CC1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1CCCCC1 OYXVZBBRUTWJAG-GOSISDBHSA-N 0.000 claims 1
- FYTOAIFDENPSKD-QGZVFWFLSA-N (1R)-1-[2-[[6-[2-(dimethylamino)ethyl]-7,8-dihydro-5H-1,6-naphthyridin-2-yl]amino]-8-(4-fluoropiperidin-1-yl)pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound CN(CCN1CC=2C=CC(=NC=2CC1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1CCC(CC1)F)C FYTOAIFDENPSKD-QGZVFWFLSA-N 0.000 claims 1
- BAJPRKKZJZZXQM-GOSISDBHSA-N (1R)-1-[2-[[6-[2-(dimethylamino)ethyl]-7,8-dihydro-5H-1,6-naphthyridin-2-yl]amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound CN(CCN1CC=2C=CC(=NC=2CC1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1CCCCC1)C BAJPRKKZJZZXQM-GOSISDBHSA-N 0.000 claims 1
- WUJPUEMOUJWWID-QGZVFWFLSA-N (1R)-1-[2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]pyridazin-3-yl]amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound OCCN1CCN(CC1)C1=CC=C(N=N1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1CCCCC1 WUJPUEMOUJWWID-QGZVFWFLSA-N 0.000 claims 1
- NBLSOUSUCAKPHY-GOSISDBHSA-N (1R)-1-[2-[[6-methyl-5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound CC1=C(C=CC(=N1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1CCCCC1)N1CCN(CC1)C NBLSOUSUCAKPHY-GOSISDBHSA-N 0.000 claims 1
- IBDTVXOPNQDVOR-QGZVFWFLSA-N (1R)-1-[2-[[6-methyl-5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]-8-pyrrolidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound CC1=C(C=CC(=N1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1CCCC1)N1CCN(CC1)C IBDTVXOPNQDVOR-QGZVFWFLSA-N 0.000 claims 1
- HROCRHDTEOBHSK-GOSISDBHSA-N (1R)-1-[8-(1,1-dioxo-1,4-thiazinan-4-yl)-2-[[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound O=S1(CCN(CC1)C1=NC(=CC2=C1N=C(N=C2)NC1=NC=C(C=C1)CN1CCN(CC1)CCO)[C@@H](C)O)=O HROCRHDTEOBHSK-GOSISDBHSA-N 0.000 claims 1
- OMDLVCALXFROJK-GOSISDBHSA-N (1R)-1-[8-(2,2-dimethylpyrrolidin-1-yl)-2-[[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound CC1(N(CCC1)C1=NC(=CC2=C1N=C(N=C2)NC1=NC=C(C=C1)CN1CCN(CC1)C)[C@@H](C)O)C OMDLVCALXFROJK-GOSISDBHSA-N 0.000 claims 1
- WKVDPDJHXRLQIH-LJQANCHMSA-N (1R)-1-[8-(2,2-dimethylpyrrolidin-1-yl)-2-[[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound CC1(N(CCC1)C1=NC(=CC2=C1N=C(N=C2)NC1=NC=C(C=C1)CN1CCN(CC1)CCO)[C@@H](C)O)C WKVDPDJHXRLQIH-LJQANCHMSA-N 0.000 claims 1
- PNHNANGMSAPSGC-CTWPCTMYSA-N (1R)-1-[8-(2,5-dimethylpyrrolidin-1-yl)-2-[[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound CC1N(C(CC1)C)C1=NC(=CC2=C1N=C(N=C2)NC1=NC=C(C=C1)CN1CCN(CC1)C)[C@@H](C)O PNHNANGMSAPSGC-CTWPCTMYSA-N 0.000 claims 1
- BOPIJOJEUKOBLH-SOAGJPPSSA-N (1R)-1-[8-(2,5-dimethylpyrrolidin-1-yl)-2-[[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound CC1N(C(CC1)C)C1=NC(=CC2=C1N=C(N=C2)NC1=NC=C(C=C1)CN1CCN(CC1)CCO)[C@@H](C)O BOPIJOJEUKOBLH-SOAGJPPSSA-N 0.000 claims 1
- GDEHLABZWGFQRV-LJQANCHMSA-N (1R)-1-[8-(2-azaspiro[3.3]heptan-2-yl)-2-[[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound C1N(CC11CCC1)C1=NC(=CC2=C1N=C(N=C2)NC1=NC=C(C=C1)CN1CCN(CC1)CCO)[C@@H](C)O GDEHLABZWGFQRV-LJQANCHMSA-N 0.000 claims 1
- IEOIRYZVJWLWDG-OAHLLOKOSA-N (1R)-1-[8-(3,3-difluoroazetidin-1-yl)-2-[[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound FC1(CN(C1)C1=NC(=CC2=C1N=C(N=C2)NC1=NC=C(C=C1)CN1CCN(CC1)C)[C@@H](C)O)F IEOIRYZVJWLWDG-OAHLLOKOSA-N 0.000 claims 1
- DSBJYZVKIHTQQJ-GOSISDBHSA-N (1R)-1-[8-(3,3-dimethylpyrrolidin-1-yl)-2-[[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound CC1(CN(CC1)C1=NC(=CC2=C1N=C(N=C2)NC1=NC=C(C=C1)CN1CCN(CC1)C)[C@@H](C)O)C DSBJYZVKIHTQQJ-GOSISDBHSA-N 0.000 claims 1
- XOSYWZQBBLOJNG-LJQANCHMSA-N (1R)-1-[8-(3,3-dimethylpyrrolidin-1-yl)-2-[[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound CC1(CN(CC1)C1=NC(=CC2=C1N=C(N=C2)NC1=NC=C(C=C1)CN1CCN(CC1)CCO)[C@@H](C)O)C XOSYWZQBBLOJNG-LJQANCHMSA-N 0.000 claims 1
- VHXIXDAHLGCERH-SOAGJPPSSA-N (1R)-1-[8-(3,4-dimethylpyrrolidin-1-yl)-2-[[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound CC1CN(CC1C)C1=NC(=CC2=C1N=C(N=C2)NC1=NC=C(C=C1)CN1CCN(CC1)CCO)[C@@H](C)O VHXIXDAHLGCERH-SOAGJPPSSA-N 0.000 claims 1
- IPAIZGQEXSGGGR-PBPGXSGUSA-N (1R)-1-[8-(3-azabicyclo[3.1.0]hexan-3-yl)-2-[[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound C12CN(CC2C1)C1=NC(=CC2=C1N=C(N=C2)NC1=NC=C(C=C1)CN1CCN(CC1)C)[C@@H](C)O IPAIZGQEXSGGGR-PBPGXSGUSA-N 0.000 claims 1
- AUWUDYBCQBQSQH-MDMXATFFSA-N (1R)-1-[8-(3-azabicyclo[3.1.0]hexan-3-yl)-2-[[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound C12CN(CC2C1)C1=NC(=CC2=C1N=C(N=C2)NC1=NC=C(C=C1)CN1CCN(CC1)CCO)[C@@H](C)O AUWUDYBCQBQSQH-MDMXATFFSA-N 0.000 claims 1
- XWFDKBJGRMTHLH-CYBMUJFWSA-N (1R)-1-[8-(4,4-difluoropiperidin-1-yl)-2-(5,6,7,8-tetrahydro-1,6-naphthyridin-2-ylamino)pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound FC1(CCN(CC1)C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCNCC=2C=C1)[C@@H](C)O)F XWFDKBJGRMTHLH-CYBMUJFWSA-N 0.000 claims 1
- JOVRFZYCUZTRPT-QGZVFWFLSA-N (1R)-1-[8-(4,4-difluoropiperidin-1-yl)-2-[[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound FC1(CCN(CC1)C1=NC(=CC2=C1N=C(N=C2)NC1=NC=C(C=C1)CN1CCN(CC1)C)[C@@H](C)O)F JOVRFZYCUZTRPT-QGZVFWFLSA-N 0.000 claims 1
- UTTRECIMDLXUFT-GOSISDBHSA-N (1R)-1-[8-(4,4-difluoropiperidin-1-yl)-2-[[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound FC1(CCN(CC1)C1=NC(=CC2=C1N=C(N=C2)NC1=NC=C(C=C1)CN1CCN(CC1)CCO)[C@@H](C)O)F UTTRECIMDLXUFT-GOSISDBHSA-N 0.000 claims 1
- SHTDNMQHZOBBTH-OAHLLOKOSA-N (1R)-1-[8-(4,4-difluoropiperidin-1-yl)-2-[[6-(2-hydroxyethyl)-7,8-dihydro-5H-1,6-naphthyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound FC1(CCN(CC1)C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)CCO)[C@@H](C)O)F SHTDNMQHZOBBTH-OAHLLOKOSA-N 0.000 claims 1
- BOEZMSJIAJPXAQ-QGZVFWFLSA-N (1R)-1-[8-(4,4-difluoropiperidin-1-yl)-2-[[6-[2-(dimethylamino)ethyl]-7,8-dihydro-5H-1,6-naphthyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound FC1(CCN(CC1)C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)CCN(C)C)[C@@H](C)O)F BOEZMSJIAJPXAQ-QGZVFWFLSA-N 0.000 claims 1
- RWHATQFAKMFTKF-CYBMUJFWSA-N (1R)-1-[8-(4-fluoropiperidin-1-yl)-2-(5,6,7,8-tetrahydro-1,6-naphthyridin-2-ylamino)pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound FC1CCN(CC1)C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCNCC=2C=C1)[C@@H](C)O RWHATQFAKMFTKF-CYBMUJFWSA-N 0.000 claims 1
- YYUMBRIFBJAVMC-GOSISDBHSA-N (1R)-1-[8-(4-fluoropiperidin-1-yl)-2-[[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound FC1CCN(CC1)C1=NC(=CC2=C1N=C(N=C2)NC1=NC=C(C=C1)CN1CCN(CC1)CCO)[C@@H](C)O YYUMBRIFBJAVMC-GOSISDBHSA-N 0.000 claims 1
- BEVNNGCJQGXUPD-OAHLLOKOSA-N (1R)-1-[8-(4-fluoropiperidin-1-yl)-2-[[6-(2-hydroxyethyl)-7,8-dihydro-5H-1,6-naphthyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound FC1CCN(CC1)C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)CCO)[C@@H](C)O BEVNNGCJQGXUPD-OAHLLOKOSA-N 0.000 claims 1
- DJWNNMKFIHUYOM-OAHLLOKOSA-N (1R)-1-[8-(4-fluoropiperidin-1-yl)-2-[[6-(4-methylpiperazin-1-yl)pyridazin-3-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound FC1CCN(CC1)C1=NC(=CC2=C1N=C(N=C2)NC=1N=NC(=CC=1)N1CCN(CC1)C)[C@@H](C)O DJWNNMKFIHUYOM-OAHLLOKOSA-N 0.000 claims 1
- DPCBBWDASGDWOQ-MDMXATFFSA-N (1R)-1-[8-(7-azabicyclo[2.2.1]heptan-7-yl)-2-[[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=C(C=C1)CN1CCN(CC1)C)[C@@H](C)O DPCBBWDASGDWOQ-MDMXATFFSA-N 0.000 claims 1
- ISTJXQXDGGWGIZ-KMFTYDHNSA-N (1R)-1-[8-(7-azabicyclo[2.2.1]heptan-7-yl)-2-[[5-[4-(2-hydroxyethyl)piperazin-1-yl]-6-methylpyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC(=C(C=C1)N1CCN(CC1)CCO)C)[C@@H](C)O ISTJXQXDGGWGIZ-KMFTYDHNSA-N 0.000 claims 1
- AJQMDGAAEXCJHI-PDYGVTHMSA-N (1R)-1-[8-(7-azabicyclo[2.2.1]heptan-7-yl)-2-[[5-[[(2S)-2,4-dimethylpiperazin-1-yl]methyl]pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=C(C=C1)CN1[C@H](CN(CC1)C)C)[C@@H](C)O AJQMDGAAEXCJHI-PDYGVTHMSA-N 0.000 claims 1
- PDHPFVYZRAJRAP-OSFYOIPJSA-N (1R)-1-[8-(7-azabicyclo[2.2.1]heptan-7-yl)-2-[[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=C(C=C1)CN1CCN(CC1)CCO)[C@@H](C)O PDHPFVYZRAJRAP-OSFYOIPJSA-N 0.000 claims 1
- FMWYNIXPPIRKPV-IPJUCJBFSA-N (1R)-1-[8-(7-azabicyclo[2.2.1]heptan-7-yl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]pyridazin-3-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC=1N=NC(=CC=1)N1CCN(CC1)CCO)[C@@H](C)O FMWYNIXPPIRKPV-IPJUCJBFSA-N 0.000 claims 1
- ORQXQNSSQRJLBW-QHGAOEGBSA-N (1R)-1-[8-(7-azabicyclo[2.2.1]heptan-7-yl)-2-[[6-methyl-5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC(=C(C=C1)N1CCN(CC1)C)C)[C@@H](C)O ORQXQNSSQRJLBW-QHGAOEGBSA-N 0.000 claims 1
- SHMOSVCWZLMMKI-OSFYOIPJSA-N (1R)-1-[8-(8-azabicyclo[3.2.1]octan-8-yl)-2-[[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound C12CCCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=C(C=C1)CN1CCN(CC1)C)[C@@H](C)O SHMOSVCWZLMMKI-OSFYOIPJSA-N 0.000 claims 1
- KYCQTNWMRIFWJX-YUVSOPLDSA-N (1R)-1-[8-(8-azabicyclo[3.2.1]octan-8-yl)-2-[[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound C12CCCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=C(C=C1)CN1CCN(CC1)CCO)[C@@H](C)O KYCQTNWMRIFWJX-YUVSOPLDSA-N 0.000 claims 1
- NESOHQJIEADIOJ-LJQANCHMSA-N (1R)-1-[8-(azepan-1-yl)-2-[[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound N1(CCCCCC1)C1=NC(=CC2=C1N=C(N=C2)NC1=NC=C(C=C1)CN1CCN(CC1)C)[C@@H](C)O NESOHQJIEADIOJ-LJQANCHMSA-N 0.000 claims 1
- CPDCGVNUKMXTTQ-HXUWFJFHSA-N (1R)-1-[8-(azepan-1-yl)-2-[[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound N1(CCCCCC1)C1=NC(=CC2=C1N=C(N=C2)NC1=NC=C(C=C1)CN1CCN(CC1)CCO)[C@@H](C)O CPDCGVNUKMXTTQ-HXUWFJFHSA-N 0.000 claims 1
- IEVGLDJJNOXZNZ-MRXNPFEDSA-N (1R)-1-[8-(azetidin-1-yl)-2-[[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound N1(CCC1)C1=NC(=CC2=C1N=C(N=C2)NC1=NC=C(C=C1)CN1CCN(CC1)C)[C@@H](C)O IEVGLDJJNOXZNZ-MRXNPFEDSA-N 0.000 claims 1
- YYJQUFBKTOYYEY-QGZVFWFLSA-N (1R)-1-[8-(azetidin-1-yl)-2-[[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound N1(CCC1)C1=NC(=CC2=C1N=C(N=C2)NC1=NC=C(C=C1)CN1CCN(CC1)CCO)[C@@H](C)O YYJQUFBKTOYYEY-QGZVFWFLSA-N 0.000 claims 1
- HMEBYNLAJWEYJX-LJQANCHMSA-N (1R)-1-[8-(cyclohexen-1-yl)-2-[[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound C1(=CCCCC1)C1=NC(=CC2=C1N=C(N=C2)NC1=NC=C(C=C1)CN1CCN(CC1)CCO)[C@@H](C)O HMEBYNLAJWEYJX-LJQANCHMSA-N 0.000 claims 1
- BCUIITGNDHJXBO-YLJYHZDGSA-N (1R)-1-[8-[(3R)-3-fluoropiperidin-1-yl]-2-[[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound F[C@H]1CN(CCC1)C1=NC(=CC2=C1N=C(N=C2)NC1=NC=C(C=C1)CN1CCN(CC1)C)[C@@H](C)O BCUIITGNDHJXBO-YLJYHZDGSA-N 0.000 claims 1
- NWJDJEQNLAUDGG-WIYYLYMNSA-N (1R)-1-[8-[(3R)-3-fluoropiperidin-1-yl]-2-[[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound F[C@H]1CN(CCC1)C1=NC(=CC2=C1N=C(N=C2)NC1=NC=C(C=C1)CN1CCN(CC1)CCO)[C@@H](C)O NWJDJEQNLAUDGG-WIYYLYMNSA-N 0.000 claims 1
- DHIIIMVLEJVDSR-VQIMIIECSA-N (1R)-1-[8-[(3R)-3-fluoropyrrolidin-1-yl]-2-[[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound F[C@H]1CN(CC1)C1=NC(=CC2=C1N=C(N=C2)NC1=NC=C(C=C1)CN1CCN(CC1)C)[C@@H](C)O DHIIIMVLEJVDSR-VQIMIIECSA-N 0.000 claims 1
- ATACZPWNHCGEPO-YLJYHZDGSA-N (1R)-1-[8-[(3R)-3-fluoropyrrolidin-1-yl]-2-[[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound F[C@H]1CN(CC1)C1=NC(=CC2=C1N=C(N=C2)NC1=NC=C(C=C1)CN1CCN(CC1)CCO)[C@@H](C)O ATACZPWNHCGEPO-YLJYHZDGSA-N 0.000 claims 1
- BCUIITGNDHJXBO-XLIONFOSSA-N (1R)-1-[8-[(3S)-3-fluoropiperidin-1-yl]-2-[[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound F[C@@H]1CN(CCC1)C1=NC(=CC2=C1N=C(N=C2)NC1=NC=C(C=C1)CN1CCN(CC1)C)[C@@H](C)O BCUIITGNDHJXBO-XLIONFOSSA-N 0.000 claims 1
- NWJDJEQNLAUDGG-NQIIRXRSSA-N (1R)-1-[8-[(3S)-3-fluoropiperidin-1-yl]-2-[[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound F[C@@H]1CN(CCC1)C1=NC(=CC2=C1N=C(N=C2)NC1=NC=C(C=C1)CN1CCN(CC1)CCO)[C@@H](C)O NWJDJEQNLAUDGG-NQIIRXRSSA-N 0.000 claims 1
- DHIIIMVLEJVDSR-APWZRJJASA-N (1R)-1-[8-[(3S)-3-fluoropyrrolidin-1-yl]-2-[[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound F[C@@H]1CN(CC1)C1=NC(=CC2=C1N=C(N=C2)NC1=NC=C(C=C1)CN1CCN(CC1)C)[C@@H](C)O DHIIIMVLEJVDSR-APWZRJJASA-N 0.000 claims 1
- ATACZPWNHCGEPO-XLIONFOSSA-N (1R)-1-[8-[(3S)-3-fluoropyrrolidin-1-yl]-2-[[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound F[C@@H]1CN(CC1)C1=NC(=CC2=C1N=C(N=C2)NC1=NC=C(C=C1)CN1CCN(CC1)CCO)[C@@H](C)O ATACZPWNHCGEPO-XLIONFOSSA-N 0.000 claims 1
- YRLGYSVOQLJDCC-MRXNPFEDSA-N (1R)-1-[8-cyclopropyl-2-[[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound C1(CC1)C1=NC(=CC2=C1N=C(N=C2)NC1=NC=C(C=C1)CN1CCN(CC1)CCO)[C@@H](C)O YRLGYSVOQLJDCC-MRXNPFEDSA-N 0.000 claims 1
- BFBKKBBJYDKTAC-CQSZACIVSA-N (1R)-1-[8-piperidin-1-yl-2-(5,6,7,8-tetrahydro-1,6-naphthyridin-2-ylamino)pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound N1(CCCCC1)C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCNCC=2C=C1)[C@@H](C)O BFBKKBBJYDKTAC-CQSZACIVSA-N 0.000 claims 1
- LLRZZARBRLHWIZ-MRXNPFEDSA-N (1R)-1-[8-piperidin-1-yl-2-[(5-piperidin-4-yloxypyridin-2-yl)amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound N1(CCCCC1)C1=NC(=CC2=C1N=C(N=C2)NC1=NC=C(C=C1)OC1CCNCC1)[C@@H](C)O LLRZZARBRLHWIZ-MRXNPFEDSA-N 0.000 claims 1
- MZNICJZIAXPYLZ-QHCPKHFHSA-N (1S)-1-[2-[[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]pyridin-2-yl]amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]propan-1-ol Chemical compound OCCN1CCN(CC1)CC=1C=CC(=NC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@H](CC)O)N1CCCCC1 MZNICJZIAXPYLZ-QHCPKHFHSA-N 0.000 claims 1
- CZKOKNLMOCMUAJ-HXUWFJFHSA-N (2R)-1-[2-[[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]pyridin-2-yl]amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]propan-2-ol Chemical compound OCCN1CCN(CC1)CC=1C=CC(=NC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)C[C@@H](C)O)N1CCCCC1 CZKOKNLMOCMUAJ-HXUWFJFHSA-N 0.000 claims 1
- NALKAQZGXWYRRJ-WOJBJXKFSA-N (2R)-1-[4-[[6-[[6-[(1R)-1-hydroxyethyl]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-yl]amino]pyridin-3-yl]methyl]piperazin-1-yl]propan-2-ol Chemical compound O[C@H](C)C1=CC2=C(N=C(N=C2)NC2=CC=C(C=N2)CN2CCN(CC2)C[C@@H](C)O)C(=N1)N1CCCCC1 NALKAQZGXWYRRJ-WOJBJXKFSA-N 0.000 claims 1
- MCYKVXLMSISDEP-FQEVSTJZSA-N (2R)-2-[2-[[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]pyridin-2-yl]amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]propan-1-ol Chemical compound OCCN1CCN(CC1)CC=1C=CC(=NC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@H](CO)C)N1CCCCC1 MCYKVXLMSISDEP-FQEVSTJZSA-N 0.000 claims 1
- BGPXZTOYTCYHMT-KRWDZBQOSA-N (2R)-2-[2-[[6-(2-hydroxyethyl)-7,8-dihydro-5H-1,6-naphthyridin-2-yl]amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]propan-1-ol Chemical compound OCCN1CC=2C=CC(=NC=2CC1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@H](CO)C)N1CCCCC1 BGPXZTOYTCYHMT-KRWDZBQOSA-N 0.000 claims 1
- CZKOKNLMOCMUAJ-FQEVSTJZSA-N (2S)-1-[2-[[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]pyridin-2-yl]amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]propan-2-ol Chemical compound OCCN1CCN(CC1)CC=1C=CC(=NC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)C[C@H](C)O)N1CCCCC1 CZKOKNLMOCMUAJ-FQEVSTJZSA-N 0.000 claims 1
- NMHHNUZVRPNOMR-KRWDZBQOSA-N (2S)-1-[2-[[6-(2-hydroxyethyl)-7,8-dihydro-5H-1,6-naphthyridin-2-yl]amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]propan-2-ol Chemical compound OCCN1CC=2C=CC(=NC=2CC1)NC=1N=CC2=C(N=1)C(=NC(=C2)C[C@H](C)O)N1CCCCC1 NMHHNUZVRPNOMR-KRWDZBQOSA-N 0.000 claims 1
- MCYKVXLMSISDEP-HXUWFJFHSA-N (2S)-2-[2-[[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]pyridin-2-yl]amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]propan-1-ol Chemical compound OCCN1CCN(CC1)CC=1C=CC(=NC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](CO)C)N1CCCCC1 MCYKVXLMSISDEP-HXUWFJFHSA-N 0.000 claims 1
- BGPXZTOYTCYHMT-QGZVFWFLSA-N (2S)-2-[2-[[6-(2-hydroxyethyl)-7,8-dihydro-5H-1,6-naphthyridin-2-yl]amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]propan-1-ol Chemical compound OCCN1CC=2C=CC(=NC=2CC1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](CO)C)N1CCCCC1 BGPXZTOYTCYHMT-QGZVFWFLSA-N 0.000 claims 1
- OIPDZMNOGOINFN-GOSISDBHSA-N 1-(2-hydroxyethyl)-4-[6-[[6-[(1R)-1-hydroxyethyl]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-yl]amino]pyridin-3-yl]-1,4-diazepan-5-one Chemical compound OCCN1CCN(C(CC1)=O)C=1C=NC(=CC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1CCCCC1 OIPDZMNOGOINFN-GOSISDBHSA-N 0.000 claims 1
- GBQHVDKDHISZSC-UHFFFAOYSA-N 1-[2-[(5-piperazin-1-ylpyridin-2-yl)amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]ethanone Chemical compound N1(CCNCC1)C=1C=CC(=NC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)C(C)=O)N1CCCCC1 GBQHVDKDHISZSC-UHFFFAOYSA-N 0.000 claims 1
- RSUPYOLFKGWNJT-UHFFFAOYSA-N 1-[2-[[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]propan-1-ol Chemical compound CN1CCN(CC1)CC=1C=CC(=NC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)C(CC)O)N1CCCCC1 RSUPYOLFKGWNJT-UHFFFAOYSA-N 0.000 claims 1
- IPZBEZAHOHQZDE-UHFFFAOYSA-N 1-[2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-2-(3-fluoroazetidin-1-yl)ethanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(CN1CC(C1)F)=O)C1COC1 IPZBEZAHOHQZDE-UHFFFAOYSA-N 0.000 claims 1
- JJHTYOKXYBROCI-UHFFFAOYSA-N 1-[2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-2-(3-fluoropiperidin-1-yl)ethanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(CN1CC(CCC1)F)=O)C1COC1 JJHTYOKXYBROCI-UHFFFAOYSA-N 0.000 claims 1
- QOWRAGQHWGHENY-UHFFFAOYSA-N 1-[2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-2-(3-fluoropyrrolidin-1-yl)ethanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(CN1CC(CC1)F)=O)C1COC1 QOWRAGQHWGHENY-UHFFFAOYSA-N 0.000 claims 1
- YAZKPAGRDHTYPU-UHFFFAOYSA-N 1-[2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-2-(3-hydroxyazetidin-1-yl)ethanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(CN1CC(C1)O)=O)C1COC1 YAZKPAGRDHTYPU-UHFFFAOYSA-N 0.000 claims 1
- IBPYPRFTTDARHI-UHFFFAOYSA-N 1-[2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-2-(3-hydroxypiperidin-1-yl)ethanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(CN1CC(CCC1)O)=O)C1COC1 IBPYPRFTTDARHI-UHFFFAOYSA-N 0.000 claims 1
- RHAZYKQMKNQUIN-UHFFFAOYSA-N 1-[2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-2-(3-hydroxypyrrolidin-1-yl)ethanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(CN1CC(CC1)O)=O)C1COC1 RHAZYKQMKNQUIN-UHFFFAOYSA-N 0.000 claims 1
- WTQUPHJCTGYISA-UHFFFAOYSA-N 1-[2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-2-(4-fluoropiperidin-1-yl)ethanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(CN1CCC(CC1)F)=O)C1COC1 WTQUPHJCTGYISA-UHFFFAOYSA-N 0.000 claims 1
- AGZAVWKBPBTQQM-UHFFFAOYSA-N 1-[2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-2-(4-hydroxypiperidin-1-yl)ethanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(CN1CCC(CC1)O)=O)C1COC1 AGZAVWKBPBTQQM-UHFFFAOYSA-N 0.000 claims 1
- YYKXZNZWOMPMDT-UHFFFAOYSA-N 1-[2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-2-(azetidin-1-yl)ethanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(CN1CCC1)=O)C1COC1 YYKXZNZWOMPMDT-UHFFFAOYSA-N 0.000 claims 1
- MNUBWKVBVLIHKL-UHFFFAOYSA-N 1-[2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-2-piperidin-1-ylethanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(CN1CCCCC1)=O)C1COC1 MNUBWKVBVLIHKL-UHFFFAOYSA-N 0.000 claims 1
- ZBXWJDPVVBKSQR-UHFFFAOYSA-N 1-[2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-2-pyrrolidin-1-ylethanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(CN1CCCC1)=O)C1COC1 ZBXWJDPVVBKSQR-UHFFFAOYSA-N 0.000 claims 1
- UPHBZHKQWRKNHE-YMTQGWHGSA-N 1-[2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-2-(3-fluoroazetidin-1-yl)ethanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(CN1CC(C1)F)=O)[C@@H](C)O UPHBZHKQWRKNHE-YMTQGWHGSA-N 0.000 claims 1
- MEAKSPMMOCFUQP-NRKTVSCNSA-N 1-[2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-2-(3-fluoropiperidin-1-yl)ethanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(CN1CC(CCC1)F)=O)[C@@H](C)O MEAKSPMMOCFUQP-NRKTVSCNSA-N 0.000 claims 1
- CHDHOVXBPVYEJM-LAQKFSSHSA-N 1-[2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-2-(3-fluoropyrrolidin-1-yl)ethanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(CN1CC(CC1)F)=O)[C@@H](C)O CHDHOVXBPVYEJM-LAQKFSSHSA-N 0.000 claims 1
- SWMFWHNECGLINL-PBPGXSGUSA-N 1-[2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-2-(3-hydroxyazetidin-1-yl)ethanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(CN1CC(C1)O)=O)[C@@H](C)O SWMFWHNECGLINL-PBPGXSGUSA-N 0.000 claims 1
- VJMYMQYBQCQSEI-NRKTVSCNSA-N 1-[2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-2-(3-hydroxypiperidin-1-yl)ethanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(CN1CC(CCC1)O)=O)[C@@H](C)O VJMYMQYBQCQSEI-NRKTVSCNSA-N 0.000 claims 1
- DQKUZXPHQVVLEW-LAQKFSSHSA-N 1-[2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-2-(3-hydroxypyrrolidin-1-yl)ethanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(CN1CC(CC1)O)=O)[C@@H](C)O DQKUZXPHQVVLEW-LAQKFSSHSA-N 0.000 claims 1
- KBVFLFSGKXFSKS-WDGBRCNXSA-N 1-[2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-2-(4-fluoropiperidin-1-yl)ethanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(CN1CCC(CC1)F)=O)[C@@H](C)O KBVFLFSGKXFSKS-WDGBRCNXSA-N 0.000 claims 1
- CERQNNIYKHVLLD-OSFYOIPJSA-N 1-[2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-2-(4-hydroxypiperidin-1-yl)ethanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(CN1CCC(CC1)O)=O)[C@@H](C)O CERQNNIYKHVLLD-OSFYOIPJSA-N 0.000 claims 1
- KCRJERIRLGHWHM-MDMXATFFSA-N 1-[2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-2-(azetidin-1-yl)ethanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(CN1CCC1)=O)[C@@H](C)O KCRJERIRLGHWHM-MDMXATFFSA-N 0.000 claims 1
- VPSCQTCRHIZUTP-YUVSOPLDSA-N 1-[2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-2-piperidin-1-ylethanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(CN1CCCCC1)=O)[C@@H](C)O VPSCQTCRHIZUTP-YUVSOPLDSA-N 0.000 claims 1
- PAILDYXDWAVGQK-OSFYOIPJSA-N 1-[2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-2-pyrrolidin-1-ylethanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(CN1CCCC1)=O)[C@@H](C)O PAILDYXDWAVGQK-OSFYOIPJSA-N 0.000 claims 1
- XIEDHTLCDNLPNA-UHFFFAOYSA-N 1-[6-(difluoromethyl)-2-[[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-8-yl]piperidin-4-ol Chemical compound FC(C1=CC2=C(N=C(N=C2)NC2=NC=C(C=C2)CN2CCN(CC2)CCO)C(=N1)N1CCC(CC1)O)F XIEDHTLCDNLPNA-UHFFFAOYSA-N 0.000 claims 1
- WJRXVMLOCWJZSL-UHFFFAOYSA-N 1-[6-(hydroxymethyl)-2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-8-yl]piperidin-2-one Chemical compound OCC1=CC2=C(N=C(N=C2)NC2=NC=C(C=C2)N2CCN(CC2)C)C(=N1)N1C(CCCC1)=O WJRXVMLOCWJZSL-UHFFFAOYSA-N 0.000 claims 1
- DQVWSRGCGVTQAG-XPCCGILXSA-N 1-[6-[(1R)-1-hydroxyethyl]-2-[(6-piperazin-1-ylpyridazin-3-yl)amino]pyrido[3,4-d]pyrimidin-8-yl]piperidine-2-carboxylic acid Chemical compound O[C@H](C)C1=CC2=C(N=C(N=C2)NC=2N=NC(=CC=2)N2CCNCC2)C(=N1)N1C(CCCC1)C(=O)O DQVWSRGCGVTQAG-XPCCGILXSA-N 0.000 claims 1
- PQQGJXHPTQNTJC-GICMACPYSA-N 1-[6-[(1R)-1-hydroxyethyl]-2-[(6-piperazin-1-ylpyridazin-3-yl)amino]pyrido[3,4-d]pyrimidin-8-yl]piperidine-3-carboxylic acid Chemical compound O[C@H](C)C1=CC2=C(N=C(N=C2)NC=2N=NC(=CC=2)N2CCNCC2)C(=N1)N1CC(CCC1)C(=O)O PQQGJXHPTQNTJC-GICMACPYSA-N 0.000 claims 1
- IMDSFMMHXCINFU-JBZHPUCOSA-N 1-[6-[(1R)-1-hydroxyethyl]-2-[(6-piperazin-1-ylpyridazin-3-yl)amino]pyrido[3,4-d]pyrimidin-8-yl]pyrrolidine-2-carboxylic acid Chemical compound O[C@H](C)C1=CC2=C(N=C(N=C2)NC=2N=NC(=CC=2)N2CCNCC2)C(=N1)N1C(CCC1)C(=O)O IMDSFMMHXCINFU-JBZHPUCOSA-N 0.000 claims 1
- UWAUVVDGAKLQBE-NYRJJRHWSA-N 1-[6-[(1R)-1-hydroxyethyl]-2-[[5-(piperazin-1-ylmethyl)pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-8-yl]pyrrolidine-2-carboxylic acid Chemical compound O[C@H](C)C1=CC2=C(N=C(N=C2)NC2=NC=C(C=C2)CN2CCNCC2)C(=N1)N1C(CCC1)C(=O)O UWAUVVDGAKLQBE-NYRJJRHWSA-N 0.000 claims 1
- IIDQDLWFDOCWBA-QGZVFWFLSA-N 1-[6-[(1R)-1-hydroxyethyl]-2-[[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-8-yl]piperidin-4-ol Chemical compound O[C@H](C)C1=CC2=C(N=C(N=C2)NC2=NC=C(C=C2)CN2CCN(CC2)C)C(=N1)N1CCC(CC1)O IIDQDLWFDOCWBA-QGZVFWFLSA-N 0.000 claims 1
- CVCLKWBRRIGVPF-GOSISDBHSA-N 1-[6-[(1R)-1-hydroxyethyl]-2-[[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-8-yl]piperidin-4-ol Chemical compound O[C@H](C)C1=CC2=C(N=C(N=C2)NC2=NC=C(C=C2)CN2CCN(CC2)CCO)C(=N1)N1CCC(CC1)O CVCLKWBRRIGVPF-GOSISDBHSA-N 0.000 claims 1
- UXUWNTQRBXXAPA-GOSISDBHSA-N 1-[6-[(1R)-1-hydroxyethyl]-2-[[5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-8-yl]piperidine-4-carboxylic acid Chemical compound O[C@H](C)C1=CC2=C(N=C(N=C2)NC2=NC=C(C=C2)CN2CCN(CC2)CCO)C(=N1)N1CCC(CC1)C(=O)O UXUWNTQRBXXAPA-GOSISDBHSA-N 0.000 claims 1
- YHMSPNKEZKKJAI-QGZVFWFLSA-N 1-[6-[(1R)-1-hydroxyethyl]-2-[[5-[[4-(hydroxymethyl)piperidin-1-yl]methyl]pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-8-yl]piperidin-4-ol Chemical compound O[C@H](C)C1=CC2=C(N=C(N=C2)NC2=NC=C(C=C2)CN2CCC(CC2)CO)C(=N1)N1CCC(CC1)O YHMSPNKEZKKJAI-QGZVFWFLSA-N 0.000 claims 1
- IAMOCLGQCMDFJL-UHFFFAOYSA-N 1-[6-[[6-(2-hydroxyethyl)-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-yl]amino]pyridin-3-yl]piperazin-2-one Chemical compound OCCC1=CC2=C(N=C(N=C2)NC2=CC=C(C=N2)N2C(CNCC2)=O)C(=N1)N1CCCCC1 IAMOCLGQCMDFJL-UHFFFAOYSA-N 0.000 claims 1
- UYACJIQHLLNNCC-UHFFFAOYSA-N 1-[6-[[6-(hydroxymethyl)-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-yl]amino]pyridin-3-yl]piperazin-2-one Chemical compound OCC1=CC2=C(N=C(N=C2)NC2=CC=C(C=N2)N2C(CNCC2)=O)C(=N1)N1CCCCC1 UYACJIQHLLNNCC-UHFFFAOYSA-N 0.000 claims 1
- NAIMEYJUSXYEAX-OAHLLOKOSA-N 1-[6-[[6-[(1R)-1-hydroxyethyl]-8-morpholin-4-ylpyrido[3,4-d]pyrimidin-2-yl]amino]pyridin-3-yl]-4-methylpiperazin-2-one Chemical compound O[C@H](C)C1=CC2=C(N=C(N=C2)NC2=CC=C(C=N2)N2C(CN(CC2)C)=O)C(=N1)N1CCOCC1 NAIMEYJUSXYEAX-OAHLLOKOSA-N 0.000 claims 1
- GVOGWFHJYBCZDT-OAHLLOKOSA-N 1-[6-[[6-[(1R)-1-hydroxyethyl]-8-phenylpyrido[3,4-d]pyrimidin-2-yl]amino]pyridin-3-yl]piperazin-2-one Chemical compound O[C@H](C)C1=CC2=C(N=C(N=C2)NC2=CC=C(C=N2)N2C(CNCC2)=O)C(=N1)C1=CC=CC=C1 GVOGWFHJYBCZDT-OAHLLOKOSA-N 0.000 claims 1
- ZEXWTWGNRXAQCE-MRXNPFEDSA-N 1-[6-[[6-[(1R)-1-hydroxyethyl]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-yl]amino]pyridin-3-yl]-1,4-diazepan-2-one Chemical compound O[C@H](C)C1=CC2=C(N=C(N=C2)NC2=CC=C(C=N2)N2C(CNCCC2)=O)C(=N1)N1CCCCC1 ZEXWTWGNRXAQCE-MRXNPFEDSA-N 0.000 claims 1
- YFHBFJJDGQCZGU-MRXNPFEDSA-N 1-[6-[[6-[(1R)-1-hydroxyethyl]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-yl]amino]pyridin-3-yl]-4-methylpiperazin-2-one Chemical compound O[C@H](C)C1=CC2=C(N=C(N=C2)NC2=CC=C(C=N2)N2C(CN(CC2)C)=O)C(=N1)N1CCCCC1 YFHBFJJDGQCZGU-MRXNPFEDSA-N 0.000 claims 1
- HOXZMIJRDSGOIC-OAHLLOKOSA-N 1-[6-[[6-[(1R)-1-hydroxyethyl]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-yl]amino]pyridin-3-yl]piperazin-2-one Chemical compound O[C@H](C)C1=CC2=C(N=C(N=C2)NC2=CC=C(C=N2)N2C(CNCC2)=O)C(=N1)N1CCCCC1 HOXZMIJRDSGOIC-OAHLLOKOSA-N 0.000 claims 1
- YSCPJHOIQFHVEU-OAHLLOKOSA-N 1-[6-[[6-[(1R)-1-hydroxyethyl]-8-pyrrolidin-1-ylpyrido[3,4-d]pyrimidin-2-yl]amino]pyridin-3-yl]-4-methylpiperazin-2-one Chemical compound O[C@H](C)C1=CC2=C(N=C(N=C2)NC2=CC=C(C=N2)N2C(CN(CC2)C)=O)C(=N1)N1CCCC1 YSCPJHOIQFHVEU-OAHLLOKOSA-N 0.000 claims 1
- VJQQKZIIXZRWOB-CQSZACIVSA-N 1-[6-[[6-[(1R)-1-hydroxyethyl]-8-pyrrolidin-1-ylpyrido[3,4-d]pyrimidin-2-yl]amino]pyridin-3-yl]piperazin-2-one Chemical compound O[C@H](C)C1=CC2=C(N=C(N=C2)NC2=CC=C(C=N2)N2C(CNCC2)=O)C(=N1)N1CCCC1 VJQQKZIIXZRWOB-CQSZACIVSA-N 0.000 claims 1
- IAHRCYOEMMJHIR-HXUWFJFHSA-N 1-[6-[[6-[(1R)-1-hydroxypropyl]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-yl]amino]pyridin-3-yl]-1,4-diazepan-2-one Chemical compound O[C@H](CC)C1=CC2=C(N=C(N=C2)NC2=CC=C(C=N2)N2C(CNCCC2)=O)C(=N1)N1CCCCC1 IAHRCYOEMMJHIR-HXUWFJFHSA-N 0.000 claims 1
- CFBXBBUAKQKACH-INIZCTEOSA-N 1-[6-[[6-[(2R)-1-hydroxypropan-2-yl]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-yl]amino]pyridin-3-yl]piperazin-2-one Chemical compound OC[C@H](C)C1=CC2=C(N=C(N=C2)NC2=CC=C(C=N2)N2C(CNCC2)=O)C(=N1)N1CCCCC1 CFBXBBUAKQKACH-INIZCTEOSA-N 0.000 claims 1
- AGKZEQVLUBONAZ-MRXNPFEDSA-N 1-[6-[[6-[(2R)-2-hydroxypropyl]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-yl]amino]pyridin-3-yl]piperazin-2-one Chemical compound O[C@@H](CC1=CC2=C(N=C(N=C2)NC2=CC=C(C=N2)N2C(CNCC2)=O)C(=N1)N1CCCCC1)C AGKZEQVLUBONAZ-MRXNPFEDSA-N 0.000 claims 1
- CFBXBBUAKQKACH-MRXNPFEDSA-N 1-[6-[[6-[(2S)-1-hydroxypropan-2-yl]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-yl]amino]pyridin-3-yl]piperazin-2-one Chemical compound OC[C@@H](C)C1=CC2=C(N=C(N=C2)NC2=CC=C(C=N2)N2C(CNCC2)=O)C(=N1)N1CCCCC1 CFBXBBUAKQKACH-MRXNPFEDSA-N 0.000 claims 1
- AGKZEQVLUBONAZ-INIZCTEOSA-N 1-[6-[[6-[(2S)-2-hydroxypropyl]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-yl]amino]pyridin-3-yl]piperazin-2-one Chemical compound O[C@H](CC1=CC2=C(N=C(N=C2)NC2=CC=C(C=N2)N2C(CNCC2)=O)C(=N1)N1CCCCC1)C AGKZEQVLUBONAZ-INIZCTEOSA-N 0.000 claims 1
- GEMNBUCGWRBLIN-CQSZACIVSA-N 1-[6-[[8-(4,4-difluoropiperidin-1-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]pyridin-3-yl]piperazin-2-one Chemical compound FC1(CCN(CC1)C1=NC(=CC2=C1N=C(N=C2)NC1=CC=C(C=N1)N1C(CNCC1)=O)[C@@H](C)O)F GEMNBUCGWRBLIN-CQSZACIVSA-N 0.000 claims 1
- HLERATFKXQIDJF-CQSZACIVSA-N 1-[6-[[8-(4-fluoropiperidin-1-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]pyridin-3-yl]piperazin-2-one Chemical compound FC1CCN(CC1)C1=NC(=CC2=C1N=C(N=C2)NC1=CC=C(C=N1)N1C(CNCC1)=O)[C@@H](C)O HLERATFKXQIDJF-CQSZACIVSA-N 0.000 claims 1
- LQHSWMSPYSOKRB-FAEJEUNOSA-N 1-[6-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]pyridin-3-yl]-4-methylpiperazin-2-one Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=CC=C(C=N1)N1C(CN(CC1)C)=O)[C@@H](C)O LQHSWMSPYSOKRB-FAEJEUNOSA-N 0.000 claims 1
- WRZJQEHZUYPLQE-IPJUCJBFSA-N 1-[6-[[8-(8-azabicyclo[3.2.1]octan-8-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]pyridin-3-yl]-4-methylpiperazin-2-one Chemical compound C12CCCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=CC=C(C=N1)N1C(CN(CC1)C)=O)[C@@H](C)O WRZJQEHZUYPLQE-IPJUCJBFSA-N 0.000 claims 1
- VODGWRSCAWFORD-CYBMUJFWSA-N 1-[6-[[8-(azetidin-1-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]pyridin-3-yl]piperazin-2-one Chemical compound N1(CCC1)C1=NC(=CC2=C1N=C(N=C2)NC1=CC=C(C=N1)N1C(CNCC1)=O)[C@@H](C)O VODGWRSCAWFORD-CYBMUJFWSA-N 0.000 claims 1
- JSPCGGHWAWJDCI-GFCCVEGCSA-N 1-[6-[[8-cyclopropyl-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]pyridin-3-yl]piperazin-2-one Chemical compound C1(CC1)C1=NC(=CC2=C1N=C(N=C2)NC1=CC=C(C=N1)N1C(CNCC1)=O)[C@@H](C)O JSPCGGHWAWJDCI-GFCCVEGCSA-N 0.000 claims 1
- TVTJATWXWZJIKN-UHFFFAOYSA-N 1-[8-morpholin-4-yl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[3,4-d]pyrimidin-6-yl]propan-1-ol Chemical compound N1(CCOCC1)C1=NC(=CC2=C1N=C(N=C2)NC1=NC=C(C=C1)N1CCNCC1)C(CC)O TVTJATWXWZJIKN-UHFFFAOYSA-N 0.000 claims 1
- HSISEDFMVILRKH-MRXNPFEDSA-N 1-[[6-[[6-[(1R)-1-hydroxyethyl]-8-morpholin-4-ylpyrido[3,4-d]pyrimidin-2-yl]amino]pyridin-3-yl]methyl]piperidin-4-ol Chemical compound O[C@H](C)C1=CC2=C(N=C(N=C2)NC2=CC=C(C=N2)CN2CCC(CC2)O)C(=N1)N1CCOCC1 HSISEDFMVILRKH-MRXNPFEDSA-N 0.000 claims 1
- BTDMHOVDAHGRJI-QGZVFWFLSA-N 1-[[6-[[6-[(1R)-1-hydroxyethyl]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-yl]amino]pyridin-3-yl]methyl]piperidin-4-ol Chemical compound O[C@H](C)C1=CC2=C(N=C(N=C2)NC2=CC=C(C=N2)CN2CCC(CC2)O)C(=N1)N1CCCCC1 BTDMHOVDAHGRJI-QGZVFWFLSA-N 0.000 claims 1
- QLKDAIGNGODQDD-MRXNPFEDSA-N 1-[[6-[[6-[(1R)-1-hydroxyethyl]-8-pyrrolidin-1-ylpyrido[3,4-d]pyrimidin-2-yl]amino]pyridin-3-yl]methyl]piperidin-4-ol Chemical compound O[C@H](C)C1=CC2=C(N=C(N=C2)NC2=CC=C(C=N2)CN2CCC(CC2)O)C(=N1)N1CCCC1 QLKDAIGNGODQDD-MRXNPFEDSA-N 0.000 claims 1
- NIAZXFKCZTXAAN-UHFFFAOYSA-N 2-[2-[(6-piperazin-1-ylpyridazin-3-yl)amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound N1(CCNCC1)C1=CC=C(N=N1)NC=1N=CC2=C(N=1)C(=NC(=C2)CCO)N1CCCCC1 NIAZXFKCZTXAAN-UHFFFAOYSA-N 0.000 claims 1
- HNNMDGKETWPUDL-UHFFFAOYSA-N 2-[2-[[5-(piperazin-1-ylmethyl)pyridin-2-yl]amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound N1(CCNCC1)CC=1C=CC(=NC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)CCO)N1CCCCC1 HNNMDGKETWPUDL-UHFFFAOYSA-N 0.000 claims 1
- RZUZNYQEISHFPC-UHFFFAOYSA-N 2-[2-[[6-(2-hydroxyethyl)-7,8-dihydro-5H-1,6-naphthyridin-2-yl]amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound OCCN1CC=2C=CC(=NC=2CC1)NC=1N=CC2=C(N=1)C(=NC(=C2)CCO)N1CCCCC1 RZUZNYQEISHFPC-UHFFFAOYSA-N 0.000 claims 1
- YFSVEVIQMNFRKK-UHFFFAOYSA-N 2-[2-[[6-(hydroxymethyl)-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]ethanol Chemical compound OCC1=CC2=C(N=C(N=C2)NC2=NC=3CCN(CC=3C=C2)CCO)C(=N1)N1CCCCC1 YFSVEVIQMNFRKK-UHFFFAOYSA-N 0.000 claims 1
- LMFXLSNZJRXJJO-MRXNPFEDSA-N 2-[2-[[6-[(1R)-1-hydroxyethyl]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]acetonitrile Chemical compound O[C@H](C)C1=CC2=C(N=C(N=C2)NC2=NC=3CCN(CC=3C=C2)CC#N)C(=N1)N1CCCCC1 LMFXLSNZJRXJJO-MRXNPFEDSA-N 0.000 claims 1
- VHERWLMBJLSQCD-UHFFFAOYSA-N 2-[2-[[6-[2-(dimethylamino)ethyl]-7,8-dihydro-5H-1,6-naphthyridin-2-yl]amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound CN(CCN1CC=2C=CC(=NC=2CC1)NC=1N=CC2=C(N=1)C(=NC(=C2)CCO)N1CCCCC1)C VHERWLMBJLSQCD-UHFFFAOYSA-N 0.000 claims 1
- TUWUKQNZLDEESM-UHFFFAOYSA-N 2-[4-[[6-[[6-(difluoromethyl)-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-yl]amino]pyridin-3-yl]methyl]piperazin-1-yl]ethanol Chemical compound FC(C1=CC2=C(N=C(N=C2)NC2=CC=C(C=N2)CN2CCN(CC2)CCO)C(=N1)N1CCCCC1)F TUWUKQNZLDEESM-UHFFFAOYSA-N 0.000 claims 1
- HUIGNZMFZFFAHD-UHFFFAOYSA-N 2-[4-[[6-[[6-(hydroxymethyl)-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-yl]amino]pyridin-3-yl]methyl]piperazin-1-yl]ethanol Chemical compound OCC1=CC2=C(N=C(N=C2)NC2=CC=C(C=N2)CN2CCN(CC2)CCO)C(=N1)N1CCCCC1 HUIGNZMFZFFAHD-UHFFFAOYSA-N 0.000 claims 1
- RUCKOJUPZOBJOO-UHFFFAOYSA-N 2-[4-[[6-[[6-(oxetan-3-yl)-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-yl]amino]pyridin-3-yl]methyl]piperazin-1-yl]ethanol Chemical compound O1CC(C1)C1=CC2=C(N=C(N=C2)NC2=CC=C(C=N2)CN2CCN(CC2)CCO)C(=N1)N1CCCCC1 RUCKOJUPZOBJOO-UHFFFAOYSA-N 0.000 claims 1
- XQBIYHDDIBHMHY-UHFFFAOYSA-N 2-[4-[[6-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]pyridin-3-yl]methyl]piperazin-1-yl]ethanol Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=CC=C(C=N1)CN1CCN(CC1)CCO)C1COC1 XQBIYHDDIBHMHY-UHFFFAOYSA-N 0.000 claims 1
- KLTJFSGBMRCJAE-UHFFFAOYSA-N 2-[8-morpholin-4-yl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound N1(CCOCC1)C1=NC(=CC2=C1N=C(N=C2)NC1=NC=C(C=C1)N1CCNCC1)CCO KLTJFSGBMRCJAE-UHFFFAOYSA-N 0.000 claims 1
- ULBONANIGCZHMY-UHFFFAOYSA-N 2-[8-piperidin-1-yl-2-(5,6,7,8-tetrahydro-1,6-naphthyridin-2-ylamino)pyrido[3,4-d]pyrimidin-6-yl]ethanol Chemical compound N1(CCCCC1)C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCNCC=2C=C1)CCO ULBONANIGCZHMY-UHFFFAOYSA-N 0.000 claims 1
- AQQJXHHDWBEZQT-QGZVFWFLSA-N 3-[2-[[6-[(1R)-1-hydroxyethyl]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]propan-1-ol Chemical compound O[C@H](C)C1=CC2=C(N=C(N=C2)NC2=NC=3CCN(CC=3C=C2)CCCO)C(=N1)N1CCCCC1 AQQJXHHDWBEZQT-QGZVFWFLSA-N 0.000 claims 1
- GRSSZLJBBNULGY-GOSISDBHSA-N 4-(2-hydroxyethyl)-1-[6-[[6-[(1R)-1-hydroxyethyl]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-yl]amino]pyridin-3-yl]-1,4-diazepan-2-one Chemical compound OCCN1CC(N(CCC1)C=1C=NC(=CC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1CCCCC1)=O GRSSZLJBBNULGY-GOSISDBHSA-N 0.000 claims 1
- OPPXUMLQOQJTTP-QGZVFWFLSA-N 4-(2-hydroxyethyl)-1-[6-[[6-[(1R)-1-hydroxyethyl]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-yl]amino]pyridin-3-yl]piperazin-2-one Chemical compound OCCN1CC(N(CC1)C=1C=NC(=CC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1CCCCC1)=O OPPXUMLQOQJTTP-QGZVFWFLSA-N 0.000 claims 1
- WLEZCGYLPYNFAA-QGZVFWFLSA-N 4-[6-[[6-[(1R)-1-hydroxyethyl]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-yl]amino]pyridin-3-yl]-1-methyl-1,4-diazepan-5-one Chemical compound O[C@H](C)C1=CC2=C(N=C(N=C2)NC2=CC=C(C=N2)N2CCN(CCC2=O)C)C(=N1)N1CCCCC1 WLEZCGYLPYNFAA-QGZVFWFLSA-N 0.000 claims 1
- OBZJBCYLLPIFFP-MRXNPFEDSA-N 4-[6-[[6-[(1R)-1-hydroxyethyl]-8-pyrrolidin-1-ylpyrido[3,4-d]pyrimidin-2-yl]amino]pyridin-3-yl]-1-methyl-1,4-diazepan-5-one Chemical compound O[C@H](C)C1=CC2=C(N=C(N=C2)NC2=CC=C(C=N2)N2CCN(CCC2=O)C)C(=N1)N1CCCC1 OBZJBCYLLPIFFP-MRXNPFEDSA-N 0.000 claims 1
- RQXCKZHVKYKQER-UHFFFAOYSA-N 6-(1-methoxyethyl)-8-[4-(methoxymethyl)piperidin-1-yl]-N-[5-(piperazin-1-ylmethyl)pyridin-2-yl]pyrido[3,4-d]pyrimidin-2-amine Chemical compound COC(C)C1=CC2=C(N=C(N=C2)NC2=NC=C(C=C2)CN2CCNCC2)C(=N1)N1CCC(CC1)COC RQXCKZHVKYKQER-UHFFFAOYSA-N 0.000 claims 1
- PLEIPDQZANDDPT-UHFFFAOYSA-N 6-(1-methoxyethyl)-N-[5-(piperazin-1-ylmethyl)pyridin-2-yl]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-amine Chemical compound COC(C)C1=CC2=C(N=C(N=C2)NC2=NC=C(C=C2)CN2CCNCC2)C(=N1)N1CCCCC1 PLEIPDQZANDDPT-UHFFFAOYSA-N 0.000 claims 1
- USGRSAVCTLQGAD-UHFFFAOYSA-N 6-(difluoromethyl)-8-morpholin-4-yl-N-(5-piperazin-1-ylpyridin-2-yl)pyrido[3,4-d]pyrimidin-2-amine [8-morpholin-4-yl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[3,4-d]pyrimidin-6-yl]methanol Chemical compound FC(C1=CC2=C(N=C(N=C2)NC2=NC=C(C=C2)N2CCNCC2)C(=N1)N1CCOCC1)F.N1(CCOCC1)C1=NC(=CC2=C1N=C(N=C2)NC2=NC=C(C=C2)N2CCNCC2)CO USGRSAVCTLQGAD-UHFFFAOYSA-N 0.000 claims 1
- OTXGIMATVARHND-UHFFFAOYSA-N 6-(difluoromethyl)-8-phenyl-N-(5-piperazin-1-ylpyridin-2-yl)pyrido[3,4-d]pyrimidin-2-amine 6-(difluoromethyl)-N-(5-piperazin-1-ylpyridin-2-yl)-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-amine Chemical compound FC(C1=CC2=C(N=C(N=C2)NC2=NC=C(C=C2)N2CCNCC2)C(=N1)C1=CC=CC=C1)F.FC(C1=CC2=C(N=C(N=C2)NC2=NC=C(C=C2)N2CCNCC2)C(=N1)N1CCCCC1)F OTXGIMATVARHND-UHFFFAOYSA-N 0.000 claims 1
- PUDJAKRIDYOFOS-UHFFFAOYSA-N 6-(difluoromethyl)-N-[5-(4-methylpiperazin-1-yl)pyridin-2-yl]-8-morpholin-4-ylpyrido[3,4-d]pyrimidin-2-amine Chemical compound FC(C1=CC2=C(N=C(N=C2)NC2=NC=C(C=C2)N2CCN(CC2)C)C(=N1)N1CCOCC1)F PUDJAKRIDYOFOS-UHFFFAOYSA-N 0.000 claims 1
- RZCPLNFSMAXYJG-UHFFFAOYSA-N 6-(difluoromethyl)-N-[5-(4-methylpiperazin-1-yl)pyridin-2-yl]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-amine Chemical compound FC(C1=CC2=C(N=C(N=C2)NC2=NC=C(C=C2)N2CCN(CC2)C)C(=N1)N1CCCCC1)F RZCPLNFSMAXYJG-UHFFFAOYSA-N 0.000 claims 1
- NYXDALOFWIGHES-UHFFFAOYSA-N 6-(oxolan-3-yl)-N-(6-piperazin-1-ylpyridazin-3-yl)-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-amine Chemical compound O1CC(CC1)C1=CC2=C(N=C(N=C2)NC=2N=NC(=CC=2)N2CCNCC2)C(=N1)N1CCCCC1 NYXDALOFWIGHES-UHFFFAOYSA-N 0.000 claims 1
- JAJJORSUCSANSB-UHFFFAOYSA-N 6-(oxolan-3-yl)-N-[5-(piperazin-1-ylmethyl)pyridin-2-yl]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-amine Chemical compound O1CC(CC1)C1=CC2=C(N=C(N=C2)NC2=NC=C(C=C2)CN2CCNCC2)C(=N1)N1CCCCC1 JAJJORSUCSANSB-UHFFFAOYSA-N 0.000 claims 1
- UDQCSXZBPKMCNZ-MRXNPFEDSA-N 6-[(1R)-1-methoxyethyl]-N-(6-piperazin-1-ylpyridazin-3-yl)-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-amine Chemical compound CO[C@H](C)C1=CC2=C(N=C(N=C2)NC=2N=NC(=CC=2)N2CCNCC2)C(=N1)N1CCCCC1 UDQCSXZBPKMCNZ-MRXNPFEDSA-N 0.000 claims 1
- PLEIPDQZANDDPT-GOSISDBHSA-N 6-[(1R)-1-methoxyethyl]-N-[5-(piperazin-1-ylmethyl)pyridin-2-yl]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-amine Chemical compound CO[C@H](C)C1=CC2=C(N=C(N=C2)NC2=NC=C(C=C2)CN2CCNCC2)C(=N1)N1CCCCC1 PLEIPDQZANDDPT-GOSISDBHSA-N 0.000 claims 1
- FDDXLLNQBSFLCQ-UHFFFAOYSA-N 8-(1,2,3,3a,4,5,7,7a-octahydropyrrolo[2,3-c]pyridin-6-yl)-6-(1-methoxyethyl)-N-[5-(piperazin-1-ylmethyl)pyridin-2-yl]pyrido[3,4-d]pyrimidin-2-amine Chemical compound N1CCC2C1CN(CC2)C1=NC(=CC2=C1N=C(N=C2)NC1=NC=C(C=C1)CN1CCNCC1)C(C)OC FDDXLLNQBSFLCQ-UHFFFAOYSA-N 0.000 claims 1
- JASOIFFILUGOOP-OAHLLOKOSA-N 8-(4-fluoropiperidin-1-yl)-6-[(1R)-1-methoxyethyl]-N-(6-piperazin-1-ylpyridazin-3-yl)pyrido[3,4-d]pyrimidin-2-amine Chemical compound FC1CCN(CC1)C1=NC(=CC2=C1N=C(N=C2)NC=1N=NC(=CC=1)N1CCNCC1)[C@@H](C)OC JASOIFFILUGOOP-OAHLLOKOSA-N 0.000 claims 1
- YEVXCMJQXRTBHA-MRXNPFEDSA-N 8-(4-fluoropiperidin-1-yl)-6-[(1R)-1-methoxyethyl]-N-[6-(4-methylpiperazin-1-yl)pyridazin-3-yl]pyrido[3,4-d]pyrimidin-2-amine Chemical compound FC1CCN(CC1)C1=NC(=CC2=C1N=C(N=C2)NC=1N=NC(=CC=1)N1CCN(CC1)C)[C@@H](C)OC YEVXCMJQXRTBHA-MRXNPFEDSA-N 0.000 claims 1
- MZFJWCUDBMRGPI-UHFFFAOYSA-N 8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxolan-3-yl)-N-(6-piperazin-1-ylpyridazin-3-yl)pyrido[3,4-d]pyrimidin-2-amine Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC=1N=NC(=CC=1)N1CCNCC1)C1COCC1 MZFJWCUDBMRGPI-UHFFFAOYSA-N 0.000 claims 1
- OTEXUCABEBDHRB-UHFFFAOYSA-N 8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxolan-3-yl)-N-[5-(piperazin-1-ylmethyl)pyridin-2-yl]pyrido[3,4-d]pyrimidin-2-amine Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=C(C=C1)CN1CCNCC1)C1COCC1 OTEXUCABEBDHRB-UHFFFAOYSA-N 0.000 claims 1
- GTQDPOHHALGGLE-UHFFFAOYSA-N C1(=CC=CC=C1)C1=NC(=CC2=C1N=C(N=C2)NC2=NC=C(C=C2)N2CCNCC2)CO.N2(CCNCC2)C=2C=CC(=NC2)NC=2N=CC1=C(N2)C(=NC(=C1)CO)N1CCCCC1 Chemical compound C1(=CC=CC=C1)C1=NC(=CC2=C1N=C(N=C2)NC2=NC=C(C=C2)N2CCNCC2)CO.N2(CCNCC2)C=2C=CC(=NC2)NC=2N=CC1=C(N2)C(=NC(=C1)CO)N1CCCCC1 GTQDPOHHALGGLE-UHFFFAOYSA-N 0.000 claims 1
- AEZYQCPVBLCGGN-UHFFFAOYSA-N CC1=C(C=CC=C1)C1=NC(=CC2=C1N=C(N=C2)NC2=NC=C(C=C2)N2CCNCC2)CO.CC2=CC=C(C=C2)C2=NC(=CC1=C2N=C(N=C1)NC1=NC=C(C=C1)N1CCNCC1)CO Chemical compound CC1=C(C=CC=C1)C1=NC(=CC2=C1N=C(N=C2)NC2=NC=C(C=C2)N2CCNCC2)CO.CC2=CC=C(C=C2)C2=NC(=CC1=C2N=C(N=C1)NC1=NC=C(C=C1)N1CCNCC1)CO AEZYQCPVBLCGGN-UHFFFAOYSA-N 0.000 claims 1
- YJIITGYYODCIMW-UHFFFAOYSA-N CC1=C(N=C(C=2N=C(N=CC21)NC2=NC=C(C=C2)N2CCNCC2)N2CCOCC2)CO.COCC2=CC1=C(N=C(N=C1)NC1=NC=C(C=C1)N1CCNCC1)C(=N2)N2CCOCC2 Chemical compound CC1=C(N=C(C=2N=C(N=CC21)NC2=NC=C(C=C2)N2CCNCC2)N2CCOCC2)CO.COCC2=CC1=C(N=C(N=C1)NC1=NC=C(C=C1)N1CCNCC1)C(=N2)N2CCOCC2 YJIITGYYODCIMW-UHFFFAOYSA-N 0.000 claims 1
- IIDSKOOFKSWTSO-UHFFFAOYSA-N CN1CCN(CC1)C=1C=CC(=NC1)NC=1N=CC2=C(N1)C(=NC(=C2)CO)C2=CC=CC=C2.C2(CCCCC2)C2=NC(=CC1=C2N=C(N=C1)NC1=NC=C(C=C1)N1CCN(CC1)C)CO Chemical compound CN1CCN(CC1)C=1C=CC(=NC1)NC=1N=CC2=C(N1)C(=NC(=C2)CO)C2=CC=CC=C2.C2(CCCCC2)C2=NC(=CC1=C2N=C(N=C1)NC1=NC=C(C=C1)N1CCN(CC1)C)CO IIDSKOOFKSWTSO-UHFFFAOYSA-N 0.000 claims 1
- DVDZDLIPNYQTSC-UHFFFAOYSA-N FC(C1=CC2=C(N=C(N=C2)NC2=NC=C(C=C2)N2CCNCC2)C(=N1)C1=COC=C1)F.FC(C1=CC2=C(N=C(N=C2)NC2=NC=C(C=C2)N2CCNCC2)C(=N1)C1=C(C=CC=C1)C)F Chemical compound FC(C1=CC2=C(N=C(N=C2)NC2=NC=C(C=C2)N2CCNCC2)C(=N1)C1=COC=C1)F.FC(C1=CC2=C(N=C(N=C2)NC2=NC=C(C=C2)N2CCNCC2)C(=N1)C1=C(C=CC=C1)C)F DVDZDLIPNYQTSC-UHFFFAOYSA-N 0.000 claims 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 1
- YJGFCOHLRFMDQW-UHFFFAOYSA-N N-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidine-6-carboxamide Chemical compound CNC(=O)C1=CC2=C(N=C(N=C2)NC2=NC=C(C=C2)N2CCNCC2)C(=N1)N1CCCCC1 YJGFCOHLRFMDQW-UHFFFAOYSA-N 0.000 claims 1
- OOJINIZBJRSREA-UHFFFAOYSA-N N1(CCNCC1)C=1C=CC(=NC1)NC=1N=CC2=C(N1)C(=NC(=C2)C(=O)N)N2CCCCC2.CN(C(=O)C2=CC1=C(N=C(N=C1)NC1=NC=C(C=C1)N1CCNCC1)C(=N2)N2CCCCC2)C Chemical compound N1(CCNCC1)C=1C=CC(=NC1)NC=1N=CC2=C(N1)C(=NC(=C2)C(=O)N)N2CCCCC2.CN(C(=O)C2=CC1=C(N=C(N=C1)NC1=NC=C(C=C1)N1CCNCC1)C(=N2)N2CCCCC2)C OOJINIZBJRSREA-UHFFFAOYSA-N 0.000 claims 1
- IQJLVMABVAEFOV-UHFFFAOYSA-N N1(CCNCC1)C=1C=CC(=NC1)NC=1N=CC2=C(N1)C(=NC(=C2)C(=O)O)N2CCCCC2.C2(=CCCCC2)C2=NC(=CC1=C2N=C(N=C1)NC1=NC=C(C=C1)N1CCN(CC1)C)CO Chemical compound N1(CCNCC1)C=1C=CC(=NC1)NC=1N=CC2=C(N1)C(=NC(=C2)C(=O)O)N2CCCCC2.C2(=CCCCC2)C2=NC(=CC1=C2N=C(N=C1)NC1=NC=C(C=C1)N1CCN(CC1)C)CO IQJLVMABVAEFOV-UHFFFAOYSA-N 0.000 claims 1
- HOJGFSMTDBYZGO-UHFFFAOYSA-N N1(CCNCC1)C=1C=CC(=NC1)NC=1N=CC2=C(N1)C(=NC(=C2)C(=O)OC)N2CCCCC2.N2(CCNCC2)C=2C=CC(=NC2)NC=2N=CC1=C(N2)C(=NC(=C1)C(C)O)N1CCCCC1 Chemical compound N1(CCNCC1)C=1C=CC(=NC1)NC=1N=CC2=C(N1)C(=NC(=C2)C(=O)OC)N2CCCCC2.N2(CCNCC2)C=2C=CC(=NC2)NC=2N=CC1=C(N2)C(=NC(=C1)C(C)O)N1CCCCC1 HOJGFSMTDBYZGO-UHFFFAOYSA-N 0.000 claims 1
- UBLJVCOLIWETID-UHFFFAOYSA-N N1(CCNCC1)CC=1C=CC(=NC1)NC=1N=CC2=C(N1)C(=NC(=C2)CO)N2CCCCC2.N2(CCNCC2)C2=CC=C(N=N2)NC=2N=CC1=C(N2)C(=NC(=C1)CO)N1CCCCC1 Chemical compound N1(CCNCC1)CC=1C=CC(=NC1)NC=1N=CC2=C(N1)C(=NC(=C2)CO)N2CCCCC2.N2(CCNCC2)C2=CC=C(N=N2)NC=2N=CC1=C(N2)C(=NC(=C1)CO)N1CCCCC1 UBLJVCOLIWETID-UHFFFAOYSA-N 0.000 claims 1
- HAJTYHBLVFSRSK-UHFFFAOYSA-N O1C=C(C=C1)C1=NC(=CC2=C1N=C(N=C2)NC2=NC=C(C=C2)N2CCNCC2)CO.N2(CCNCC2)C=2C=CC(=NC2)NC=2N=CC1=C(N2)C(=NC(=C1)CO)C1=CSC=C1 Chemical compound O1C=C(C=C1)C1=NC(=CC2=C1N=C(N=C2)NC2=NC=C(C=C2)N2CCNCC2)CO.N2(CCNCC2)C=2C=CC(=NC2)NC=2N=CC1=C(N2)C(=NC(=C1)CO)C1=CSC=C1 HAJTYHBLVFSRSK-UHFFFAOYSA-N 0.000 claims 1
- CTPCHQLYUJVBFZ-OXQOHEQNSA-N [(2R)-azetidin-2-yl]-[2-[[6-[(1R)-1-hydroxyethyl]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]methanone Chemical compound N1[C@H](CC1)C(=O)N1CC=2C=CC(=NC=2CC1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1CCCCC1 CTPCHQLYUJVBFZ-OXQOHEQNSA-N 0.000 claims 1
- LPPBKOOZIMFQHN-HXUWFJFHSA-N [1-(2-hydroxyethyl)piperidin-4-yl]-[2-[[6-[(1R)-1-hydroxyethyl]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]methanone Chemical compound OCCN1CCC(CC1)C(=O)N1CC=2C=CC(=NC=2CC1)NC=1N=CC2=C(N=1)C(=NC(=C2)[C@@H](C)O)N1CCCCC1 LPPBKOOZIMFQHN-HXUWFJFHSA-N 0.000 claims 1
- GVKBWOCQQWWTDN-UHFFFAOYSA-N [1-[6-(1-methoxyethyl)-2-[[5-(piperazin-1-ylmethyl)pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-8-yl]piperidin-4-yl]methanol Chemical compound COC(C)C1=CC2=C(N=C(N=C2)NC2=NC=C(C=C2)CN2CCNCC2)C(=N1)N1CCC(CC1)CO GVKBWOCQQWWTDN-UHFFFAOYSA-N 0.000 claims 1
- KUZXNXDDHJVOPH-UHFFFAOYSA-N [2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]-8-morpholin-4-ylpyrido[3,4-d]pyrimidin-6-yl]methanol Chemical compound CN1CCN(CC1)C=1C=CC(=NC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)CO)N1CCOCC1 KUZXNXDDHJVOPH-UHFFFAOYSA-N 0.000 claims 1
- FKDXFAISKNGIQW-UHFFFAOYSA-N [2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]methanol Chemical compound CN1CCN(CC1)C=1C=CC(=NC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)CO)N1CCCCC1 FKDXFAISKNGIQW-UHFFFAOYSA-N 0.000 claims 1
- MGHQBHADGGKJFT-UHFFFAOYSA-N [2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]-8-thiophen-3-ylpyrido[3,4-d]pyrimidin-6-yl]methanol Chemical compound CN1CCN(CC1)C=1C=CC(=NC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)CO)C1=CSC=C1 MGHQBHADGGKJFT-UHFFFAOYSA-N 0.000 claims 1
- VKQCXVAHXHYQHP-LJQANCHMSA-N [2-[[6-[(1R)-1-hydroxyethyl]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-(1-methylpiperidin-4-yl)methanone Chemical compound O[C@H](C)C1=CC2=C(N=C(N=C2)NC2=NC=3CCN(CC=3C=C2)C(=O)C2CCN(CC2)C)C(=N1)N1CCCCC1 VKQCXVAHXHYQHP-LJQANCHMSA-N 0.000 claims 1
- CQOKCRVDKMUBNP-XMSQKQJNSA-N [2-[[6-[(1R)-1-hydroxyethyl]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2R)-piperidin-2-yl]methanone Chemical compound O[C@H](C)C1=CC2=C(N=C(N=C2)NC2=NC=3CCN(CC=3C=C2)C(=O)[C@@H]2NCCCC2)C(=N1)N1CCCCC1 CQOKCRVDKMUBNP-XMSQKQJNSA-N 0.000 claims 1
- QBLFRTJKTJACQQ-DYESRHJHSA-N [2-[[6-[(1R)-1-hydroxyethyl]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2R)-pyrrolidin-2-yl]methanone Chemical compound O[C@H](C)C1=CC2=C(N=C(N=C2)NC2=NC=3CCN(CC=3C=C2)C(=O)[C@@H]2NCCC2)C(=N1)N1CCCCC1 QBLFRTJKTJACQQ-DYESRHJHSA-N 0.000 claims 1
- LYNCQZZAZGBXKP-ZWDAVXSWSA-N [2-[[6-[(1R)-1-hydroxyethyl]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2R,4R)-4-hydroxypyrrolidin-2-yl]methanone Chemical compound O[C@H](C)C1=CC2=C(N=C(N=C2)NC2=NC=3CCN(CC=3C=C2)C(=O)[C@@H]2NC[C@@H](C2)O)C(=N1)N1CCCCC1 LYNCQZZAZGBXKP-ZWDAVXSWSA-N 0.000 claims 1
- LYNCQZZAZGBXKP-GTCCEBARSA-N [2-[[6-[(1R)-1-hydroxyethyl]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2R,4S)-4-hydroxypyrrolidin-2-yl]methanone Chemical compound O[C@H](C)C1=CC2=C(N=C(N=C2)NC2=NC=3CCN(CC=3C=C2)C(=O)[C@@H]2NC[C@H](C2)O)C(=N1)N1CCCCC1 LYNCQZZAZGBXKP-GTCCEBARSA-N 0.000 claims 1
- GOLMFDBIYRBNLR-RTBURBONSA-N [2-[[6-[(1R)-1-hydroxyethyl]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(3R)-piperidin-3-yl]methanone Chemical compound O[C@H](C)C1=CC2=C(N=C(N=C2)NC2=NC=3CCN(CC=3C=C2)C(=O)[C@H]2CNCCC2)C(=N1)N1CCCCC1 GOLMFDBIYRBNLR-RTBURBONSA-N 0.000 claims 1
- BQKQWVSGWWDGEV-MSOLQXFVSA-N [2-[[6-[(1R)-1-hydroxyethyl]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(3S)-pyrrolidin-3-yl]methanone Chemical compound O[C@H](C)C1=CC2=C(N=C(N=C2)NC2=NC=3CCN(CC=3C=C2)C(=O)[C@@H]2CNCC2)C(=N1)N1CCCCC1 BQKQWVSGWWDGEV-MSOLQXFVSA-N 0.000 claims 1
- GOFUYVHRRPNUAN-PLEWWHCXSA-N [2-[[6-[(1R)-1-hydroxyethyl]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-morpholin-2-ylmethanone Chemical compound O[C@H](C)C1=CC2=C(N=C(N=C2)NC2=NC=3CCN(CC=3C=C2)C(=O)C2CNCCO2)C(=N1)N1CCCCC1 GOFUYVHRRPNUAN-PLEWWHCXSA-N 0.000 claims 1
- WUPJMPUEYIREPY-PLEWWHCXSA-N [2-[[6-[(1R)-1-hydroxyethyl]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-morpholin-3-ylmethanone Chemical compound O[C@H](C)C1=CC2=C(N=C(N=C2)NC2=NC=3CCN(CC=3C=C2)C(=O)C2NCCOC2)C(=N1)N1CCCCC1 WUPJMPUEYIREPY-PLEWWHCXSA-N 0.000 claims 1
- AFUYQWKTHXNDFZ-GOSISDBHSA-N [2-[[6-[(1R)-1-hydroxyethyl]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-piperidin-4-ylmethanone Chemical compound O[C@H](C)C1=CC2=C(N=C(N=C2)NC2=NC=3CCN(CC=3C=C2)C(=O)C2CCNCC2)C(=N1)N1CCCCC1 AFUYQWKTHXNDFZ-GOSISDBHSA-N 0.000 claims 1
- LTBNGFWIHAJTNX-UHFFFAOYSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-(1-methylazetidin-3-yl)methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)C1CN(C1)C)C1COC1 LTBNGFWIHAJTNX-UHFFFAOYSA-N 0.000 claims 1
- ZATQEPVVUXSSFL-UHFFFAOYSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-(4-methylmorpholin-2-yl)methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)C1CN(CCO1)C)C1COC1 ZATQEPVVUXSSFL-UHFFFAOYSA-N 0.000 claims 1
- YGLOWKQNEDSNAL-UHFFFAOYSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-(4-methylmorpholin-3-yl)methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)C1N(CCOC1)C)C1COC1 YGLOWKQNEDSNAL-UHFFFAOYSA-N 0.000 claims 1
- PCNYIGRNWXMYBX-XUNZJTMSSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2R)-1-(2-hydroxyethyl)azetidin-2-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@@H]1N(CC1)CCO)C1COC1 PCNYIGRNWXMYBX-XUNZJTMSSA-N 0.000 claims 1
- NOLHFWLGJSRPSZ-PUUKEUDRSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2R)-1-(2-hydroxyethyl)piperidin-2-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@@H]1N(CCCC1)CCO)C1COC1 NOLHFWLGJSRPSZ-PUUKEUDRSA-N 0.000 claims 1
- AYHMPJFOVHDVBV-QGPIEZSZSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2R)-1-(2-hydroxyethyl)pyrrolidin-2-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@@H]1N(CCC1)CCO)C1COC1 AYHMPJFOVHDVBV-QGPIEZSZSA-N 0.000 claims 1
- PQBZGJGILWVHRH-SLXFGWRHSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2R)-1-methylazetidin-2-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@@H]1N(CC1)C)C1COC1 PQBZGJGILWVHRH-SLXFGWRHSA-N 0.000 claims 1
- IXCLYJCSGMHASC-QGPIEZSZSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2R)-1-methylpiperidin-2-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@@H]1N(CCCC1)C)C1COC1 IXCLYJCSGMHASC-QGPIEZSZSA-N 0.000 claims 1
- YBLBRSPJTZLIIR-XUNZJTMSSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2R)-1-methylpyrrolidin-2-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@@H]1N(CCC1)C)C1COC1 YBLBRSPJTZLIIR-XUNZJTMSSA-N 0.000 claims 1
- MEUIUMLBJJOXMZ-SHZLTDHESA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2R,4R)-4-hydroxy-1-(2-hydroxyethyl)pyrrolidin-2-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@@H]1N(C[C@@H](C1)O)CCO)C1COC1 MEUIUMLBJJOXMZ-SHZLTDHESA-N 0.000 claims 1
- IQRDNXVAYNREHB-FEIQLAPHSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2R,4R)-4-hydroxy-1-methylpyrrolidin-2-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@@H]1N(C[C@@H](C1)O)C)C1COC1 IQRDNXVAYNREHB-FEIQLAPHSA-N 0.000 claims 1
- MEUIUMLBJJOXMZ-KCRWFKQWSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2R,4S)-4-hydroxy-1-(2-hydroxyethyl)pyrrolidin-2-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@@H]1N(C[C@H](C1)O)CCO)C1COC1 MEUIUMLBJJOXMZ-KCRWFKQWSA-N 0.000 claims 1
- IQRDNXVAYNREHB-BBLPBDBVSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2R,4S)-4-hydroxy-1-methylpyrrolidin-2-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@@H]1N(C[C@H](C1)O)C)C1COC1 IQRDNXVAYNREHB-BBLPBDBVSA-N 0.000 claims 1
- PCNYIGRNWXMYBX-OWWUNANSSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2S)-1-(2-hydroxyethyl)azetidin-2-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@H]1N(CC1)CCO)C1COC1 PCNYIGRNWXMYBX-OWWUNANSSA-N 0.000 claims 1
- NOLHFWLGJSRPSZ-CXTIUDGFSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2S)-1-(2-hydroxyethyl)piperidin-2-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@H]1N(CCCC1)CCO)C1COC1 NOLHFWLGJSRPSZ-CXTIUDGFSA-N 0.000 claims 1
- AYHMPJFOVHDVBV-JGZAQREWSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2S)-1-(2-hydroxyethyl)pyrrolidin-2-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@H]1N(CCC1)CCO)C1COC1 AYHMPJFOVHDVBV-JGZAQREWSA-N 0.000 claims 1
- PQBZGJGILWVHRH-VUNKPPBISA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2S)-1-methylazetidin-2-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@H]1N(CC1)C)C1COC1 PQBZGJGILWVHRH-VUNKPPBISA-N 0.000 claims 1
- IXCLYJCSGMHASC-JGZAQREWSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2S)-1-methylpiperidin-2-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@H]1N(CCCC1)C)C1COC1 IXCLYJCSGMHASC-JGZAQREWSA-N 0.000 claims 1
- YBLBRSPJTZLIIR-OWWUNANSSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2S)-1-methylpyrrolidin-2-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@H]1N(CCC1)C)C1COC1 YBLBRSPJTZLIIR-OWWUNANSSA-N 0.000 claims 1
- MEUIUMLBJJOXMZ-GLSWWRQESA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2S,4R)-4-hydroxy-1-(2-hydroxyethyl)pyrrolidin-2-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@H]1N(C[C@@H](C1)O)CCO)C1COC1 MEUIUMLBJJOXMZ-GLSWWRQESA-N 0.000 claims 1
- IQRDNXVAYNREHB-SGDKSWKTSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2S,4R)-4-hydroxy-1-methylpyrrolidin-2-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@H]1N(C[C@@H](C1)O)C)C1COC1 IQRDNXVAYNREHB-SGDKSWKTSA-N 0.000 claims 1
- MEUIUMLBJJOXMZ-CBGCIVQGSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2S,4S)-4-hydroxy-1-(2-hydroxyethyl)pyrrolidin-2-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@H]1N(C[C@H](C1)O)CCO)C1COC1 MEUIUMLBJJOXMZ-CBGCIVQGSA-N 0.000 claims 1
- IQRDNXVAYNREHB-YQDNHFOKSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2S,4S)-4-hydroxy-1-methylpyrrolidin-2-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@H]1N(C[C@H](C1)O)C)C1COC1 IQRDNXVAYNREHB-YQDNHFOKSA-N 0.000 claims 1
- KEXWRFUNPRUREE-BURHJUHKSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(3R)-1-(2-hydroxyethyl)piperidin-3-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@H]1CN(CCC1)CCO)C1COC1 KEXWRFUNPRUREE-BURHJUHKSA-N 0.000 claims 1
- ZDRKZEZFTOHGNW-QUVATAORSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(3R)-1-(2-hydroxyethyl)pyrrolidin-3-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@H]1CN(CC1)CCO)C1COC1 ZDRKZEZFTOHGNW-QUVATAORSA-N 0.000 claims 1
- BICMKOWLPZQMNM-QUVATAORSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(3R)-1-methylpiperidin-3-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@H]1CN(CCC1)C)C1COC1 BICMKOWLPZQMNM-QUVATAORSA-N 0.000 claims 1
- ZQUZXDAWILNLKU-YUVSOPLDSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(3R)-1-methylpyrrolidin-3-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@H]1CN(CC1)C)C1COC1 ZQUZXDAWILNLKU-YUVSOPLDSA-N 0.000 claims 1
- KEXWRFUNPRUREE-ANYOXOOPSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(3S)-1-(2-hydroxyethyl)piperidin-3-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@@H]1CN(CCC1)CCO)C1COC1 KEXWRFUNPRUREE-ANYOXOOPSA-N 0.000 claims 1
- ZDRKZEZFTOHGNW-XOYNAWAESA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(3S)-1-(2-hydroxyethyl)pyrrolidin-3-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@@H]1CN(CC1)CCO)C1COC1 ZDRKZEZFTOHGNW-XOYNAWAESA-N 0.000 claims 1
- BICMKOWLPZQMNM-XOYNAWAESA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(3S)-1-methylpiperidin-3-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@@H]1CN(CCC1)C)C1COC1 BICMKOWLPZQMNM-XOYNAWAESA-N 0.000 claims 1
- ZQUZXDAWILNLKU-BVVFMGSASA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(3S)-1-methylpyrrolidin-3-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@@H]1CN(CC1)C)C1COC1 ZQUZXDAWILNLKU-BVVFMGSASA-N 0.000 claims 1
- JZSQRPSYEWUSGE-UHFFFAOYSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[1-(2-hydroxyethyl)azetidin-3-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)C1CN(C1)CCO)C1COC1 JZSQRPSYEWUSGE-UHFFFAOYSA-N 0.000 claims 1
- SVQJLWDLTFWMSZ-UHFFFAOYSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[4-(2-hydroxyethyl)morpholin-2-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)C1CN(CCO1)CCO)C1COC1 SVQJLWDLTFWMSZ-UHFFFAOYSA-N 0.000 claims 1
- ITLOWLVHVSXTDW-UHFFFAOYSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-(oxetan-3-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[4-(2-hydroxyethyl)morpholin-3-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)C1N(CCOC1)CCO)C1COC1 ITLOWLVHVSXTDW-UHFFFAOYSA-N 0.000 claims 1
- XUYSULDQRYRYQR-ODRTWGCCSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-(4-methylmorpholin-2-yl)methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)C1CN(CCO1)C)[C@@H](C)O XUYSULDQRYRYQR-ODRTWGCCSA-N 0.000 claims 1
- TZGLZGWVCUHEOP-ODRTWGCCSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-(4-methylmorpholin-3-yl)methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)C1N(CCOC1)C)[C@@H](C)O TZGLZGWVCUHEOP-ODRTWGCCSA-N 0.000 claims 1
- GBDBUYZCESVQKT-PAZOXZGKSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2R)-1-(2-hydroxyethyl)azetidin-2-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@@H]1N(CC1)CCO)[C@@H](C)O GBDBUYZCESVQKT-PAZOXZGKSA-N 0.000 claims 1
- WZOSNGPKPXLRSK-QCBCVPOISA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2R)-1-(2-hydroxyethyl)piperidin-2-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@@H]1N(CCCC1)CCO)[C@@H](C)O WZOSNGPKPXLRSK-QCBCVPOISA-N 0.000 claims 1
- JFGWZFKCGDANEU-CISKAWLMSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2R)-1-(2-hydroxyethyl)pyrrolidin-2-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@@H]1N(CCC1)CCO)[C@@H](C)O JFGWZFKCGDANEU-CISKAWLMSA-N 0.000 claims 1
- TZYIFWPRVRCRSI-SKGVNOBPSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2R)-1-methylazetidin-2-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@@H]1N(CC1)C)[C@@H](C)O TZYIFWPRVRCRSI-SKGVNOBPSA-N 0.000 claims 1
- KRFRSJNCIRSSDP-CISKAWLMSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2R)-1-methylpiperidin-2-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@@H]1N(CCCC1)C)[C@@H](C)O KRFRSJNCIRSSDP-CISKAWLMSA-N 0.000 claims 1
- RHNZBIABGXFQAP-PAZOXZGKSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2R)-1-methylpyrrolidin-2-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@@H]1N(CCC1)C)[C@@H](C)O RHNZBIABGXFQAP-PAZOXZGKSA-N 0.000 claims 1
- UPKDPMZMKWYAPG-MQHDHJEOSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2R,4R)-4-hydroxy-1-(2-hydroxyethyl)pyrrolidin-2-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@@H]1N(C[C@@H](C1)O)CCO)[C@@H](C)O UPKDPMZMKWYAPG-MQHDHJEOSA-N 0.000 claims 1
- JWOYUFBEGUFLSS-QGOPZODISA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2R,4R)-4-hydroxy-1-methylpyrrolidin-2-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@@H]1N(C[C@@H](C1)O)C)[C@@H](C)O JWOYUFBEGUFLSS-QGOPZODISA-N 0.000 claims 1
- UPKDPMZMKWYAPG-QKBOKIJISA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2R,4S)-4-hydroxy-1-(2-hydroxyethyl)pyrrolidin-2-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@@H]1N(C[C@H](C1)O)CCO)[C@@H](C)O UPKDPMZMKWYAPG-QKBOKIJISA-N 0.000 claims 1
- JWOYUFBEGUFLSS-TUWQWXMESA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2R,4S)-4-hydroxy-1-methylpyrrolidin-2-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@@H]1N(C[C@H](C1)O)C)[C@@H](C)O JWOYUFBEGUFLSS-TUWQWXMESA-N 0.000 claims 1
- GBDBUYZCESVQKT-KAHMTJTRSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2S)-1-(2-hydroxyethyl)azetidin-2-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@H]1N(CC1)CCO)[C@@H](C)O GBDBUYZCESVQKT-KAHMTJTRSA-N 0.000 claims 1
- WZOSNGPKPXLRSK-YVTVTNRGSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2S)-1-(2-hydroxyethyl)piperidin-2-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@H]1N(CCCC1)CCO)[C@@H](C)O WZOSNGPKPXLRSK-YVTVTNRGSA-N 0.000 claims 1
- JFGWZFKCGDANEU-ZMEKMKMMSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2S)-1-(2-hydroxyethyl)pyrrolidin-2-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@H]1N(CCC1)CCO)[C@@H](C)O JFGWZFKCGDANEU-ZMEKMKMMSA-N 0.000 claims 1
- TZYIFWPRVRCRSI-TYYZCITMSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2S)-1-methylazetidin-2-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@H]1N(CC1)C)[C@@H](C)O TZYIFWPRVRCRSI-TYYZCITMSA-N 0.000 claims 1
- KRFRSJNCIRSSDP-ZMEKMKMMSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2S)-1-methylpiperidin-2-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@H]1N(CCCC1)C)[C@@H](C)O KRFRSJNCIRSSDP-ZMEKMKMMSA-N 0.000 claims 1
- RHNZBIABGXFQAP-KAHMTJTRSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2S)-1-methylpyrrolidin-2-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@H]1N(CCC1)C)[C@@H](C)O RHNZBIABGXFQAP-KAHMTJTRSA-N 0.000 claims 1
- UPKDPMZMKWYAPG-DGNPGJOQSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2S,4R)-4-hydroxy-1-(2-hydroxyethyl)pyrrolidin-2-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@H]1N(C[C@@H](C1)O)CCO)[C@@H](C)O UPKDPMZMKWYAPG-DGNPGJOQSA-N 0.000 claims 1
- JWOYUFBEGUFLSS-LBWVQCIMSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2S,4R)-4-hydroxy-1-methylpyrrolidin-2-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@H]1N(C[C@@H](C1)O)C)[C@@H](C)O JWOYUFBEGUFLSS-LBWVQCIMSA-N 0.000 claims 1
- UPKDPMZMKWYAPG-XIMSXLIXSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2S,4S)-4-hydroxy-1-(2-hydroxyethyl)pyrrolidin-2-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@H]1N(C[C@H](C1)O)CCO)[C@@H](C)O UPKDPMZMKWYAPG-XIMSXLIXSA-N 0.000 claims 1
- JWOYUFBEGUFLSS-LDEYGISLSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(2S,4S)-4-hydroxy-1-methylpyrrolidin-2-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@H]1N(C[C@H](C1)O)C)[C@@H](C)O JWOYUFBEGUFLSS-LDEYGISLSA-N 0.000 claims 1
- XDKOCUPYOOMZSC-UAYNNQDFSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(3R)-1-(2-hydroxyethyl)piperidin-3-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@H]1CN(CCC1)CCO)[C@@H](C)O XDKOCUPYOOMZSC-UAYNNQDFSA-N 0.000 claims 1
- GMSHAPOEQPFLAO-ZEABBNLPSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(3R)-1-(2-hydroxyethyl)pyrrolidin-3-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@H]1CN(CC1)CCO)[C@@H](C)O GMSHAPOEQPFLAO-ZEABBNLPSA-N 0.000 claims 1
- OKYADSCKEYZKKL-ZEABBNLPSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(3R)-1-methylpiperidin-3-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@H]1CN(CCC1)C)[C@@H](C)O OKYADSCKEYZKKL-ZEABBNLPSA-N 0.000 claims 1
- BSBLHMOKSQIZEK-AZIUHJDESA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(3R)-1-methylpyrrolidin-3-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@H]1CN(CC1)C)[C@@H](C)O BSBLHMOKSQIZEK-AZIUHJDESA-N 0.000 claims 1
- XDKOCUPYOOMZSC-WPNHWPQCSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(3S)-1-(2-hydroxyethyl)piperidin-3-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@@H]1CN(CCC1)CCO)[C@@H](C)O XDKOCUPYOOMZSC-WPNHWPQCSA-N 0.000 claims 1
- GMSHAPOEQPFLAO-MDHDCJJKSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(3S)-1-(2-hydroxyethyl)pyrrolidin-3-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@@H]1CN(CC1)CCO)[C@@H](C)O GMSHAPOEQPFLAO-MDHDCJJKSA-N 0.000 claims 1
- OKYADSCKEYZKKL-MDHDCJJKSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(3S)-1-methylpiperidin-3-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@@H]1CN(CCC1)C)[C@@H](C)O OKYADSCKEYZKKL-MDHDCJJKSA-N 0.000 claims 1
- BSBLHMOKSQIZEK-LGRHEBEHSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[(3S)-1-methylpyrrolidin-3-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)[C@@H]1CN(CC1)C)[C@@H](C)O BSBLHMOKSQIZEK-LGRHEBEHSA-N 0.000 claims 1
- DOTRAOVKAAWLNV-PPNDLDFTSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[1-(2-hydroxyethyl)azetidin-3-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)C1CN(C1)CCO)[C@@H](C)O DOTRAOVKAAWLNV-PPNDLDFTSA-N 0.000 claims 1
- BFXLZQHFTBYBLV-NOSFMEOYSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[4-(2-hydroxyethyl)morpholin-2-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)C1CN(CCO1)CCO)[C@@H](C)O BFXLZQHFTBYBLV-NOSFMEOYSA-N 0.000 claims 1
- JGQGHAHJHIDNKV-NOSFMEOYSA-N [2-[[8-(7-azabicyclo[2.2.1]heptan-7-yl)-6-[(1R)-1-hydroxyethyl]pyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-[4-(2-hydroxyethyl)morpholin-3-yl]methanone Chemical compound C12CCC(CC1)N2C1=NC(=CC2=C1N=C(N=C2)NC1=NC=2CCN(CC=2C=C1)C(=O)C1N(CCOC1)CCO)[C@@H](C)O JGQGHAHJHIDNKV-NOSFMEOYSA-N 0.000 claims 1
- ZLUOCCJODZFLQX-UHFFFAOYSA-N [8-(2-methylphenyl)-2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]methanol Chemical compound CC1=C(C=CC=C1)C1=NC(=CC2=C1N=C(N=C2)NC1=NC=C(C=C1)N1CCN(CC1)C)CO ZLUOCCJODZFLQX-UHFFFAOYSA-N 0.000 claims 1
- SHKZWEPMVZEMJD-UHFFFAOYSA-N [8-(4-methylphenyl)-2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]methanol Chemical compound CC1=CC=C(C=C1)C1=NC(=CC2=C1N=C(N=C2)NC1=NC=C(C=C1)N1CCN(CC1)C)CO SHKZWEPMVZEMJD-UHFFFAOYSA-N 0.000 claims 1
- VIAHRWWGEBARBY-UHFFFAOYSA-N [8-(furan-3-yl)-2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]methanol Chemical compound O1C=C(C=C1)C1=NC(=CC2=C1N=C(N=C2)NC1=NC=C(C=C1)N1CCN(CC1)C)CO VIAHRWWGEBARBY-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 claims 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 1
- RNQWSIBLGFRMBH-UHFFFAOYSA-N morpholin-2-yl-[2-[[6-(oxetan-3-yl)-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]methanone Chemical compound N1CC(OCC1)C(=O)N1CC=2C=CC(=NC=2CC1)NC=1N=CC2=C(N=1)C(=NC(=C2)C1COC1)N1CCCCC1 RNQWSIBLGFRMBH-UHFFFAOYSA-N 0.000 claims 1
- LBQWKBAFKXDSGQ-UHFFFAOYSA-N morpholin-3-yl-[2-[[6-(oxetan-3-yl)-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-yl]amino]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]methanone Chemical compound N1C(COCC1)C(=O)N1CC=2C=CC(=NC=2CC1)NC=1N=CC2=C(N=1)C(=NC(=C2)C1COC1)N1CCCCC1 LBQWKBAFKXDSGQ-UHFFFAOYSA-N 0.000 claims 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 258
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 228
- 239000000243 solution Substances 0.000 description 193
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 168
- 238000006243 chemical reaction Methods 0.000 description 133
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 99
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 87
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 75
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 74
- 238000003786 synthesis reaction Methods 0.000 description 59
- 230000015572 biosynthetic process Effects 0.000 description 58
- 230000000694 effects Effects 0.000 description 55
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 53
- 239000012043 crude product Substances 0.000 description 49
- 239000000706 filtrate Substances 0.000 description 47
- 239000011541 reaction mixture Substances 0.000 description 47
- 239000007787 solid Substances 0.000 description 47
- 238000005481 NMR spectroscopy Methods 0.000 description 43
- 238000000034 method Methods 0.000 description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 37
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 36
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 36
- 230000008569 process Effects 0.000 description 36
- 239000012074 organic phase Substances 0.000 description 35
- 102000015792 Cyclin-Dependent Kinase 2 Human genes 0.000 description 30
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 30
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 30
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 30
- 0 *C(C(O)=C(C=C)N)=* Chemical compound *C(C(O)=C(C=C)N)=* 0.000 description 29
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 27
- 238000012360 testing method Methods 0.000 description 25
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 239000012131 assay buffer Substances 0.000 description 24
- 239000000203 mixture Substances 0.000 description 23
- 238000010898 silica gel chromatography Methods 0.000 description 23
- 102000004190 Enzymes Human genes 0.000 description 22
- 108090000790 Enzymes Proteins 0.000 description 22
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 22
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 21
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 19
- 238000012799 strong cation exchange Methods 0.000 description 19
- 239000000047 product Substances 0.000 description 18
- 239000002904 solvent Substances 0.000 description 18
- 239000003153 chemical reaction reagent Substances 0.000 description 16
- 238000010790 dilution Methods 0.000 description 16
- 239000012895 dilution Substances 0.000 description 16
- 238000010992 reflux Methods 0.000 description 16
- 239000000758 substrate Substances 0.000 description 16
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 15
- 239000003960 organic solvent Substances 0.000 description 15
- 238000000746 purification Methods 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 13
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 12
- 102000006313 Cyclin D3 Human genes 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 239000011347 resin Substances 0.000 description 12
- 229920005989 resin Polymers 0.000 description 12
- 229920006395 saturated elastomer Polymers 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 11
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 239000002585 base Substances 0.000 description 11
- 238000010511 deprotection reaction Methods 0.000 description 11
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 11
- 235000017557 sodium bicarbonate Nutrition 0.000 description 11
- 108010058545 Cyclin D3 Proteins 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 10
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 239000008346 aqueous phase Substances 0.000 description 10
- 150000001924 cycloalkanes Chemical class 0.000 description 10
- 229910000027 potassium carbonate Inorganic materials 0.000 description 10
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 102000016736 Cyclin Human genes 0.000 description 9
- 108050006400 Cyclin Proteins 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 9
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
- 125000000217 alkyl group Chemical group 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 229910052751 metal Inorganic materials 0.000 description 9
- 239000002184 metal Substances 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 8
- 239000007995 HEPES buffer Substances 0.000 description 8
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 8
- 108091000080 Phosphotransferase Proteins 0.000 description 8
- 150000004945 aromatic hydrocarbons Chemical group 0.000 description 8
- 150000001721 carbon Chemical group 0.000 description 8
- 125000004122 cyclic group Chemical group 0.000 description 8
- 150000002390 heteroarenes Chemical group 0.000 description 8
- 102000020233 phosphotransferase Human genes 0.000 description 8
- 102100025191 Cyclin-A2 Human genes 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 230000018199 S phase Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000002953 preparative HPLC Methods 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 108010060273 Cyclin A2 Proteins 0.000 description 6
- 102000003910 Cyclin D Human genes 0.000 description 6
- 108090000259 Cyclin D Proteins 0.000 description 6
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 6
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 6
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 6
- 101001109518 Homo sapiens N-acetylneuraminate lyase Proteins 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 102100022686 N-acetylneuraminate lyase Human genes 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 229910021529 ammonia Inorganic materials 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 230000022131 cell cycle Effects 0.000 description 6
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 6
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 230000018791 negative regulation of catalytic activity Effects 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 150000003335 secondary amines Chemical group 0.000 description 6
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 5
- 108050002653 Retinoblastoma protein Proteins 0.000 description 5
- OLHYMNHWFJXDIZ-OAHLLOKOSA-N [(1R)-1-(2-methylsulfanyl-8-phenylpyrido[3,4-d]pyrimidin-6-yl)ethyl] benzoate Chemical compound CSc1ncc2cc(nc(-c3ccccc3)c2n1)[C@@H](C)OC(=O)c1ccccc1 OLHYMNHWFJXDIZ-OAHLLOKOSA-N 0.000 description 5
- 230000005856 abnormality Effects 0.000 description 5
- 150000001335 aliphatic alkanes Chemical class 0.000 description 5
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 5
- 239000012148 binding buffer Substances 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 230000006369 cell cycle progression Effects 0.000 description 5
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 5
- 210000003414 extremity Anatomy 0.000 description 5
- 239000011737 fluorine Substances 0.000 description 5
- 208000005017 glioblastoma Diseases 0.000 description 5
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 125000004434 sulfur atom Chemical group 0.000 description 5
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 4
- FWOPEZLPZOXDSJ-UHFFFAOYSA-N (2-methylsulfanyl-7-oxidopyrido[3,4-d]pyrimidin-7-ium-6-yl)methyl benzoate Chemical compound C(C1=CC=CC=C1)(=O)OCC1=CC2=C(N=C(N=C2)SC)C=[N+]1[O-] FWOPEZLPZOXDSJ-UHFFFAOYSA-N 0.000 description 4
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- 108091007914 CDKs Proteins 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 230000010190 G1 phase Effects 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- 101100446506 Mus musculus Fgf3 gene Proteins 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- 102100033254 Tumor suppressor ARF Human genes 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 238000003149 assay kit Methods 0.000 description 4
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 235000015165 citric acid Nutrition 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000004020 luminiscence type Methods 0.000 description 4
- 125000005322 morpholin-1-yl group Chemical group 0.000 description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- UHHKSVZZTYJVEG-UHFFFAOYSA-N oxepane Chemical compound C1CCCOCC1 UHHKSVZZTYJVEG-UHFFFAOYSA-N 0.000 description 4
- 230000010287 polarization Effects 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- HCQHKSLBDWELKJ-UHFFFAOYSA-N (5-bromo-2-methylsulfanyl-8-morpholin-4-ylpyrido[3,4-d]pyrimidin-6-yl)methyl benzoate Chemical compound CSc1ncc2c(Br)c(COC(=O)c3ccccc3)nc(N3CCOCC3)c2n1 HCQHKSLBDWELKJ-UHFFFAOYSA-N 0.000 description 3
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
- BJFGWSAEUJMSQP-UHFFFAOYSA-N 2-methylsulfanyl-8-piperidin-1-ylpyrido[3,4-d]pyrimidine-6-carbaldehyde Chemical compound CSc1ncc2cc(C=O)nc(N3CCCCC3)c2n1 BJFGWSAEUJMSQP-UHFFFAOYSA-N 0.000 description 3
- ZGPXFHZCGJWAHJ-UHFFFAOYSA-N 2-methylsulfanyl-8-piperidin-1-ylpyrido[3,4-d]pyrimidine-6-carboxylic acid Chemical compound CSc1ncc2cc(nc(N3CCCCC3)c2n1)C(O)=O ZGPXFHZCGJWAHJ-UHFFFAOYSA-N 0.000 description 3
- XOLRQDLRONKNCY-UHFFFAOYSA-N 6-(difluoromethyl)-2-methylsulfanyl-8-piperidin-1-ylpyrido[3,4-d]pyrimidine Chemical compound CSc1ncc2cc(nc(N3CCCCC3)c2n1)C(F)F XOLRQDLRONKNCY-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 3
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 3
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 206010023232 Joint swelling Diseases 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- BEJUXMXVDMUROC-OAHLLOKOSA-N [(1R)-1-(2-methylsulfanyl-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl)ethyl] benzoate Chemical compound CSc1ncc2cc(nc(N3CCCCC3)c2n1)[C@@H](C)OC(=O)c1ccccc1 BEJUXMXVDMUROC-OAHLLOKOSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 210000003423 ankle Anatomy 0.000 description 3
- 230000008499 blood brain barrier function Effects 0.000 description 3
- 210000001218 blood-brain barrier Anatomy 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 150000001925 cycloalkenes Chemical class 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- SXZIXHOMFPUIRK-UHFFFAOYSA-N diphenylmethanimine Chemical compound C=1C=CC=CC=1C(=N)C1=CC=CC=C1 SXZIXHOMFPUIRK-UHFFFAOYSA-N 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 150000005748 halopyridines Chemical class 0.000 description 3
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- 210000002437 synoviocyte Anatomy 0.000 description 3
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- JMPIHDODDOMEAE-UHFFFAOYSA-N (2-methylsulfanyl-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl)methanol Chemical compound CSc1ncc2cc(CO)nc(N3CCCCC3)c2n1 JMPIHDODDOMEAE-UHFFFAOYSA-N 0.000 description 2
- PQIIZSGDSIYMNX-UHFFFAOYSA-N (5-methyl-2-methylsulfanyl-8-morpholin-4-ylpyrido[3,4-d]pyrimidin-6-yl)methyl benzoate Chemical compound CSc1ncc2c(C)c(COC(=O)c3ccccc3)nc(N3CCOCC3)c2n1 PQIIZSGDSIYMNX-UHFFFAOYSA-N 0.000 description 2
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 description 2
- YETODIXQMRZKEG-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydropyrrolo[2,3-c]pyrrole Chemical compound C1NCC2NCCC21 YETODIXQMRZKEG-UHFFFAOYSA-N 0.000 description 2
- XJKNACDCUAFDHD-UHFFFAOYSA-N 1,4-diazabicyclo[3.2.2]nonane Chemical compound C1CC2CCN1CCN2 XJKNACDCUAFDHD-UHFFFAOYSA-N 0.000 description 2
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 2
- UQPXYEYBUROSJF-UHFFFAOYSA-N 1,6-diazaspiro[3.3]heptane Chemical compound N1CCC11CNC1 UQPXYEYBUROSJF-UHFFFAOYSA-N 0.000 description 2
- RHRMCNWRSJMIFI-UHFFFAOYSA-N 1,9-diazaspiro[4.5]decane Chemical compound C1CCNC21CNCCC2 RHRMCNWRSJMIFI-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 2
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 2
- HNRMPXKDFBEGFZ-UHFFFAOYSA-N 2,2-dimethylbutane Chemical compound CCC(C)(C)C HNRMPXKDFBEGFZ-UHFFFAOYSA-N 0.000 description 2
- FLTJDUOFAQWHDF-UHFFFAOYSA-N 2,2-dimethylhexane Chemical compound CCCCC(C)(C)C FLTJDUOFAQWHDF-UHFFFAOYSA-N 0.000 description 2
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical compound CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 2
- DJWDAKFSDBOQJK-UHFFFAOYSA-N 2,5-diazabicyclo[2.2.2]octane Chemical compound C1NC2CCC1NC2 DJWDAKFSDBOQJK-UHFFFAOYSA-N 0.000 description 2
- UDSAJFSYJMHNFI-UHFFFAOYSA-N 2,6-diazaspiro[3.3]heptane Chemical compound C1NCC11CNC1 UDSAJFSYJMHNFI-UHFFFAOYSA-N 0.000 description 2
- OXPIFHNJGOJJQZ-UHFFFAOYSA-N 2,7-diazaspiro[3.4]octane Chemical compound C1NCC11CNCC1 OXPIFHNJGOJJQZ-UHFFFAOYSA-N 0.000 description 2
- DROZYMFJWSYDRY-UHFFFAOYSA-N 2,7-diazaspiro[3.5]nonane Chemical compound C1NCC11CCNCC1 DROZYMFJWSYDRY-UHFFFAOYSA-N 0.000 description 2
- WYZZNMWIWHRXRM-UHFFFAOYSA-N 2,8-diazaspiro[4.5]decane Chemical compound C1NCCC21CCNCC2 WYZZNMWIWHRXRM-UHFFFAOYSA-N 0.000 description 2
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- JVSWJIKNEAIKJW-UHFFFAOYSA-N 2-Methylheptane Chemical compound CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 2
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 2
- QPEJAHMNOVMSOZ-UHFFFAOYSA-N 2-azaspiro[3.3]heptane Chemical compound C1CCC21CNC2 QPEJAHMNOVMSOZ-UHFFFAOYSA-N 0.000 description 2
- BKOOMYPCSUNDGP-UHFFFAOYSA-N 2-methylbut-2-ene Chemical compound CC=C(C)C BKOOMYPCSUNDGP-UHFFFAOYSA-N 0.000 description 2
- LKDJYZBKCVSODK-UHFFFAOYSA-N 3,8-diazabicyclo[3.2.1]octane Chemical compound C1NCC2CCC1N2 LKDJYZBKCVSODK-UHFFFAOYSA-N 0.000 description 2
- UVAUUPIGGGXRTK-UHFFFAOYSA-N 3-(4-formyl-2-methylsulfanylpyrimidin-5-yl)prop-2-ynyl benzoate Chemical compound C(C1=CC=CC=C1)(=O)OCC#CC=1C(=NC(=NC=1)SC)C=O UVAUUPIGGGXRTK-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- PFEOZHBOMNWTJB-UHFFFAOYSA-N 3-methylpentane Chemical compound CCC(C)CC PFEOZHBOMNWTJB-UHFFFAOYSA-N 0.000 description 2
- RLPYXXBIHMUZRE-UHFFFAOYSA-N 4,7-diazaspiro[2.5]octane Chemical compound C1CC11NCCNC1 RLPYXXBIHMUZRE-UHFFFAOYSA-N 0.000 description 2
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 2
- YJEWVVYJOJJLBP-UHFFFAOYSA-N 5-bromo-2-methylsulfanylpyrimidine-4-carboxylic acid Chemical compound CSC1=NC=C(Br)C(C(O)=O)=N1 YJEWVVYJOJJLBP-UHFFFAOYSA-N 0.000 description 2
- ATXXLNCPVSUCNK-UHFFFAOYSA-N 5-bromo-2-nitropyridine Chemical compound [O-][N+](=O)C1=CC=C(Br)C=N1 ATXXLNCPVSUCNK-UHFFFAOYSA-N 0.000 description 2
- JGKHUCYPAAYQDK-UHFFFAOYSA-N 6-(difluoromethyl)-2-methylsulfonyl-8-piperidin-1-ylpyrido[3,4-d]pyrimidine Chemical compound CS(=O)(=O)c1ncc2cc(nc(N3CCCCC3)c2n1)C(F)F JGKHUCYPAAYQDK-UHFFFAOYSA-N 0.000 description 2
- BMNPVMQSUPTGFD-UHFFFAOYSA-N 6-aminopyridine-3-carbaldehyde Chemical compound NC1=CC=C(C=O)C=N1 BMNPVMQSUPTGFD-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- BDPSROJWSFODMQ-UHFFFAOYSA-N C(C1=CC=CC=C1)(=O)OC1=CC2=C(N=C(N=C2)SC)C(=N1)Cl Chemical compound C(C1=CC=CC=C1)(=O)OC1=CC2=C(N=C(N=C2)SC)C(=N1)Cl BDPSROJWSFODMQ-UHFFFAOYSA-N 0.000 description 2
- DOFPPYUUEATYEE-UHFFFAOYSA-N CC(C)N(CC1)CCC1F Chemical compound CC(C)N(CC1)CCC1F DOFPPYUUEATYEE-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 108010058546 Cyclin D1 Proteins 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 description 2
- 101000738559 Homo sapiens G1/S-specific cyclin-D3 Proteins 0.000 description 2
- 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 description 2
- 101000733249 Homo sapiens Tumor suppressor ARF Proteins 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 102100030416 Stromelysin-1 Human genes 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- POESYSDANPKCHF-BBUZXQMBSA-N [(1R)-1-(2-methylsulfinyl-8-phenylpyrido[3,4-d]pyrimidin-6-yl)ethyl] benzoate Chemical compound C[C@@H](OC(=O)c1ccccc1)c1cc2cnc(nc2c(n1)-c1ccccc1)S(C)=O POESYSDANPKCHF-BBUZXQMBSA-N 0.000 description 2
- VQWRZCQOQCYGKX-BBUZXQMBSA-N [(1R)-1-(2-methylsulfinyl-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl)ethyl] benzoate Chemical compound C[C@@H](OC(=O)c1ccccc1)c1cc2cnc(nc2c(n1)N1CCCCC1)S(C)=O VQWRZCQOQCYGKX-BBUZXQMBSA-N 0.000 description 2
- FUPGCQOGILUDAJ-OAHLLOKOSA-N [(1R)-1-(2-methylsulfonyl-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl)ethyl] benzoate Chemical compound C[C@@H](OC(=O)c1ccccc1)c1cc2cnc(nc2c(n1)N1CCCCC1)S(C)(=O)=O FUPGCQOGILUDAJ-OAHLLOKOSA-N 0.000 description 2
- POZNCJUASPQAMS-SNVBAGLBSA-N [(1R)-1-(8-chloro-2-methylsulfanylpyrido[3,4-d]pyrimidin-6-yl)ethyl] benzoate Chemical compound C(C1=CC=CC=C1)(=O)O[C@H](C)C1=CC2=C(N=C(N=C2)SC)C(=N1)Cl POZNCJUASPQAMS-SNVBAGLBSA-N 0.000 description 2
- RNZXLANTCZBMLU-OAQYLSRUSA-N [(1R)-1-[2-[[5-(7-oxo-1,4-diazepan-1-yl)pyridin-2-yl]amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl]ethyl] benzoate Chemical compound C[C@@H](OC(=O)c1ccccc1)c1cc2cnc(Nc3ccc(cn3)N3CCNCCC3=O)nc2c(n1)N1CCCCC1 RNZXLANTCZBMLU-OAQYLSRUSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- MKCBRYIXFFGIKN-UHFFFAOYSA-N bicyclo[1.1.1]pentane Chemical compound C1C2CC1C2 MKCBRYIXFFGIKN-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical class OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 2
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N diisobutylaluminium hydride Substances CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 231100000025 genetic toxicology Toxicity 0.000 description 2
- 230000001738 genotoxic effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000002140 halogenating effect Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 102000054350 human CHI3L1 Human genes 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 2
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- DUBRVDSVZCWPCN-UHFFFAOYSA-N methyl 2-[[5-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]pyridin-2-yl]amino]-8-piperidin-1-ylpyrido[3,4-d]pyrimidine-6-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1CCN(CC1)C=1C=CC(=NC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)C(=O)OC)N1CCCCC1 DUBRVDSVZCWPCN-UHFFFAOYSA-N 0.000 description 2
- NCSXYVNCZAJQCV-UHFFFAOYSA-N methyl 2-methylsulfanyl-8-piperidin-1-ylpyrido[3,4-d]pyrimidine-6-carboxylate Chemical compound COC(=O)c1cc2cnc(SC)nc2c(n1)N1CCCCC1 NCSXYVNCZAJQCV-UHFFFAOYSA-N 0.000 description 2
- MYZJIEWTRJTWCD-UHFFFAOYSA-N methyl 5-bromo-2-methylsulfanylpyrimidine-4-carboxylate Chemical compound COC(=O)C1=NC(SC)=NC=C1Br MYZJIEWTRJTWCD-UHFFFAOYSA-N 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- CRSOQBOWXPBRES-UHFFFAOYSA-N neopentane Chemical compound CC(C)(C)C CRSOQBOWXPBRES-UHFFFAOYSA-N 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000016273 neuron death Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 2
- 125000002524 organometallic group Chemical group 0.000 description 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 2
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 2
- 229960004390 palbociclib Drugs 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 2
- 230000003439 radiotherapeutic effect Effects 0.000 description 2
- 229910052705 radium Inorganic materials 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229910052701 rubidium Inorganic materials 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- BELUUODUXKCIGQ-VXGBXAGGSA-N tert-butyl (3R,4R)-3-fluoro-4-(6-nitropyridin-3-yl)oxypiperidine-1-carboxylate Chemical compound F[C@@H]1CN(CC[C@H]1OC=1C=NC(=CC=1)[N+](=O)[O-])C(=O)OC(C)(C)C BELUUODUXKCIGQ-VXGBXAGGSA-N 0.000 description 2
- MIXODQAAOQHDTG-UHFFFAOYSA-N tert-butyl 4-(6-chloropyridazin-3-yl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=C(Cl)N=N1 MIXODQAAOQHDTG-UHFFFAOYSA-N 0.000 description 2
- SUWKOEMQNOBJEQ-UHFFFAOYSA-N tert-butyl 4-(6-nitropyridin-3-yl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=C([N+]([O-])=O)N=C1 SUWKOEMQNOBJEQ-UHFFFAOYSA-N 0.000 description 2
- VJBODLGQJYWHLB-UHFFFAOYSA-N tert-butyl 4-[6-(benzhydrylideneamino)pyridazin-3-yl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C(N=N1)=CC=C1N=C(C=1C=CC=CC=1)C1=CC=CC=C1 VJBODLGQJYWHLB-UHFFFAOYSA-N 0.000 description 2
- JCRGYAPMIOKAPD-UHFFFAOYSA-N tert-butyl 4-[6-[(6-formyl-8-morpholin-4-ylpyrido[3,4-d]pyrimidin-2-yl)amino]pyridin-3-yl]piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCN(CC1)c1ccc(Nc2ncc3cc(C=O)nc(N4CCOCC4)c3n2)nc1 JCRGYAPMIOKAPD-UHFFFAOYSA-N 0.000 description 2
- WDEXPNWPIAISNF-XMMPIXPASA-N tert-butyl 4-[6-[[6-[(1R)-1-benzoyloxyethyl]-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-2-yl]amino]pyridin-3-yl]-5-oxo-1,4-diazepane-1-carboxylate Chemical compound C[C@@H](OC(=O)c1ccccc1)c1cc2cnc(Nc3ccc(cn3)N3CCN(CCC3=O)C(=O)OC(C)(C)C)nc2c(n1)N1CCCCC1 WDEXPNWPIAISNF-XMMPIXPASA-N 0.000 description 2
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 2
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 2
- XSROQCDVUIHRSI-UHFFFAOYSA-N thietane Chemical compound C1CSC1 XSROQCDVUIHRSI-UHFFFAOYSA-N 0.000 description 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 2
- 229930192474 thiophene Natural products 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- JXPOLSKBTUYKJB-UHFFFAOYSA-N xi-2,3-Dimethylhexane Chemical compound CCCC(C)C(C)C JXPOLSKBTUYKJB-UHFFFAOYSA-N 0.000 description 2
- WGECXQBGLLYSFP-UHFFFAOYSA-N (+-)-2,3-dimethyl-pentane Natural products CCC(C)C(C)C WGECXQBGLLYSFP-UHFFFAOYSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- VSSRNQPRQJNGTL-UHFFFAOYSA-N (2-methylsulfanyl-8-morpholin-4-ylpyrido[3,4-d]pyrimidin-6-yl)methyl benzoate Chemical compound C(C1=CC=CC=C1)(=O)OCC1=CC2=C(N=C(N=C2)SC)C(=N1)N1CCOCC1 VSSRNQPRQJNGTL-UHFFFAOYSA-N 0.000 description 1
- ABEASYSZQOEURX-UHFFFAOYSA-N (2-methylsulfanyl-8-piperidin-1-ylpyrido[3,4-d]pyrimidin-6-yl)methyl benzoate Chemical compound CSc1ncc2cc(COC(=O)c3ccccc3)nc(N3CCCCC3)c2n1 ABEASYSZQOEURX-UHFFFAOYSA-N 0.000 description 1
- BXPVOXKLIXPTBZ-UHFFFAOYSA-N (5-bromo-2-methylsulfanylpyrimidin-4-yl)-methoxymethanol Chemical compound BrC=1C(=NC(=NC=1)SC)C(O)OC BXPVOXKLIXPTBZ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- NCNYEGJDGNOYJX-NSCUHMNNSA-N (e)-2,3-dibromo-4-oxobut-2-enoic acid Chemical compound OC(=O)C(\Br)=C(/Br)C=O NCNYEGJDGNOYJX-NSCUHMNNSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- ILROLYQPRYHHFG-UHFFFAOYSA-N 1-$l^{1}-oxidanylprop-2-en-1-one Chemical group [O]C(=O)C=C ILROLYQPRYHHFG-UHFFFAOYSA-N 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- QIJIUJYANDSEKG-UHFFFAOYSA-N 2,4,4-trimethylpentan-2-amine Chemical compound CC(C)(C)CC(C)(C)N QIJIUJYANDSEKG-UHFFFAOYSA-N 0.000 description 1
- GBBSAMQTQCPOBF-UHFFFAOYSA-N 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane Chemical compound CB1OB(C)OB(C)O1 GBBSAMQTQCPOBF-UHFFFAOYSA-N 0.000 description 1
- QTMAZYGAVHCKKX-UHFFFAOYSA-N 2-[(4-amino-5-bromopyrrolo[2,3-d]pyrimidin-7-yl)methoxy]propane-1,3-diol Chemical compound NC1=NC=NC2=C1C(Br)=CN2COC(CO)CO QTMAZYGAVHCKKX-UHFFFAOYSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
- SKCNYHLTRZIINA-UHFFFAOYSA-N 2-chloro-5-(chloromethyl)pyridine Chemical compound ClCC1=CC=C(Cl)N=C1 SKCNYHLTRZIINA-UHFFFAOYSA-N 0.000 description 1
- KAKCLWUKLSECEM-UHFFFAOYSA-N 2-ethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound C1=NC(CC)=CC=C1B1OC(C)(C)C(C)(C)O1 KAKCLWUKLSECEM-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- FFWASDWPUAKZQI-UHFFFAOYSA-N 2-methylsulfonylethyl 4-methylbenzenesulfonate Chemical compound CC1=CC=C(S(=O)(=O)OCCS(C)(=O)=O)C=C1 FFWASDWPUAKZQI-UHFFFAOYSA-N 0.000 description 1
- GUSWJGOYDXFJSI-UHFFFAOYSA-N 3,6-dichloropyridazine Chemical compound ClC1=CC=C(Cl)N=N1 GUSWJGOYDXFJSI-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 125000006618 5- to 10-membered aromatic heterocyclic group Chemical group 0.000 description 1
- CGSNAFXWSKLADR-UHFFFAOYSA-N 5-[[4-[2-[tert-butyl(diphenyl)silyl]oxyethyl]piperazin-1-yl]methyl]pyridin-2-amine Chemical compound [Si](C1=CC=CC=C1)(C1=CC=CC=C1)(C(C)(C)C)OCCN1CCN(CC1)CC=1C=CC(=NC=1)N CGSNAFXWSKLADR-UHFFFAOYSA-N 0.000 description 1
- JPGNEVZOYHXNLA-UHFFFAOYSA-N 5-bromo-2-methylsulfanylpyrimidine-4-carbaldehyde Chemical compound CSC1=NC=C(Br)C(C=O)=N1 JPGNEVZOYHXNLA-UHFFFAOYSA-N 0.000 description 1
- CGFYNRVHPARGFY-UHFFFAOYSA-N 5-fluoro-2-nitropyridine Chemical compound [O-][N+](=O)C1=CC=C(F)C=N1 CGFYNRVHPARGFY-UHFFFAOYSA-N 0.000 description 1
- XZGRUEIFRPTITR-UHFFFAOYSA-N 6-(4-methylpiperazin-1-yl)pyridazin-3-amine Chemical compound C1CN(C)CCN1C1=CC=C(N)N=N1 XZGRUEIFRPTITR-UHFFFAOYSA-N 0.000 description 1
- KDVBYUUGYXUXNL-UHFFFAOYSA-N 6-aminopyridine-3-carbonitrile Chemical compound NC1=CC=C(C#N)C=N1 KDVBYUUGYXUXNL-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 1
- AVOUFLVOSUCIRA-UHFFFAOYSA-N BrC=1C(=NC(=NC=1)C)C=S Chemical compound BrC=1C(=NC(=NC=1)C)C=S AVOUFLVOSUCIRA-UHFFFAOYSA-N 0.000 description 1
- VAKUSQBOHAREJM-UHFFFAOYSA-N BrC=1C(=NC(=NC=1)SC)COCO Chemical compound BrC=1C(=NC(=NC=1)SC)COCO VAKUSQBOHAREJM-UHFFFAOYSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100022595 Broad substrate specificity ATP-binding cassette transporter ABCG2 Human genes 0.000 description 1
- KVTCBSLOCYSWQT-UHFFFAOYSA-N CC(C)C1=N[I]=C(CN2CCN(C)CC2)C=C1 Chemical compound CC(C)C1=N[I]=C(CN2CCN(C)CC2)C=C1 KVTCBSLOCYSWQT-UHFFFAOYSA-N 0.000 description 1
- HRQBLYONPKWINY-UHFFFAOYSA-N CC(C)N(CC1)CCC1(F)F Chemical compound CC(C)N(CC1)CCC1(F)F HRQBLYONPKWINY-UHFFFAOYSA-N 0.000 description 1
- KLHSLNFJBDMFRF-UHFFFAOYSA-N CC(C)N(CCC1)CC1=[F] Chemical compound CC(C)N(CCC1)CC1=[F] KLHSLNFJBDMFRF-UHFFFAOYSA-N 0.000 description 1
- XLZMWNWNBXSZKF-UHFFFAOYSA-N CC(C)N1CCOCC1 Chemical compound CC(C)N1CCOCC1 XLZMWNWNBXSZKF-UHFFFAOYSA-N 0.000 description 1
- WCLSTFXEDVYDGD-INIZCTEOSA-N CC(C)[C@H]1NC(CCN(C2)C3CCCCC3)=C2C=C1 Chemical compound CC(C)[C@H]1NC(CCN(C2)C3CCCCC3)=C2C=C1 WCLSTFXEDVYDGD-INIZCTEOSA-N 0.000 description 1
- KWHBNVSMNKLFLR-UHFFFAOYSA-N CC(C)c(cc1)nc(C)c1N1CCN(C)CC1 Chemical compound CC(C)c(cc1)nc(C)c1N1CCN(C)CC1 KWHBNVSMNKLFLR-UHFFFAOYSA-N 0.000 description 1
- QZPJKQKBKPKNSX-UHFFFAOYSA-N CC(C)c(cc1)ncc1N1CCN(C)CC1 Chemical compound CC(C)c(cc1)ncc1N1CCN(C)CC1 QZPJKQKBKPKNSX-UHFFFAOYSA-N 0.000 description 1
- VPJBDGPLTMAXSG-UHFFFAOYSA-N CC(C)c(cc1)ncc1OC1CCNCC1 Chemical compound CC(C)c(cc1)ncc1OC1CCNCC1 VPJBDGPLTMAXSG-UHFFFAOYSA-N 0.000 description 1
- NBUVUAWVQBDKHA-UHFFFAOYSA-N CC(C)c1ccc(CN(CC2)C(C)C[N-]C)c2n1 Chemical compound CC(C)c1ccc(CN(CC2)C(C)C[N-]C)c2n1 NBUVUAWVQBDKHA-UHFFFAOYSA-N 0.000 description 1
- KXBTYFPKIANFHD-UHFFFAOYSA-N CC(C)c1ccc(CN(CC2COC2)CC2)c2n1 Chemical compound CC(C)c1ccc(CN(CC2COC2)CC2)c2n1 KXBTYFPKIANFHD-UHFFFAOYSA-N 0.000 description 1
- UNKYEHVTIPIDMZ-UHFFFAOYSA-N CC(C)c1ncc(C[N-]C[IH]N(C)C)cc1 Chemical compound CC(C)c1ncc(C[N-]C[IH]N(C)C)cc1 UNKYEHVTIPIDMZ-UHFFFAOYSA-N 0.000 description 1
- PFYPDUUXDADWKC-UHFFFAOYSA-N CC(C)c1ncccc1 Chemical compound CC(C)c1ncccc1 PFYPDUUXDADWKC-UHFFFAOYSA-N 0.000 description 1
- DJQIFLMHBCJCAI-UHFFFAOYSA-N CC1C2C1CC(C)C2 Chemical compound CC1C2C1CC(C)C2 DJQIFLMHBCJCAI-UHFFFAOYSA-N 0.000 description 1
- MYOMDBMKRUGPBS-NEKULIJUSA-N CSC(/N=C/C([C@@H]1C=COC1)N/C(/C(F)F)=C\C=C)=N Chemical compound CSC(/N=C/C([C@@H]1C=COC1)N/C(/C(F)F)=C\C=C)=N MYOMDBMKRUGPBS-NEKULIJUSA-N 0.000 description 1
- ZOCNQOMDGOPQSV-TZEQAPKZSA-N C[C@H](C(N=C(C1CC1)C1N2)=CC1N=C2S(C)=O)OC(C/C=C\C=C/C)=O Chemical compound C[C@H](C(N=C(C1CC1)C1N2)=CC1N=C2S(C)=O)OC(C/C=C\C=C/C)=O ZOCNQOMDGOPQSV-TZEQAPKZSA-N 0.000 description 1
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- FTLLMEBBPYSHIH-UHFFFAOYSA-N Cc1ncc(CN2CCN(CCOC)CC2)cc1 Chemical compound Cc1ncc(CN2CCN(CCOC)CC2)cc1 FTLLMEBBPYSHIH-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 102000002554 Cyclin A Human genes 0.000 description 1
- 108010068192 Cyclin A Proteins 0.000 description 1
- 102000003909 Cyclin E Human genes 0.000 description 1
- 108090000257 Cyclin E Proteins 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 108010093502 E2F Transcription Factors Proteins 0.000 description 1
- 102000001388 E2F Transcription Factors Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100030011 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 102000008016 Eukaryotic Initiation Factor-3 Human genes 0.000 description 1
- 108010089790 Eukaryotic Initiation Factor-3 Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229910004039 HBF4 Inorganic materials 0.000 description 1
- 101000823298 Homo sapiens Broad substrate specificity ATP-binding cassette transporter ABCG2 Proteins 0.000 description 1
- 101000934320 Homo sapiens Cyclin-A2 Proteins 0.000 description 1
- 101000715854 Homo sapiens Cyclin-dependent kinase 2 Proteins 0.000 description 1
- 101000715942 Homo sapiens Cyclin-dependent kinase 4 Proteins 0.000 description 1
- 101000911961 Homo sapiens Cyclin-dependent kinase 6 Proteins 0.000 description 1
- 101000604027 Homo sapiens Nuclear protein localization protein 4 homolog Proteins 0.000 description 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- NTRMCJGYLNJGAB-UHFFFAOYSA-N IN1C(CC2)CCC2C1 Chemical compound IN1C(CC2)CCC2C1 NTRMCJGYLNJGAB-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100348848 Mus musculus Notch4 gene Proteins 0.000 description 1
- 101100317378 Mus musculus Wnt3 gene Proteins 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102100038438 Nuclear protein localization protein 4 homolog Human genes 0.000 description 1
- XBRAAKHVHJRYBN-UHFFFAOYSA-N O-methyl 5-bromo-2-methylpyrimidine-4-carbothioate Chemical compound BrC=1C(=NC(=NC=1)C)C(=S)OC XBRAAKHVHJRYBN-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241001111421 Pannus Species 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 101000767160 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Intracellular protein transport protein USO1 Proteins 0.000 description 1
- 101100094105 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) NPL6 gene Proteins 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 102000018075 Subfamily B ATP Binding Cassette Transporter Human genes 0.000 description 1
- 108010091105 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- QUXXJWJRFDFBIC-OAQYLSRUSA-N [(1R)-1-[8-piperazin-1-yl-2-[[5-(piperazin-1-ylmethyl)pyridin-2-yl]amino]pyrido[3,4-d]pyrimidin-6-yl]ethyl] benzoate Chemical compound C(C1=CC=CC=C1)(=O)O[C@H](C)C1=CC2=C(N=C(N=C2)NC2=NC=C(C=C2)CN2CCNCC2)C(=N1)N1CCNCC1 QUXXJWJRFDFBIC-OAQYLSRUSA-N 0.000 description 1
- NGKYLPZUHZTIMZ-LJQANCHMSA-N [(1R)-1-[8-piperidin-1-yl-2-(5,6,7,8-tetrahydro-1,6-naphthyridin-2-ylamino)pyrido[3,4-d]pyrimidin-6-yl]ethyl] benzoate Chemical compound C(C1=CC=CC=C1)(=O)O[C@H](C)C1=CC2=C(N=C(N=C2)NC2=NC=3CCNCC=3C=C2)C(=N1)N1CCCCC1 NGKYLPZUHZTIMZ-LJQANCHMSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 150000005303 alkyl halide derivatives Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 1
- 229950010817 alvocidib Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 230000003286 arthritogenic effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000000668 atmospheric pressure chemical ionisation mass spectrometry Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WXNOJTUTEXAZLD-UHFFFAOYSA-L benzonitrile;dichloropalladium Chemical compound Cl[Pd]Cl.N#CC1=CC=CC=C1.N#CC1=CC=CC=C1 WXNOJTUTEXAZLD-UHFFFAOYSA-L 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- VIQRCOQXIHFJND-UHFFFAOYSA-N bicyclo[2.2.2]oct-2-ene Chemical compound C1CC2CCC1C=C2 VIQRCOQXIHFJND-UHFFFAOYSA-N 0.000 description 1
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical compound C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- ZFXVRMSLJDYJCH-UHFFFAOYSA-N calcium magnesium Chemical compound [Mg].[Ca] ZFXVRMSLJDYJCH-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 231100001157 chemotherapeutic toxicity Toxicity 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- CFBGXYDUODCMNS-UHFFFAOYSA-N cyclobutene Chemical compound C1CC=C1 CFBGXYDUODCMNS-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004976 cyclobutylene group Chemical group 0.000 description 1
- ZXIJMRYMVAMXQP-UHFFFAOYSA-N cycloheptene Chemical compound C1CCC=CCC1 ZXIJMRYMVAMXQP-UHFFFAOYSA-N 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000004956 cyclohexylene group Chemical group 0.000 description 1
- FNIATMYXUPOJRW-UHFFFAOYSA-N cyclohexylidene Chemical group [C]1CCCCC1 FNIATMYXUPOJRW-UHFFFAOYSA-N 0.000 description 1
- WJTCGQSWYFHTAC-UHFFFAOYSA-N cyclooctane Chemical compound C1CCCCCCC1 WJTCGQSWYFHTAC-UHFFFAOYSA-N 0.000 description 1
- 239000004914 cyclooctane Substances 0.000 description 1
- URYYVOIYTNXXBN-UPHRSURJSA-N cyclooctene Chemical compound C1CCC\C=C/CC1 URYYVOIYTNXXBN-UPHRSURJSA-N 0.000 description 1
- 239000004913 cyclooctene Substances 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000004979 cyclopentylene group Chemical group 0.000 description 1
- 125000004980 cyclopropylene group Chemical group 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000350 glycoloyl group Chemical group O=C([*])C([H])([H])O[H] 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000005216 haloheteroaryl group Chemical class 0.000 description 1
- 102000054634 human CDK2 Human genes 0.000 description 1
- 102000048992 human CDK4 Human genes 0.000 description 1
- 102000048993 human CDK6 Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 235000013847 iso-butane Nutrition 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical compound C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- CRGZYKWWYNQGEC-UHFFFAOYSA-N magnesium;methanolate Chemical compound [Mg+2].[O-]C.[O-]C CRGZYKWWYNQGEC-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- SDDKIZNHOCEXTF-UHFFFAOYSA-N methyl carbamimidothioate Chemical compound CSC(N)=N SDDKIZNHOCEXTF-UHFFFAOYSA-N 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- PKDBSOOYVOEUQR-UHFFFAOYSA-N mucobromic acid Natural products OC1OC(=O)C(Br)=C1Br PKDBSOOYVOEUQR-UHFFFAOYSA-N 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000006548 oncogenic transformation Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- FIYYMXYOBLWYQO-UHFFFAOYSA-N ortho-iodylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1I(=O)=O FIYYMXYOBLWYQO-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 208000030761 polycystic kidney disease Diseases 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- NBDHEMWCIUHARG-UHFFFAOYSA-N prop-2-ynyl benzoate Chemical compound C#CCOC(=O)C1=CC=CC=C1 NBDHEMWCIUHARG-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000021014 regulation of cell growth Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 102200082402 rs751610198 Human genes 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- QRUBYZBWAOOHSV-UHFFFAOYSA-M silver trifluoromethanesulfonate Chemical compound [Ag+].[O-]S(=O)(=O)C(F)(F)F QRUBYZBWAOOHSV-UHFFFAOYSA-M 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- BJYHKTCNIMBULR-UHFFFAOYSA-N spiro[3.3]hept-2-ene Chemical compound C1CCC21C=CC2 BJYHKTCNIMBULR-UHFFFAOYSA-N 0.000 description 1
- LBJQKYPPYSCCBH-UHFFFAOYSA-N spiro[3.3]heptane Chemical compound C1CCC21CCC2 LBJQKYPPYSCCBH-UHFFFAOYSA-N 0.000 description 1
- LMUMMJCCZMWLEN-UHFFFAOYSA-N spiro[3.3]heptyl Chemical group [CH]1CCC11CCC1 LMUMMJCCZMWLEN-UHFFFAOYSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- BOCYOPFQMUJTEG-VXGBXAGGSA-N tert-butyl (3R,4R)-4-(6-aminopyridin-3-yl)oxy-3-fluoropiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC[C@@H](Oc2ccc(N)nc2)[C@H](F)C1 BOCYOPFQMUJTEG-VXGBXAGGSA-N 0.000 description 1
- XRNLYXKYODGLMI-YUMQZZPRSA-N tert-butyl (3s,4s)-3-fluoro-4-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC[C@H](O)[C@@H](F)C1 XRNLYXKYODGLMI-YUMQZZPRSA-N 0.000 description 1
- LPZHKCVGWZFNDC-UHFFFAOYSA-N tert-butyl 2-chloro-7,8-dihydro-5h-1,6-naphthyridine-6-carboxylate Chemical compound ClC1=CC=C2CN(C(=O)OC(C)(C)C)CCC2=N1 LPZHKCVGWZFNDC-UHFFFAOYSA-N 0.000 description 1
- FCMLWBBLOASUSO-UHFFFAOYSA-N tert-butyl 3-oxopiperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNC(=O)C1 FCMLWBBLOASUSO-UHFFFAOYSA-N 0.000 description 1
- QBQVUQPRZYYTGL-UHFFFAOYSA-N tert-butyl 4-(6-aminopyridazin-3-yl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=C(N)N=N1 QBQVUQPRZYYTGL-UHFFFAOYSA-N 0.000 description 1
- RRCJBVSTRMKBGB-UHFFFAOYSA-N tert-butyl 4-(6-aminopyridin-3-yl)-3-oxopiperazine-1-carboxylate Chemical compound O=C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=C(N)N=C1 RRCJBVSTRMKBGB-UHFFFAOYSA-N 0.000 description 1
- FQLFLTDHELNXEX-UHFFFAOYSA-N tert-butyl 4-(6-aminopyridin-3-yl)-5-oxo-1,4-diazepane-1-carboxylate Chemical compound O=C1CCN(C(=O)OC(C)(C)C)CCN1C1=CC=C(N)N=C1 FQLFLTDHELNXEX-UHFFFAOYSA-N 0.000 description 1
- RMULRXHUNOVPEI-UHFFFAOYSA-N tert-butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=C(N)N=C1 RMULRXHUNOVPEI-UHFFFAOYSA-N 0.000 description 1
- ADUPCCFGSFHSEM-UHFFFAOYSA-N tert-butyl 4-(6-nitropyridin-3-yl)-3-oxopiperazine-1-carboxylate Chemical compound O=C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=C([N+]([O-])=O)N=C1 ADUPCCFGSFHSEM-UHFFFAOYSA-N 0.000 description 1
- UOIMSYSBTIGWJJ-UHFFFAOYSA-N tert-butyl 4-[(6-aminopyridin-3-yl)methyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1CC1=CC=C(N)N=C1 UOIMSYSBTIGWJJ-UHFFFAOYSA-N 0.000 description 1
- WSHKEFXXKBOHIX-UHFFFAOYSA-N tert-butyl 4-[6-[[6-(benzoyloxymethyl)-8-morpholin-4-ylpyrido[3,4-d]pyrimidin-2-yl]amino]pyridin-3-yl]piperazine-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1CCN(CC1)C=1C=NC(=CC=1)NC=1N=CC2=C(N=1)C(=NC(=C2)COC(C1=CC=CC=C1)=O)N1CCOCC1 WSHKEFXXKBOHIX-UHFFFAOYSA-N 0.000 description 1
- VJAHMDQRVLEOFG-UHFFFAOYSA-N tert-butyl 4-chlorosulfonylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(S(Cl)(=O)=O)CC1 VJAHMDQRVLEOFG-UHFFFAOYSA-N 0.000 description 1
- VHTGWHWKPHHGHK-UHFFFAOYSA-N tert-butyl-diphenyl-(2-piperazin-1-ylethoxy)silane Chemical compound C=1C=CC=CC=1[Si](C=1C=CC=CC=1)(C(C)(C)C)OCCN1CCNCC1 VHTGWHWKPHHGHK-UHFFFAOYSA-N 0.000 description 1
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- VOVUARRWDCVURC-UHFFFAOYSA-N thiirane Chemical compound C1CS1 VOVUARRWDCVURC-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- MWKJTNBSKNUMFN-UHFFFAOYSA-N trifluoromethyltrimethylsilane Chemical compound C[Si](C)(C)C(F)(F)F MWKJTNBSKNUMFN-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- BWHDROKFUHTORW-UHFFFAOYSA-N tritert-butylphosphane Chemical compound CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 238000012447 xenograft mouse model Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
Definitions
- the present invention relates to a pyrido[3,4-d]pyrimidine derivative and a pharmaceutically acceptable salt thereof.
- the present invention relates to a compound that exhibits an inhibitory activity against cyclin-dependent kinase 4 and/or cyclin-dependent kinase 6 (hereinafter referred to as "CDK4/6") and that is useful for the prevention or treatment of rheumatoid arthritis, arteriosclerosis, pulmonary fibrosis, cerebral infarction, or cancer.
- Cell growth which is a process involving proliferation and division of cells, occurs in response to various stimuli.
- Pathological conditions caused by hyperproliferation of cells are characterized by uncontrollable cell cycle progression and thus excessive progression of the cell cycle, for example, resulting from abnormality in genes or proteins that directly or indirectly regulate the cell cycle progression.
- Substances that regulate hyperproliferation of cells through control of the cell cycle can be used for the treatment of various pathological conditions characterized by uncontrollable or unwanted cell growth.
- Cyclin-dependent kinases and associated serine/threonine protein kinases are important intracellular enzymes that play essential roles in the regulation of division and proliferation of cells. Catalytic subunits of cyclin-dependent kinases are activated by regulatory subunits known as cyclins, and multiple cyclins have been identified in mammals (NPL1).
- the retinoblastoma (Rb) protein is a checkpoint protein for transition from the G1 phase to the S phase in the cell cycle.
- the Rb protein associates with the E2F transcription factor family and inhibits the activity thereof in the absence of appropriate growth stimulation (NPLs 2 and 3).
- NPLs 2 and 3 appropriate growth stimulation
- a cell stimulated by a mitogen enters the S phase through synthesis of cyclin D, which is a CDK4/6 activator.
- the cyclin D-bound CDK 4/6 inactivates the Rb protein through phosphorylation.
- the phosphorylation of the Rb protein releases E2F in order to indirective the transcription of a gene necessary for the S phase.
- cyclin D-CDK4/6 is an important enzyme complex which controls the transition from the G1 phase to the S phase.
- CDK2 forms a complex with cyclin E and also forms a complex with cyclin A. CDK2 also acts on steps subsequent to the S phase and is responsible for DNA replication. The inhibition of CDK2 probably leads to the expression of genotoxicity (NPL5).
- Cyclin D has a molecular mechanism that positively regulates the activity of CDK4/6.
- p16 encoded by the INK4a gene negatively regulates the activity of CDK4/6 (NPL6).
- CDK inhibitors can be used for the treatment of various diseases caused by abnormal cell growth, such as cancer, cardiovascular disorder, renal disease, specific infections, and autoimmune diseases. CDK inhibitors is also expected to be effective for the treatment of diseases including but not limited to rheumatoid arthritis, arteriosclerosis, pulmonary fibrosis, cerebral infarction, and cancer. The inhibition of cell cycle progression and cell growth through CDK inhibition is expected to be effective for such a disease on the basis of the technical findings described below.
- Rheumatoid arthritis involves the formation of pannus through hyperproliferation of synovial cells. This hyperproliferation can be reduced by the introduction of p16 into an affected area of a model animal or the administration of a CDK4/6 inhibitor to the animal (NPLs 7 to 9).
- a CDK4-cyclin D complex regulates the production of MMP3 in synovial cells derived from a patient with rheumatoid arthritis.
- the negative regulation of the activity of CDK4/6 inhibits not only the proliferation but also production of MMP3 (NPL10).
- CDK4/6 inhibitors are expected to exhibit both an inhibitory effect on proliferation of synovial cells and a cartilage protective effect in rheumatoid arthritis.
- the overexpression of the CDK inhibitory protein p21 inhibits angiogenesis and subsequent growth of vascular smooth muscle and intimal hyperplasia (NPLs 11 and 12).
- Abnormal regulation of the cell cycle is also associated with polycystic kidney disease, which is characterized by growth of cysts filled with fluid in the renal tubule.
- a small-molecule CDK inhibitor is effective for the treatment of the disease (NPL13).
- the induction of expression of the cell cycle inhibitory protein p21 with an adenoviral vector is effective in a murine pulmonary fibrosis model (NPL14).
- the level of cyclin D1/CDK4 is known to increase in a rat cerebral infarction model in association with neuronal death caused by local ischemia.
- the neuronal death is reduced by administering flavopiridol, which is a nonselective CDK inhibitor (NPL15).
- the cyclin D-CDK4/6-INK4a-Rb pathway is frequently detected in human cancer caused by abnormality of any factors contributing to growth of cancer cells, such as loss of functional p16INK4a, overexpression of cyclin D1, overexpression of CDK4, or loss of functional Rb (NPLs 16 to 18).
- abnormality promotes the cell cycle progression from the G1 phase to the S phase, and this pathway certainly plays an important role in oncogenic transformation or abnormal growth of cancer cells.
- CDK4/6 inhibitors may be effective, particularly for tumors involving abnormality in genes that activate the CDK4/6 kinase activity, such as cancers involving the translocation of cyclin D, cancers involving the amplification of cyclin D, cancers involving the amplification or overexpression of CDK4 or CDK6, and cancers involving the inactivation of p16.
- CDK4/6 inhibitors may be effective for the treatment of cancers involving genetic abnormality in the upstream regulator of cyclin D, the amount of which increases due to defects in the upstream regulator.
- Glioblastoma which is a glioma manifesting a high degree of malignancy, is known to be one of the tumors on which a CDK4/6 inhibitor is expected to exert a therapeutic effect.
- a CDK4/6 inhibitor has been shown to exhibit an antiproliferative effect on the cell line derived from glioblastoma.
- it is necessary to cause migration from the blood via the blood brain barrier into the brain, or to carry out administration without transfer via the blood flow, such as intracerebral administration, intracerebral implant device, or intranasal administration.
- efflux transporters such as P-glycoproteins and BCRP.
- CDK4/6 inhibitor causes temporary cell cycle arrest to hematopoietic stem and progenitor cells, and protects them from radiotherapeutic or chemotherapeutic cytotoxicity. After the treatment with the inhibitor, hematopoietic stem and progenitor cells (HSPCs) return from the temporary dormancy and then function normally.
- HSPCs hematopoietic stem and progenitor cells
- CDK4/6 inhibitors are expected to be effective for the treatment of rheumatoid arthritis, arteriosclerosis, pulmonary fibrosis, cerebral infarction, or cancer, and the protection of bone marrow, in particular, for the treatment of rheumatoid arthritis or cancer and the protection of bone marrow.
- PTL1 and NPL21 disclose CDK4 inhibitors
- PTLs 2,3, 7 and 8 and NPLs 22 to 24 disclose CDK4/6-containing CDK inhibitors
- NPL25 discloses CDK4/FLT3 inhibitors.
- Pyrido[3,4-d]pyrimidine derivatives exhibit an inhibitory effect on Mps1 (also known as TTK) (PTL4 and PTL 6). This inhibitory effect is completely different from the CDK4/6 inhibitory effect disclosed in the present invention.
- NPL26 and NPL27 disclose that a plurality of pyrido[3,4-d]pyrimidine derivatives exhibit a CDK2 inhibitory activity, which is completely different from the superior CDK4/6 inhibitory effect exhibited by the present invention.
- PTL5 describes pyrido[3,4-d]pyrimidine derivatives known to exhibit EGFR inhibitory effects, which are completely different from the CDK4/6 inhibitory effects according to the present invention.
- An object of the present invention is to provide a compound exhibiting a superior CDK4/6 inhibitory activity.
- the present inventors have conducted extensive studies for solving the problems described above and have found that a novel pyrido[3,4-d]pyrimidine derivative represented by Formula (I) exhibits a CDK4/6 inhibitory activity.
- the present invention has been accomplished on the basis of this finding.
- the present invention includes the following aspects:
- Preferred embodiments of the compound represented by formula (I) or the pharmaceutically acceptable salt thereof as claimed in claim 1 are the subject of the dependent claims 2 to 11.
- the present invention further relates to a pharmaceutical composition, in particular one having CDK4/6 inhibitory activity, comprising such compound or pharmaceutically acceptable salt thereof as claimed in claims 12 and 13.
- the present invention relates to such compound or pharmaceutically acceptable salt thereof for use in the prevention or treatment of rheumatiod arthritis, artheriosclerosis, pulmonary fibrosis, cerebral infarction, or cancer. This is the subject of claim 14.
- the present invention pertains to a pyrido[3,4-d]pyrimidine derivative represented by one of the formulae (II), (III) or (IV) or a salt thereof as claimed in claim 15.
- the compound of the present invention exhibits a superior CDK4/6 inhibitory activity and is useful as a drug for prevention or treatment of rheumatoid arthritis, arteriosclerosis, pulmonary fibrosis, cerebral infarction, or cancer.
- (cycloalkyl)-alkyl refers to a cycloalkyl group bonded to an alkyl group such that the alkyl group is bonded to a structure other than the cycloalkyl group.
- heterocyclyl-alkyl refers to a heterocyclyl group bonded to an alkyl group such that the alkyl group is bonded to a structure other than the heterocyclyl group.
- C 3-6 cycloalkyl group substituted with zero to two -OH groups, zero to two C 1-8 alkoxy groups, and zero to six fluorine atoms refers to the case where the C 3-6 cycloalkyl group is substituted with the following substituents: zero to two -OH groups, zero to two C 1-8 alkoxy groups, and zero to six fluorine atoms.
- Examples of the substituted C 3-6 cycloalkyl group include a C 3-6 cycloalkyl group substituted with two -OH groups, one C 1-8 alkoxy group, and three fluorine atoms; a C 3-6 cycloalkyl group substituted with two C 1-8 alkoxy groups and four fluorine atoms; and a C 3-6 cycloalkyl group substituted with one -OH group, and the like.
- the C 3-6 cycloalkyl group is not substituted in the case where the number of all the substituents is zero. Moreover, as for the number of substituents, chemically possible numbers are allowed. For example, the statement "C 1 alkyl substituted with zero to six fluorine atoms" actually means "C 1 alkyl substituted with zero to three fluorine atoms".
- C 1-8 refers to a group having one to eight carbon atoms
- C 1-6 refers to a group having one to six carbon atoms
- 5- to 10-membered refers to a structure having 5 to 10 carbon atoms
- 5- or 6-membered refers to a structure having five or six carbon atoms.
- alkyl refers to a monovalent group obtained by removal of one hydrogen atom from an alkane at any carbon atom.
- alkylene refers to a divalent group obtained by removal of two hydrogen atoms from an alkane at any two different carbon atoms.
- alkane refers to a saturated aliphatic hydrocarbon.
- C 1-8 alkyl refers to a linear or branched hydrocarbon group having one to eight carbon atoms.
- Examples of the C 1-8 alkyl include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, neopentyl, isopentyl, 1,2-dimethylpropyl, n-hexyl, isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, isoheptyl, n-octyl, isooctyl, and the like.
- the alkane of "C 1-8 alkylene” as used herein refers to a linear or branched hydrocarbon having one to eight carbon atoms.
- Examples of the alkane include methane, ethane, propane, n-butane, 2-methylpropane, n-pentane, 2,2-dimethylpropane, n-hexane, 2-methylpentane, 3-methylpentane, 2,2-dimethylbutane, 2,3-dimethylbutane, n-heptane, 2,2-dimethylhexane, 2,3-dimethylhexane, n-octane, 2-methylheptane, and the like.
- cycloalkyl refers to a monovalent group obtained by removal of one hydrogen atom from a cycloalkane at any carbon atom.
- cycloalkenyl refers to a monovalent group obtained by removal of one hydrogen atom from a cycloalkene at any carbon atom.
- cycloalkylene refers to a divalent group obtained by removal of two hydrogen atoms from a cycloalkane at any two different carbon atoms.
- cycloalkylidene refers to a divalent group obtained by removal of two hydrogen atoms from a cycloalkane at any one carbon atom.
- cycloalkane refers to an alicyclic hydrocarbon.
- the cycloalkane of "C 3-12 cycloalkyl,” “C 3-12 cycloalkylene,” or “C 3-12 cycloalkylidene” as used herein refers to a monocyclic or polycyclic 3- to 12- membered aliphatic hydrocarbon ring system.
- Specific examples of the cycloalkane include cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, spiro[3.3]heptane, bicyclo[1.1.1]pentane, bicyclo[2.2.2]octane, adamantane, and the like.
- the cycloalkene of "C 4-12 cycloalkenyl” as used herein refers to a monocyclic or polycyclic 4- to 12-membered aliphatic hydrocarbon ring system.
- Specific examples of the cycloalkene include cyclobutene, cyclopentene, cyclohexene, cycloheptene, cyclooctene, spiro[3.3]heptene, and bicyclo[2.2.2]octene.
- heterocyclyl refers to a monovalent group obtained by removal of one hydrogen atom from a heterocycle at any carbon or nitrogen atom.
- heterocyclylene refers to a divalent group obtained by removal of two hydrogen atoms from a heterocycle at any two different carbon or nitrogen atoms.
- heterocyclylidene refers to a divalent group obtained by removal of two hydrogen atoms from a heterocycle at any one carbon atom.
- heterocycle refers to a partially or fully aliphatic ring system which contains one or more heteroatoms selected from sulfur, nitrogen, and oxygen atoms.
- heterocycle of "4- to 12-membered heterocyclyl,” “4- to 12-membered heterocyclylene,” or “4- to 12-membered heterocyclylidene” as used herein refers to "4- to 12-membered heterocycloalkane," “4- to 12-membered heterocycloalkane” having an unsaturated bond, a 4- to 12-membered ring system composed of a heterocycloalkane and a heteroarene or arene bonded to a portion of the heterocycloalkane, a 4- to 12-membered ring system composed of a cycloalkane and a heteroarene bonded to a portion of the cycloalkane, a 4- to 12-membered ring system containing a heteroatom and having a spiro structure, or a 4- to 12-membered ring system containing a heteroatom and having a cross-linked structure.
- 4- to 12-membered heterocycloalkane refers to a 4- to 12-membered cyclic heteroalkane; i.e., a monocyclic or polycyclic aliphatic hydrocarbon ring system containing one to four heteroatoms selected from sulfur, nitrogen, and oxygen atoms.
- the "4- to 12-membered heterocycloalkane” include aziridine, thiirane, azetidine, oxetane, thietane, tetrahydrofuran, tetrahydropyran, 1,4-dioxane, piperidine, piperazine, pyrrolidine, imidazolidine, pyrazolidine, morpholine, thiomorpholine, tetrahydrothiopyran, tetrahydrothiophene, 1,4-diazepane, oxepane, and the like.
- a compound having a "spiro structure” is composed of two cyclic structures (cycloalkanes or heterocycloalkanes) that are bonded to one common carbon atom.
- the compound include 2-azaspiro[3.3]heptane, 1,6-diazaspiro[3.3]heptane, 2,6-diazaspiro[3.3]heptane, 2,6-diazaspiro[3.4]octane, 2,7-diazaspiro[3.5]nonane, 1,7-diazaspiro[4.5]decane, 2,8-diazaspiro[4.5]decane, 4,7-diazaspiro[2.5]octane, and the like.
- a compound having a "cross-linked structure” is composed of two cyclic structures (cycloalkanes and heterocycloalkanes) that are bonded to two or more common carbon, nitrogen, or oxygen atoms.
- Examples of the compound include 2,5-diazabicyclo[2.2.2]octane, 3,8-diazabicyclo[3.2.1]octane, 1,4-diazabicyclo[3.2.2]nonane, octahydropyrrolo[3,4-b]pyrrole, and the like.
- aryl refers to a monovalent group obtained by removal of one hydrogen atom from an arene at any carbon atom.
- arylene refers to a divalent group obtained by removal of two hydrogen atoms from an arene at any two different carbon atoms.
- arene refers to an aromatic hydrocarbon
- C 6-10 aryl or “C 6-10 arylene” as used herein refers to an aromatic hydrocarbon ring system having six to ten carbon atoms.
- Specific examples of the arene include benzene, naphthalene, and the like.
- heteroaryl refers to a monovalent group obtained by removal of one hydrogen atom from a heteroarene at any carbon or nitrogen atom.
- heteroarylene refers to a divalent group obtained by removal of two hydrogen atoms from a heteroarene at any two different carbon or nitrogen atoms.
- heteroene refers to an aromatic heterocyclic ring system containing a heteroatom selected from sulfur, nitrogen, and oxygen atoms.
- heteroarene of "5- to 10-membered heteroaryl” or “5- to 10-membered heteroarylene” as used herein refers to a 5- to 10-membered aromatic heterocyclic ring system containing one to four heteroatoms selected from sulfur, nitrogen, and oxygen atoms.
- heteroarene examples include furan, thiophene, pyrrole, imidazole, pyrazole, triazole, tetrazole, thiazole, oxazole, isoxazole, oxadiazole, thiadiazole, isothiazole, pyridine, pyridazine, pyrazine, pyrimidine, quinolone, isoquinolone, benzofuran, benzothiophene, indole, indazole, benzimidazole, and the like.
- (4- to 12-membered heterocyclyl)-C 1-6 alkyl refers to a 4- to 12-membered heterocyclyl group bonded to a C 1-6 alkyl group such that the C 1-6 alkyl group is bonded to a structure other than the 4- to 12-membered heterocyclyl group.
- Specific examples of the (4- to 12-membered heterocyclyl)-C 1-6 alkyl include groups prepared by bonding of any of the above-exemplified 4- to 12-membered heterocyclyl groups to any of the above-exemplified C 1-6 alkyl groups.
- (C 6-10 aryl)-C 1-6 alkyl refers to a C 6-10 aryl group bonded to a C 1-6 alkyl group such that the C 1-6 alkyl group is bonded to a structure other than the C 6-10 aryl group.
- Specific examples of the (C 6-10 aryl)-C 1-6 alkyl include groups prepared by bonding of any of the above-exemplified C 6-10 aryl groups to any of the above-exemplified C 1-6 alkyl groups.
- (5- to 10-membered heteroaryl)-C 1-6 alkyl refers to a 5- to 10-membered heteroaryl group bonded to a C 1-6 alkyl group such that the C 1-6 alkyl group is bonded to a structure other than the 5- to 10-membered heteroaryl group.
- Specific examples of the (5- to 10-membered heteroaryl)-C 1-6 alkyl include groups prepared by bonding of any of the above-exemplified 5- to 10-membered heteroaryl groups to any of the above-exemplified C 1-6 alkyl groups.
- C 1-8 acyl refers to a C 1-7 alkyl group bonded to a carbonyl (-CO-) group such that the carbonyl group is bonded to a structure other than the C 1-7 alkyl group.
- halogen refers to fluorine, chlorine, bromine, or iodine atom.
- C 1-8 alkoxy refers to a linear, branched, or cyclic alkoxy group having one to eight carbon atoms.
- Specific examples of the C 1-8 alkoxy include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentyloxy, neopentyloxy, tert-pentyloxy, 2-methylbutoxy, n-hexyloxy, isohexyloxy, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy, cyclooctyloxy, spiro[3.3]heptyloxy, bicyclo[2.2.2]octyloxy, and the like.
- the "C 3-12 cycloalkyl" of R 1 is preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, spiro[3.3]heptyl, bicyclo[1.1.1]pentane, bicyclo[2.2.2]octyl, or adamantyl.
- the "C 3-12 cycloalkenyl" of R 1 is preferably cyclopentenyl, cyclohexenyl, or cycloheptenyl.
- the heterocycle of "4- to 12-membered heterocyclyl" in R 1 is preferably azetidine, oxetane, thietane, tetrahydrofuran, 1,4-dioxane, morpholine, thiomorpholine, tetrahydropyran, tetrahydrothiophene, or oxepane.
- the "C 6-10 aryl" of R 1 is preferably phenyl.
- the "5- to 10-membered heteroaryl" of R 1 is preferably furanyl, pyrazolyl, or thienyl.
- halogen in the substituent of R 1 is preferably fluorine or chlorine atom.
- the "-COOR 6 " in the substituent of R 1 is preferably -COOH or -COOCH 3 .
- R 7 in the substituent of R 1 is preferably methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, neopentyl, isopentyl, 1,1-dimethyl-2-methoxyethyl, 1-methyl-2-methoxyethyl, 1-methyl-2-hydroxyethyl, 2,2,2-trifluoroethyl, hydroxymethyl, or 1-methyl-2,2,2-trifluoroethyl.
- C 3-6 cycloalkyl substituted with [zero to two -OH groups, zero to two C 1-8 alkoxy groups, and zero to six fluorine atoms] in the substituent of R 1 is preferably cyclopentyl, cyclohexyl, 4-methoxycyclohexyl, or 4-isopropoxycyclohexyl.
- the 3- to 10-membered heterocyclyl substituted with [zero to two -OH groups, zero to two C 1-8 alkoxy groups, and zero to six fluorine atoms] in the substituent of R 1 is preferably tetrahydrofuranyl, tetrahydropyranyl, or 2,2-dimethyltetrahydropyranyl.
- R 1 preferably has any of the following structures:
- the "C 1-8 alkyl" of R 2 is preferably methyl, ethyl, or n-propyl, and the substituent is preferably hydroxy, methoxy, or ethoxy group or fluorine atom.
- the "C 3-8 cycloalkyl" of R 2 is preferably cyclopropyl, and the substituent is preferably hydroxy or hydroxymethyl group or fluorine atom.
- the "4- to 6-membered heterocyclyl" of R 2 is preferably oxetanyl or tetrahydro furanyl.
- the "C 1-8 acyl" of R 2 is preferably acetyl.
- the "-COOR 8 " of R 2 is preferably -COOH or -COOCH 3 .
- the "-CONR 9 R 10 " of R 2 is preferably -CON(CH 3 ) 2 .
- R 9 and R 10 of -CONR 9 R 10 of R 2 are optionally bonded via single bond or -O- to form a ring including the nitrogen atom bonded to R 9 and R 10 .
- Examples of such a ring include the following structures:
- Entire R 2 preferably has any of the following structures:
- the "C 1-8 alkyl" of R 3 is preferably methyl.
- the "halogen" of R 3 is preferably fluorine or chlorine atom.
- R 3 is preferably hydrogen, fluorine, or chlorine atom or methyl group.
- R 11 is preferably hydrogen atom or methyl, ethyl, or cyclopropyl group.
- the "C 1-8 alkylene" of A 1 is preferably methylene, ethylene, or n-propylene.
- the structure obtained by replacement of one or two sp 3 carbon atoms at any positions of A 1 is preferably -O-, -OCH 2 -, -OCH 2 CH 2 -, -OCH 2 CH 2 CH 2 -, -CH 2 O-, -CH 2 OCH 2 -, - CH 2 OCH 2 CH 2 -, -CH 2 CO-, -COCH 2 -, -CH 2 CH 2 CO-, -COCH 2 CH 2 -, -CH 2 COCH 2 -, - CH 2 COCH 2 CH 2 -, -NR 14 -, -NR 14 CH 2 -, -CH 2 NR 14 -, -NR 14 CH 2 CH 2 -, -CH 2 NR 14 CH 2 -, or - CH 2 CH 2 NR 14 -.
- the "C 1-7 alkylene" of A 2 is preferably methylene, ethylene, or n-propylene.
- the "C 3-12 cycloalkylene" of A 2 is preferably cyclopropylene, cyclobutylene, cyclopentylene, or cyclohexylene.
- the "C 3-12 cycloalkylidene" of A 2 is preferably cyclopropylidene, cyclobutylidene, cyclopentylidene, or cyclohexylidene.
- the heterocycle of "4- to 12-membered heterocyclylene" of A 2 is preferably piperidine, piperazine, pyrrolidine, morpholine, tetrahydrofuran, tetrahydropyran, 1,4-diazepane, oxepane, 2-azaspiro[3.3]heptane, 1,6-diazaspiro[3.3]heptane, 2,6-diazaspiro[3.3]heptane, 2,6-diazaspiro[3.4]octane, 2,5-diazabicyclo[2.2.2]octane, 3,8-diazabicyclo[3.2.1]octane, 2,7-diazaspiro[3.5]nonane, 1,7-diazaspiro[4.5]decane, 2,8-diazaspiro[4.5]decane, 4,7-diazaspiro[2.5]octane, 1,4-diazabicy
- the heterocycle of "4- to 12-membered heterocyclylidene" of A 2 is preferably oxetane, tetrahydrofuran, tetrahydropyran, pyrrolidine, piperidine, piperazine, morpholine, or oxepane.
- the "C 6-10 arylene" of A 2 is preferably phenylene.
- the heteroarene of "5- to 10-membered heteroarylene" of A 2 is preferably furan, thiophene, pyrrole, imidazole, pyrazole, triazole, tetrazole, thiazole, oxazole, isoxazole, oxadiazole, thiadiazole, isothiazole, pyridine, pyridazine, pyrazine, pyrimidine, quinolone, isoquinoline, benzofuran, benzothiophene, indole, indazole, or benzimidazole.
- the "halogen" of A 3 is preferably a fluorine or chlorine atom.
- the "-R 25 " of A 3 is a hydrogen atom or a methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, or tert-butyl group.
- the -R 25 substituted with a substituent is preferably a hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 2-hydroxy-2-propyl, 2-hydroxy-1-propyl, 1-hydroxy-2-propyl, 1-hydroxy-2-methyl-2-propyl, 2-hydroxy-2-methyl-1-propyl, trifluoromethyl, 2,2,2-trifluoroethyl, carboxymethyl, 1-carboxyethyl, 2-carboxyethyl, 2-carboxy-2-propyl, or cyanomethyl group.
- the "-OR 26 " of A 3 is preferably -OH, methoxy, ethoxy, or isopropoxy.
- the "-NR 27 R 28 " of A 3 is preferably amino, dimethylamino, methylamino, pyrrolidin-1-yl, piperidin-1-yl, piperazin-1-yl, or morpholin-1-yl.
- Examples of such a ring include the following structures:
- Examples of such a ring include the following structures:
- a compound having one or more preferred group is a preffered compound, and a combination of preferred groups also gives a preffered compound.
- Examples of the protective group suitable for protecting -OH of R 1 , R 2 , and R 4 as used herein include acetyl, benzoyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, benzyl, 4-methoxybenzyl, 2,4-dimethoxybenzyl, (methoxy)methyl, or 2-(trimethylsilyl)ethoxymethyl and the like.
- Examples of the protective group suitable for protecting NH amino, alkylamino, and nitrogen-containing heteroaryl of R 1 and R 4 as used herein include tert-butoxycarbonyl, benzyloxycarbonyl, benzyl, 4-methoxybenzyl, 2,4-dimethoxybenzyl, trifluoroacetyl, or 2-(trimethylsilyl)ethoxymethyl and the like.
- the compound of the present invention represented by Formula (I) may optionally be formed into a pharmaceutically acceptable salt.
- the salt include salts with inorganic acids, such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, carbonic acid, and the like; salts with organic acids, such as formic acid, acetic acid, propionic acid, trifluoroacetic acid, phthalic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, benzoic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, and the like; salts with amino acids, such as lysine, arginine, ornithine, glutamic acid, aspartic acid, and the like; salts with alkali metal
- the present invention also encompasses compounds prepared through replacement of one or more atoms of the compound represented by Formula (I) with stable isotopes or radioisotopes.
- the present invention also encompasses stereoisomers, racemates, and all acceptable optical isomers of the compound represented by Formula (I).
- Tautomers of the compound of the present invention may be generated depending on the combination of substituents.
- the present invention also encompasses such tautomers.
- R 1 , R 2 , R 3 , and R 4 shown in the following reaction schemes are as defined in Formula (I).
- the reagents or solvents and the like shown in the reaction schemes are for illustrative purposes only as described below.
- Each substituent may optionally be protected with an appropriate protective group or deprotected in an appropriate step (reference: PROTECTIVE GROUPS in ORGANIC SYNTHESIS, 4TH EDITION, John Wiley & Sons, Inc. ).
- the abbreviations of substituents, reagents, and solvents described below and in tables are as follows:
- Compound I-e which is a known compound, can be synthesized by any process known to those skilled in the art; for example, the aforementioned process.
- Compound I-e is reacted with a terminal alkyne derivative represented by the formula R 2 -C ⁇ CH in an appropriate organic solvent (e.g., THF or DMF) in the presence of an appropriate palladium catalyst (e.g., tetrakis(triphenylphosphin)palladium), appropriate copper catalyst (e.g., copper iodide (I)) and appropriate base (e.g., triethylamine) at a temperature of 0°C to the reflux temperature of the solvent, to yield compound I-f.
- an appropriate palladium catalyst e.g., tetrakis(triphenylphosphin)palladium
- appropriate copper catalyst e.g., copper iodide (I)
- base e.g., triethylamine
- Compound I-f is reacted with hydroxylamine or a salt thereof in an appropriate organic solvent (e.g., ethanol) in the presence or absence of an appropriate base (e.g., sodium acetate) at a temperature of 0°C to the reflux temperature of the solvent.
- an appropriate organic solvent e.g., ethanol
- an appropriate base e.g., sodium acetate
- the resultant hydroxyimine compound is reacted with an appropriate acid or base (e.g., silver triflate or potassium carbonate) to yield compound I-h.
- an appropriate acid or base e.g., silver triflate or potassium carbonate
- Compound I-h is reacted with an appropriate halogenating agent (e.g., thionyl chloride) in an appropriate organic solvent (e.g., dichloromethane) or under solvent-free conditions at a temperature of 0°C to 140°C, to yield compound I-i.
- an appropriate halogenating agent e.g., thionyl chloride
- an appropriate organic solvent e.g., dichloromethane
- R'-Y is a cyclic secondary amine derivative
- compound I-i is reacted with a cyclic secondary amine derivative represented by the formula R 1 -Y in an appropriate organic solvent (e.g., THF or 1,4-dioxane) or under solvent-free conditions in the presence or absence of an appropriate base (e.g., triethylamine, potassium carbonate, or sodium hydride) at a temperature within the range from 0°C to the reflux temperature of the solvent, to yield compound I-j.
- an appropriate organic solvent e.g., THF or 1,4-dioxane
- an appropriate base e.g., triethylamine, potassium carbonate, or sodium hydride
- R'-Y is an organometallic reagent such as a boric acid derivative
- compound I-i is reacted with an organometallic reagent represented by formula R'-Y such as a boric acid derivative, in the presence of an appropriate catalyst (e.g., palladium acetate or palladium chloride), in the presence or absence of an appropriate ligand (e.g., triphenylphosphine, BINAP, or dppf), in the presence or absence of an appropriate base (e.g., triethylamine, potassium carbonate , sodium hydride), in an appropriate organic solvent (e.g., THF or 1,4-dioxane), at a temperature within the range from 0°C to the reflux temperature of the solvent, to yield compound I-j.
- an appropriate catalyst e.g., palladium acetate or palladium chloride
- an appropriate ligand e.g., triphenylphosphine, BINAP, or dpp
- R 2 may be modified by any process known to those skilled in the art in view of the intended structure of the compound.
- Compound I-j is reacted with an appropriate oxidant (e.g., Oxone (R) or m-chloroperbenzoic acid) in an appropriate organic solvent (e.g., dichloromethane or water) at a temperature of 0°C to the reflux temperature of the solvent, to yield compound I-k.
- an appropriate oxidant e.g., Oxone (R) or m-chloroperbenzoic acid
- an appropriate organic solvent e.g., dichloromethane or water
- Compound I-j or compound I-k is reacted with an appropriate halogenating agent (e.g., N-chlorosuccinimide) in an appropriate organic solvent (e.g., dichloromethane or 1,2-dichloroethane) at a temperature within the range from 0°C to the reflux temperature of the solvent, to yield compound I-1.
- an appropriate halogenating agent e.g., N-chlorosuccinimide
- organic solvent e.g., dichloromethane or 1,2-dichloroethane
- Compound I-1 is reacted with an amine derivative represented by the formula R 4 -(nitrogen-containing heteroaryl with X)-NH 2 in an appropriate organic solvent (e.g., NMP, THF, or toluene) or under solvent-free conditions in the presence or absence of an appropriate base (e.g., sodium hydride, triethylamine, or N,N-diisopropyl-N-ethylamine) at a temperature of 0°C to the reflux temperature of the solvent, to yield compound I-m.
- an appropriate organic solvent e.g., NMP, THF, or toluene
- an appropriate base e.g., sodium hydride, triethylamine, or N,N-diisopropyl-N-ethylamine
- deprotection can be performed by any process known to those skilled in the art.
- deprotection can be performed through reaction of the compound with an appropriate deprotecting reagent (e.g., TFA or hydrogen chloride for a Boc protective group, lithium hydroxide for a benzoyl protective group, or hydrogen in the presence of Pd/C for a Cbz protective group) in an appropriate organic solvent (e.g., dichloromethane, methanol, or THF) or under solvent-free conditions at a temperature of 0°C to the reflux temperature of the solvent (reference: Green's Protective Groups in Organic Synthesis, 4th edition, John Wiley & Sons Inc. ).
- an appropriate deprotecting reagent e.g., TFA or hydrogen chloride for a Boc protective group, lithium hydroxide for a benzoyl protective group, or hydrogen in the presence of Pd/C for a Cbz protective group
- organic solvent e.g., dichloromethane, methanol, or T
- Compound I-m in which R 4 has a primary or secondary amine structure is reacted with an optionally substituted epoxide in an appropriate organic solvent (e.g., dichloromethane, NMP, or THF) in the presence or absence of an appropriate acid (e.g., boron trifluoride-diethyl ether complex) or an appropriate base (e.g., potassium carbonate or triethylamine) at a temperature of 0°C to the reflux temperature of the solvent, to yield compound I-n.
- an appropriate organic solvent e.g., dichloromethane, NMP, or THF
- an appropriate acid e.g., boron trifluoride-diethyl ether complex
- an appropriate base e.g., potassium carbonate or triethylamine
- Compound I-m in which R 4 has a primary or secondary amine structure is reacted with a carboxylic acid chloride, a carboxylic anhydride, or a carboxylic acid and a condensation reagent in an appropriate organic solvent (e.g., NMP, THF, or pyridine) in the presence or absence of an appropriate base (e.g., triethylamine or N,N-diisopropyl-N-ethylamine) at a temperature of 0°C to the reflux temperature of the solvent, to yield compound I-o.
- an appropriate organic solvent e.g., NMP, THF, or pyridine
- an appropriate base e.g., triethylamine or N,N-diisopropyl-N-ethylamine
- R represents a hydrogen atom, C 1-8 alkyl, 4- to 12-membered heterocyclyl, C 3-12 cycloalkyl, C 6-10 aryl, 5- to 10-membered heteroaryl, (4- to 12-membered heterocyclyl)C 1-3 alkyl, (C 3-12 cycloalkyl)C 1-3 alkyl, (C 6-10 aryl)C 1-3 alkyl, or (5-to 10-membered heteroaryl)C 1-3 alkyl.
- Compound I-m in which R 4 has a primary or secondary amine structure is reacted with sulfonic acid chloride in an appropriate organic solvent (e.g., NMP, THF, or pyridine) in the presence or absence of an appropriate base (e.g., triethylamine or N,N-diisopropyl-N-ethylamine) at a temperature of 0°C to the reflux temperature of the solvent, to yield compound I-p.
- an appropriate organic solvent e.g., NMP, THF, or pyridine
- an appropriate base e.g., triethylamine or N,N-diisopropyl-N-ethylamine
- R represents C 1-8 alkyl, 4- to 12-membered heterocyclyl, C 3-12 cycloalkyl, C 6-10 aryl, 5- to 10-membered heteroaryl, (4- to 12-membered heterocyclyl)C 1-3 alkyl, (C 3-12 cycloalkyl)C 1-3 alkyl, (C 6-10 aryl)C 1-3 alkyl, or (5- to 10-membered heteroaryl)C 1-3 alkyl.
- R b represents C 1-8 alkyl, 4- to 12-membered heterocyclyl, C 3-12 cycloalkyl, (4- to 12-membered heterocyclyl)C 1-3 alkyl, (C 3-12 cycloalkyl)C 1-3 alkyl, (C 6-10 aryl)C 1-3 alkyl, or (5- to 10-membered heteroaryl)C 1-3 alkyl.
- Compound I-m in which R 4 has a primary or secondary amine structure is reacted with a compound having a leaving group (e.g., a halogen atom or a sulfonyloxy group) in an appropriate organic solvent (e.g., NMP, THF, or pyridine) in the presence or absence of an appropriate base (e.g., triethylamine or N,N-diisopropyl-N-ethylamine) at a temperature of 0°C to the reflux temperature of the solvent, to yield compound I-r.
- a leaving group e.g., a halogen atom or a sulfonyloxy group
- an appropriate organic solvent e.g., NMP, THF, or pyridine
- an appropriate base e.g., triethylamine or N,N-diisopropyl-N-ethylamine
- R represents C 1-8 alkyl, 4- to 12-membered heterocyclyl, C 3-12 cycloalkyl, (4- to 12-membered heterocyclyl)C 1-3 alkyl, (C 3-12 cycloalkyl)C 1-3 alkyl, (C 6-10 aryl)C 1-3 alkyl, or (5-to 10-membered heteroaryl)C 1-3 alkyl.
- R 4 has a primary or secondary amine structure
- a compound having a structure of Michael acceptor in an appropriate organic solvent (e.g., methanol, THF) at a temperature of 0°C to the reflux temperature of the solvent to yield compound I-s.
- an appropriate organic solvent e.g., methanol, THF
- R a , R b , and R c form -CR a R b -CHR c - along with -C-CH-structure to which R a , R b , and R c are bonded.
- Entire -CR a R b -CHR c - represents C 1-8 alkyl, 4-to 12-membered heterocyclyl, C 3-12 cycloalkyl, (4- to 12-membered heterocyclyl)C 1-3 alkyl, (C 3-12 cycloalkyl)C 1-3 alkyl, (C 6-10 aryl)C 1-3 alkyl, or (5-to 10-membered heteroaryl)C 1-3 alkyl.
- the compound of the present invention exhibits a CDK4/6 inhibitory activity and thus is useful for the prevention or treatment of a disease associated with CDK4/6.
- the compound is useful for the treatment of rheumatoid arthritis, arteriosclerosis, pulmonary fibrosis, cerebral infarction, or cancer and the protection of bone marrow.
- the compound is effective for the treatment of rheumatoid arthritis or cancer and the protection of bone marrow.
- the compound of the present invention preferably exhibits selectivity for the CDK4/6 inhibitory activity compared to the inhibitory activity against another cyclin-dependent kinase, such as CDK2 inhibitory activity.
- selectivity of the compound is expected to reduce the expression of genotoxicity because the inhibition of CDK2 is also involved in DNA replication.
- the compound of the present invention selectively inhibits CDK4 rather than CDK2.
- the active ingredient of the present invention may be provided in any preparation form, such as a solid, semisolid, or liquid form, and the like.
- the active ingredient may be provided in any dosage form, such as an oral form or a parenteral form (e.g., an injection, a transdermal agent, an eye drop, a suppository, a nasal agent, or an inhalant, and the like).
- a drug containing the active ingredient of the present invention is prepared with a common additive used for drug preparation.
- the additive for solid drugs include excipients, such as lactose, sucrose, glucose, cornstarch, potato starch, crystalline cellulose, light silicic anhydride, synthetic aluminum silicate, magnesium aluminometasilicate, calcium hydrogen phosphate, and the like; binders, such as crystalline cellulose, carboxymethyl cellulose, hydroxypropyl cellulose, sodium carboxymethyl cellulose, poly(vinylpyrrolidone), and the like; disintegrants, such as starch, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, sodium carboxymethyl starch, and the like; lubricants, such as talc stearic acid, and the like; coating agents, such as hydroxymethyl propyl cellulose, hydroxypropyl methyl cellulose phthalate, ethyl cellulose, and the like; and colorants.
- excipients
- Examples of the additive for semisolid drugs include bases, such as white vaseline, and the like.
- Examples of the additive for liquid drugs include solvents, such as ethanol, and the like; solubilizers, such as ethanol, and the like; preservatives, such as paraoxybenzoic acid esters, and the like; isotonic agents, such as glucose, and the like; buffers, such as citric acid, and the like; antioxidants, such as L-ascorbic acid, and the like; chelators, such as EDTA, and the like; suspending agents and emulsifiers, such as polysorbate 80, and the like; and the like.
- the dose of the active ingredient of the present invention is typically about 1 to 1,000 mg/day.
- the active ingredient is typically administered once to three times a day.
- the structure of the isolated novel compound was identified by 1 H-NMR and/or mass spectrometry using single quadrupole instrumentation equipped with electron spray source and other appropriate analytical methods.
- Mucobromic acid 300 g, 1.16 mol was added to an aqueous solution (2.5 L) of 2-methyl-2-pseudothiourea sulfate (324 g, 1.16 mol) at room temperature.
- the suspension was cooled to 0°C with stirring.
- Triethylamine (486 mL, 3.49 mol) was added dropwise to the solution over four hours.
- the reaction solution was stirred overnight, and the completion of the reaction was monitored by silica gel TLC.
- the solution was then acidized with concentrated hydrochloric acid (about 250 mL).
- the resulting yellow solid was collected by filtration, and washed with water (500 mL) twice and then with diethyl ether (500 mL) twice.
- the obtained solid was dried under reduced pressure to give the title compound (160 g, yield: 55%).
- 6-Aminopyridine-3-carbonitrile (1.9 g, 16 mmol) was dissolved in THF (160 mL). The solution was cooled to -78°C with stirring. Diisobutylaluminum hydride (106.5 mL, 1.5 M toluene solution) was slowly added dropwise to the solution at -78°C. The solution was allowed to warm to 20°C with stirring and further stirred for two hours. The reaction was quenched by addition of iced water (100 mL). The solution was extracted with dichloromethane (50 mL) three times. The extracted organic phases were combined, washed with brine (100 mL) once, and dried over anhydrous sodium sulfate. The solid was filtered out, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give a crude product (1.7 g) of the title compound. The crude product was used in the subsequent reaction without further purification.
- Toluene (33 mL) was added to a mixture of 1-(2-((tert-butyldiphenylsilyl)oxy)ethyl)-4-((6-chloropyridin-3-yl)methylpiperazine (3.26 g, 6.6 mmol) synthesized in Referential Example 8, benzophenoneimine (1.33 mL, 7.92 mmol), tris(dibenzylideneacetone)dipalladium(0) (302 mg, 0.33 mmol), BINAP (411 mg, 0.66 mmol) and sodium tert-butoxide (1.27 g, 13.2 mmol). The reaction mixture was stirred under a nitrogen atmosphere at 120°C overnight.
- the reaction mixture was cooled to room temperature and filtered through a Celite pad.
- the Celite pad was washed with ethyl acetate (80 mL).
- the filtrate was washed with water and further with saturated brine.
- the organic phase was dried over anhydrous sodium sulfate.
- the solid was filtered out, and the filtrate was concentrated.
- the residue was dissolved in THF (66 mL), and aqueous citric acid solution (16 mL, 2.0 mol/L) was added to the solution.
- the solution was stirred at room temperature overnight.
- the solution was passed through a column filled with a strong cation exchange (SCX) resin to adsorb the target product.
- the resin was washed with methanol.
- Ammonia 2.0 mol/L, methanol solution
- the eluate was concentrated to give the title compound (1.17 g, yield: 37%).
- the tert-butyl 4-(6-chloropyridazin-3-yl)piperazine-1-carboxylate (59.8 mg, 0.20 mmol) prepared in Referential Example 14, benzophenone imine (43.5 mg, 0.24 mmol), tris(dibenzylideneacetone)dipalladium (9.2 mg, 0.010 mmol), BINAP (12.5 mg, 0.020 mmol) and cesium carbonate (130.3 mg, 0.40 mmol) were suspended in toluene (1.0 mL). The reaction mixture was stirred at 100°C overnight. The reaction mixture was cooled to room temperature and filtered through a Celite pad. The Celite pad was washed with ethyl acetate.
- the progress of the reaction was monitored by LC/MS. After the completion of the reaction, the solution was cooled to room temperature. The solution was diluted with water, and the aqueous phase was extracted with ethyl acetate. The extracted organic phase was washed with brine, and dried over anhydrous sodium sulfate. The solid was filtered out, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography and the resultant crude product was used in the subsequent reaction.
- the crude product was purified by preparative HPLC (acetonitrile/water/TFA system).
- the fractions containing the target product were passed through a column containing a strong cation exchange (SCX) resin to adsorb the target product onto the resin.
- SCX strong cation exchange
- the SCX column was washed with dichloromethane. Ammonia (2 mol/L, methanol solution) was further passed through the SCX column to elute the target product. The eluate was concentrated under reduced pressure to give the title compound (13.6 mg).
- the crude product thus obtained was dissolved in methanol (1.0 mL) and THF (1.0 mL). To the solution was added dropwise aqueous lithium hydroxide solution (0.075 mL, 3.0 mmol, 4 mol/L). The reaction mixture was stirred at room temperature overnight. The progress of the reaction was monitored by LC/MS. After the completion of the reaction, the solution was concentrated under reduced pressure.
- the crude product was purified by preparative HPLC (acetonitrile/water/TFA system). The fractions containing the target product were passed through a column containing a strong cation exchange (SCX) resin to adsorb the target product onto the resin. The SCX column was washed with methanol.
- SCX strong cation exchange
- the progress of the reaction was monitored by LC/MS. After the completion of the reaction, the reaction solution was cooled to room temperature, and concentrated under reduced pressure. The residue was purified by preparative HPLC. The fractions containing the target product were passed through a column containing a strong cation exchange (SCX) resin to adsorb the target product onto the resin. The SCX column was washed with methanol, and the target product was eluted with ammonia (2 mol/L, methanol solution). The eluate was concentrated under reduced pressure to give the title compound (8.6 mg, yield: 51%).
- SCX strong cation exchange
- reaction mixture was stirred at room temperature overnight. The progress of the reaction was monitored by LC/MS. After the completion of the reaction, the reaction was quenched by addition of a saturated aqueous sodium hydrogen carbonate solution (10 mL). The solution was extracted with dichloromethane (10 mL) three times. The extracted organic phases were combined and dried over anhydrous sodium sulfate. The solid was filtered out, and the filtrate was concentrated. The residue was roughly purified amine-modified silica gel column chromatography. The crude product was used in the subsequent reaction without further purification.
- the crude product thus obtained was dissolved in dichloromethane (3 mL) and TFA (1 mL). The solution was stirred at room temperature for two hours. The progress of the reaction was monitored by LC/MS. After the completion of the reaction, the reaction was quenched by addition of a saturated aqueous sodium hydrogen carbonate solution (10 mL). The solution was extracted with dichloromethane (10 mL) three times. The extracted organic phases were combined and dried over anhydrous sodium sulfate. The solid was filtered out, and the filtrate was concentrated. The residue was roughly purified amine-modified silica gel column chromatography. The crude product was used in the subsequent reaction without further purification.
- the fractions containing the target product were passed through a column containing a strong cation exchange (SCX) resin to adsorb the target product onto the resin.
- SCX strong cation exchange
- the SCX column was washed with methanol, and the target product was eluted with ammonia (2 mol/L, methanol solution). The eluate was concentrated under reduced pressure to give the title compound (38.4 mg, yield: 70%).
- the crude product thus obtained was dissolved in methanol (1.0 mL) and THF (1.0 mL).
- Aqueous lithium hydroxide solution (0.2 mL, 0.80 mmol, 4 mol/L) was added to the solution.
- the reaction solution was stirred at room temperature.
- the progress of the reaction was monitored by LC/MS.
- the solid was filtered out, and the filtrate was concentrated under reduced pressure.
- the residue was purified by preparative HPLC.
- the fractions containing the target product were passed through a column containing a strong cation exchange (SCX) resin to adsorb the target product onto the resin.
- SCX strong cation exchange
- the reaction solution was stirred at 0°C for 15 minutes, and a solution (0.25 mL, 2 mol/L) of dimethylamine in THF was added to the reaction solution.
- the reaction solution was stirred at room temperature for 16 hours.
- the progress of the reaction was monitored by LC/MS.
- the solution was concentrated under reduced pressure, and the residue was dissolved in ethyl acetate.
- the organic phase was washed with water and further with saturated brine.
- the organic phase was dried over anhydrous sodium sulfate.
- the solid was filtered out, and the filtrate was concentrated under reduced pressure to give a crude product (50 mg).
- the crude product was used in the subsequent reaction without purification.
- Each compound was analyzed for CDK4/cyclin D3 inhibitory activity with an assay kit (QS S Assist CDK4/Cyclin D3_FP Kit, available from Carna Biosciences, Inc.).
- This assay kit determines kinase activity on the basis of the IMAP technology by Molecular Devices. Specifically, the kinase activity is determined through quantification of a variation in fluorescent polarization caused by binding of a kinase-phosphorylated fluorescent substance to an IMAP-binding reagent.
- Each solution was prepared with the 10 ⁇ assay buffer attached to the kit or a separately prepared assay buffer having the same composition as the assay buffer attached to the kit.
- An assay buffer was prepared by 10-fold dilution of the 10 ⁇ assay buffer with distilled water.
- the assay buffer contains 20mM HEPES (pH 7.4), 0.01% Tween20, and 2mM dithiothreitol.
- a test compound solution was prepared by dilution of the test compound with dimethyl sulfoxide (DMSO) to a concentration 100 times higher than the final concentration and then 25-fold dilution with the assay buffer to a concentration four times higher than the final concentration.
- DMSO dimethyl sulfoxide
- An ATP/substrate/Metal solution was prepared by five-fold dilution of the 5 ⁇ ATP/substrate/Metal solution attached to the kit with the assay buffer.
- An enzyme solution was prepared by dilution of the CDK4/cyclin D3 attached to the kit with the assay buffer to a concentration twice higher than the final concentration (final concentration of CDK4/cyclin D3: 12.5 to 25 ng/well).
- a detection reagent was prepared by five-fold dilution of each of 5 ⁇ IMAP-binding buffer A and 5 ⁇ IMAP-binding buffer B with distilled water, mixing of IMAP-binding buffer A with IMAP-binding buffer B at a ratio of 85:15, and 400-fold dilution of the IMAP-binding reagent with the mixed buffer.
- test compound solution (5 ⁇ L/well) and the ATP/substrate/Metal solution (5 ⁇ L/well) were added to a 384-well plate, and the enzyme solution or the assay buffer (10 ⁇ L/well) was added to the plate (total amount of the reaction mixture: 20 ⁇ L/well) for initiation of enzymatic reaction.
- the reaction mixture had a composition of 20mM HEPES (pH 7.4), 0.01% Tween 20, 2mM dithiothreitol, 100nM FITC-labeled peptide substrate (the sequence of the substrate peptide is not disclosed by Carna Biosciences, Inc.), 100 ⁇ M ATP, 1mM magnesium chloride, 1% DMSO, and 12.5 to 25 ng/well CDK4/cyclin D3.
- the reaction was performed at room temperature for 45 minutes, and the detection reagent (60 ⁇ L/well) was then added to the plate, followed by further reaction for 30 minutes at room temperature under light shielding conditions. Subsequently, fluorescent polarization was determined with a microplate reader at an excitation wavelength of 485 nm and an emission wavelength of 535 nm.
- the percent inhibition of enzyme activity was fitted to a dose-response curve, to determine a 50% inhibitory concentration against CDK4/cyclin D3.
- Each compound was analyzed for CDK2/cyclin A2 inhibitory activity with an assay kit (QS S Assist CDK2/Cyclin A2_FP Kit, available from Carna Biosciences, Inc.).
- This assay kit determines kinase activity on the basis of the IMAP technology by Molecular Devices. Specifically, the kinase activity is determined through quantification of a variation in fluorescent polarization caused by binding of a kinase-phosphorylated fluorescent substance to an IMAP-binding reagent.
- An assay buffer was prepared by 10-fold dilution of the 10 ⁇ assay buffer attached to the kit with distilled water, and each solution was prepared with the assay buffer.
- the assay buffer contained 20mM HEPES (pH 7.4), 0.01% Tween 20, and 2mM dithiothreitol.
- a test compound solution was prepared by dilution of the test compound with dimethyl sulfoxide (DMSO) to a concentration 100 times higher than the final concentration and then 25-fold dilution with the assay buffer to a concentration four times higher than the final concentration.
- An ATP/substrate/Metal solution was prepared by five-fold dilution of the 5 ⁇ ATP/substrate/Metal solution attached to the kit with the assay buffer.
- An enzyme solution was prepared by dilution of the CDK2/cyclin A2 attached to the kit with the assay buffer to a concentration twice higher than the final concentration (final concentration of CDK2/cyclin A2: 2.5 ng/well).
- a detection reagent was prepared by five-fold dilution of 5 ⁇ IMAP-binding buffer A with distilled water and 400-fold dilution of the IMAP-binding reagent with the diluted buffer.
- test compound solution (5 ⁇ L/well) and the ATP/substrate/Metal solution (5 ⁇ L/well) were added to a 384-well plate, and the enzyme solution or the assay buffer (10 ⁇ L/well) was added to the plate (total amount of the reaction mixture: 20 ⁇ L/well) for initiation of enzymatic reaction.
- the reaction mixture had a composition of 20mM HEPES (pH 7.4), 0.01% Tween 20, 2mM dithiothreitol, 100nM FITC-labeled peptide substrate (the sequence of the substrate peptide is not disclosed by Carna Biosciences, Inc.), 30 ⁇ M ATP, 5mM magnesium chloride, 1% DMSO, and 2.5 ng/well CDK2/cyclin A2.
- the reaction was performed at room temperature for 60 minutes, and the detection reagent (60 ⁇ L/well) was then added to the plate, followed by further reaction for 30 minutes at room temperature under light shielding conditions. Subsequently, fluorescent polarization was determined with a microplate reader at an excitation wavelength of 485 nm and an emission wavelength of 535 nm.
- the percent inhibition of enzyme activity was fitted to a dose-response curve, to determine a 50% inhibitory concentration against CDK2/cyclin A2.
- CDK4 Activity symbol CDK2 Activity symbol 1 +++ + 2 +++ + 3 + + 4 ++ + 5 +++ + 6 +++ + 7 +++ + 8 ++ + 9 +++ 10 ++ 11 +++ 12 +++ 13 +++ 14 +++ 15 ++ 16 +++ 17 ++ 18 +++ 19 +++ 20 +++ 21 ++ 22 +++ 23 + 24 +++ + 25 ++ + 26 ++ + 27 ++ + 28 ++ + 29 ++ + 30 +++ + 31 ++ 32 ++ + 33 +++ + 34 ++ + 35 ++ + 36 + + 37 ++ + 38 + 39 +++ + 40 +++ + 41 +++ + 42 + + 43 +++ 44 +++ 45 +++ 46 +++ 47 ++ + 48 +++ + 49 +++ + 50 ++ + 51 +++ + 52 +++ + [Table 106] Compound No.
- CDK4 Activity symbol CDK2 Activity symbol Compound No. CDK4 Activity symbol CDK2 Activity symbol 53 +++ + 54 +++ + 55 +++ + 56 +++ + 57 +++ + 58 ++ + 59 +++ + 60 +++ + 61 +++ + 62 +++ + 63 +++ + 64 +++ + 65 +++ + 66 ++ + 67 ++ + 68 +++ + 69 +++ + 70 ++ + 71 ++ + 72 +++ + 73 ++ + 74 ++ + 75 +++ ++ 76 +++ + 77 ++ + 78 +++ + 79 +++ + 80 +++ + 81 +++ + 82 +++ + 83 +++ ++ 84 +++ + 85 ++ + 86 +++ + 87 +++ + 88 +++ + 89 +++ + 90 +++ + 91 +++ + 92 +++ + 93 +++ + 94 +++ + 95 ++ + 96 +++ + 97 +++ + 98 ++ + 99 +++ + 100 +++ + 101 +++ +
- CDK4 Activity symbol CDK2 Activity symbol Compound No. CDK4 Activity symbol CDK2 Activity symbol 105 +++ + 106 +++ + 107 +++ + 108 +++ + 109 +++ + 110 +++ + 111 +++ + 112 +++ + 113 +++ + 114 +++ + 115 +++ + 116 +++ + 117 +++ + 118 +++ + 119 +++ + 120 +++ + 121 +++ + 122 +++ + 123 +++ + 124 +++ + 125 ++ + 126 +++ + 127 +++ + 128 +++ + 129 + 130 +++ + 131 ++ + 132 +++ + 133 ++ + 134 +++ + 135 +++ + 136 +++ + 137 ++ + 138 +++ + 139 +++ + 140 +++ + 141 +++ + 142 +++ + 143 +++ + 144 +++ + 145 ++ + 146 +++ + 147 +++ + 148 +++ + 149 +++ + 150 +++ + 151 +++ + +
- CDK4 Activity symbol CDK2 Activity symbol Compound No. CDK4 Activity symbol CDK2 Activity symbol 157 +++ + 158 +++ + 159 ++ + 160 +++ + 161 +++ + 162 +++ + 163 +++ + 164 +++ + 165 +++ + 166 ++ + 167 +++ + 168 ++ + 169 ++ + 170 ++ + 171 ++ + 172 ++ + 173 +++ ++ 174 +++ + 175 +++ + 176 +++ + 177 +++ + 178 +++ + 179 +++ + 180 +++ + 181 ++ + 182 +++ + 183 +++ + 184 +++ + 185 +++ + 186 +++ + 187 +++ + 188 +++ + 189 +++ + 190 ++ + 191 ++ + 192 ++ + 193 ++ + 194 +++ + 195 ++ + 196 ++ + 197 ++ + 198 +++ + 199 +++ + 200 +++ + 201 +++ + 202 ++ + 203
- CDK4 Activity symbol CDK2 Activity symbol Compound No. CDK4 Activity symbol CDK2 Activity symbol 209 +++ + 210 +++ + 211 +++ + 212 +++ + 213 +++ + 214 +++ + 215 +++ + 216 +++ + 218
- CDK4 Activity symbol CDK2 Activity symbol Compound No. CDK4 Activity symbol CDK2 Activity symbol 250 +++ + 251 +++ + 252 +++ + 253 +++ + 254 +++ + 255 +++ + 256 +++ + 257 +++ + 258 +++ + 259 +++ + 260 +++ + 261 +++ + [Table 110] Compound No. CDK4 Activity symbol CDK2 Activity symbol Compound No.
- CDK4 Activity symbol CDK2 Activity symbol 262
- CDK4 Activity symbol CDK2 Activity symbol Compound No. CDK4 Activity symbol CDK2 Activity symbol 314 +++ + 315 +++ + 316 +++ + 317 +++ + 318 +++ + 319 +++ ++ 320 +++ + 321 +++ + 322 +++ + 323 ++ + 324 +++ + 325 +++ + 326 +++ + 327 +++ + 328 +++ + 329 +++ ++ 330 ++ + 331 ++ + 332 ++ + 333 +++ + 334 +++ + 335 ++ + 336 ++ + 337 ++ +
- CDK6/cyclin D3 inhibitory activity was determined by the off-chip mobility shift assay (MSA).
- MSA off-chip mobility shift assay
- the kinase activity is determined by quantifying the degree ofphosphorylation through electrophoretic analysis of a positive to negative change in electric charge of the substrate phosphorylated by the kinase.
- Each solution was prepared with an assay buffer containing 20mM HEPES (pH 7.5), 0.01% Triton X-100, and 2mM dithiothreitol.
- a test compound solution was prepared by dilution of the test compound with dimethyl sulfoxide (DMSO) to a concentration 100 times higher than the final concentration and then 25-fold dilution with the assay buffer to a concentration four times higher than the final concentration.
- An ATP/substrate/metal solution was prepared to have a concentration four times higher than the final concentration.
- An enzyme solution was prepared to have a concentration twice higher than the final concentration. The final enzyme concentration was adjusted to an appropriate level on the basis of the enzyme activity signal and the inhibitory activity of a positive control compound.
- test compound solution (5 ⁇ L/well) and the ATP/substrate/metal solution (5 ⁇ L/well) were added to a 384-well plate, and the enzyme solution or the assay buffer (10 ⁇ L/well) was added to the plate (total amount of the reaction mixture: 20 ⁇ L/well) for initiation of enzymatic reaction.
- the reaction mixture had a composition of 20mM HEPES (pH 7.5), 0.01% Triton X-100, 2mM dithiothreitol, 1000nM peptide substrate (DYRKtide-F), 300 ⁇ M ATP, 5mM magnesium chloride, 1% DMSO, and a predetermined concentration of CDK6/cyclin D3.
- the reaction was performed at room temperature for five hours, and a termination buffer (QuickScout Screening Assist MSA, manufactured by Carna Biosciences, Inc.) (60 ⁇ L/well) was then added to the plate for termination of the reaction. Subsequently, the substrate peptide and the phosphorylated peptide in the reaction mixture were separated from each other and quantified with LabChip 3000 (manufactured by Caliper Lifesciences). The kinase reaction was evaluated by the product ratio (P/(P+S)) calculated from the peak height (S) of the substrate peptide and the peak height (P) of the phosphorylated peptide.
- the percent inhibition of enzyme activity was fitted to a dose-response curve, to determine a 50% inhibitory concentration against CDK6/cyclin D3.
- a monoclonal antibody cocktail against type II collagen (Arthritogenic MoAb Cocktail (Chondrex #53100), 4.8 mg/mL) was intraperitoneally administered (250 ⁇ L/head) to a group of mice with collagen antibody-induced arthritis (CAIA) (vehicle/+, group of drug administration) (day 1).
- LPS LPS Solution (E. coli 01 11:B4) (Chondrex #9028), 0.5 mg/mL) was intraperitoneally administered (100 ⁇ L/head) on day 4, to induce the disease.
- the drug was evaluated on the basis of pathological scoring until day 9. The drug was orally administered consecutively from day 4 to day 8 once a day.
- mice of a non-disease-induced group (vehicle/- group)
- PBS pH 7.2, Gibco #20012-027
- LPS LPS was intraperitoneally administered on day 4.
- the drug was evaluated on the basis of the pathological scoring (score 0 to score 4 for each of the extremities, evaluated by the total score). Scoring criteria are as follows:
- test compounds to glioblastoma was evaluated according to cell proliferation assay using cell lines. An ATP amount in the cultured cells after 120 hours with a test compound was measured to evaluate an influence of the test compound over the cell proliferation.
- the cell lines used were T98G cells and U-87MG cells derived from glioblastoma, both of which were obtained from American Type Culture Collection (ATCC).
- a cell suspension (45 ⁇ L) containing a culture solution containing 10% of fetal bovine serum (FBS) was distributed into a 384-wellplate, and was cultured at 37°C with 5% CO2. After 24 hours of the culture, 5 ⁇ L of 20 mM HEPES (pH 7.4) containing the test compound was added (DMSO final concentration: 0.4%), and the cell suspension was again cultured on the same conditions.
- 25 ⁇ L of ATPlite 1-step reagent PerkinElmer was distributed into each of the wells, and the plate was shaken for two minutes. The plate was allowed to stand in a dark place for five minutes, and the luminescence was recorded on the Envision multimode reader (PerkinElmer). The test compound was evaluated in the range of 10-5 M to 10-9 M.
- the background value before the addition of the test compound was determined as follows: 5 ⁇ L of 20 mM HEPES (pH 7.4) containing 4% DMSO was distributed into wells after 24 hours of culturing, 25 ⁇ L of ATPlite 1-step reagent was added, and the luminescence as the background value was recorded. The maximum luminescence (100%) was recorded from a cell suspension cultured for 120 hours on the same conditions as above. The contents of the test compounds and their luminescence (%) were plotted, and the 50% inhibitory concentration to the maximum value of cell proliferation was calculated.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SI201730612T SI3546458T1 (sl) | 2016-11-28 | 2017-11-27 | Derivati ((piridin-2-il)-amino)pirido(3,4-d)pirimidina in ((piridazin-3-il)amino)pirido(3,4-d)pirimidina kot zaviralci CDK4/6 za zdravljenje npr. revmatoidnega artritisa, arterioskleroze, pljučne fibroze, možganske kapi ali raka |
PL17874165T PL3546458T3 (pl) | 2016-11-28 | 2017-11-27 | ((pirydyn-2-ylo)amino)pirydo[3,4-d]pirymidynowe i ((pirydazyn-3-ylo)amino)pirydo[3,4-d]pirymidynowe pochodne jako inhibitory cdk4/6 w leczeniu np. reumatoidalnego zapalenia stawów, miażdżycy tętnic, zwłóknienia płuc, zawału mózgu lub raka |
HRP20210285TT HRP20210285T1 (hr) | 2016-11-28 | 2021-02-18 | Derivati ((piridin-2-il)-amino)pirido[3,4-d]pirimidina i ((piridazin-3-il)-amino)pirido[3,4-d]pirimidina kao inhibitori cdk4/6 za liječenje npr. reumatoidnog artritisa, arterioskleroze, plućne fibroze, cerebralnog infarkta ili raka |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016229969 | 2016-11-28 | ||
PCT/JP2017/042443 WO2018097297A1 (ja) | 2016-11-28 | 2017-11-27 | ピリド[3,4-d]ピリミジン誘導体及びその薬学的に許容される塩 |
Publications (3)
Publication Number | Publication Date |
---|---|
EP3546458A1 EP3546458A1 (en) | 2019-10-02 |
EP3546458A4 EP3546458A4 (en) | 2019-10-09 |
EP3546458B1 true EP3546458B1 (en) | 2021-01-06 |
Family
ID=62194988
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17874165.8A Active EP3546458B1 (en) | 2016-11-28 | 2017-11-27 | ((pyridin-2-yl)-amino)pyrido[3,4-d]pyrimidine and ((pyridazin-3-yl)-amino)pyrido[3,4-d]pyrimidine derivatives as cdk4/6 inhibitors for treating e.g. rheumatoid arthritis, arteriosclerosis, pulmonary fibrosis, cerebral infarction or cancer |
Country Status (28)
Country | Link |
---|---|
US (1) | US11084814B2 (pl) |
EP (1) | EP3546458B1 (pl) |
JP (1) | JP6785876B2 (pl) |
KR (1) | KR102290815B1 (pl) |
CN (1) | CN110036012B (pl) |
AR (1) | AR110238A1 (pl) |
AU (1) | AU2017364807B2 (pl) |
BR (1) | BR112019010674A2 (pl) |
CA (1) | CA3043561A1 (pl) |
CL (1) | CL2019001419A1 (pl) |
CO (1) | CO2019005514A2 (pl) |
CY (1) | CY1123850T1 (pl) |
DK (1) | DK3546458T3 (pl) |
ES (1) | ES2852123T3 (pl) |
HR (1) | HRP20210285T1 (pl) |
HU (1) | HUE053220T2 (pl) |
IL (1) | IL266312B (pl) |
LT (1) | LT3546458T (pl) |
MX (1) | MX2019005803A (pl) |
MY (1) | MY196497A (pl) |
PH (1) | PH12019501171A1 (pl) |
PL (1) | PL3546458T3 (pl) |
PT (1) | PT3546458T (pl) |
SA (1) | SA519401827B1 (pl) |
SI (1) | SI3546458T1 (pl) |
TW (1) | TWI799399B (pl) |
WO (1) | WO2018097297A1 (pl) |
ZA (1) | ZA201902893B (pl) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230303564A1 (en) * | 2020-08-17 | 2023-09-28 | Medshine Discovery Inc. | Pyrimidine ring compound |
CN113636973B (zh) * | 2021-09-07 | 2023-04-07 | 山东铂源药业股份有限公司 | 一种4-(6-氨基吡啶-3-基)哌嗪-1-羧酸叔丁酯的工业化制备方法 |
WO2023155841A1 (zh) * | 2022-02-16 | 2023-08-24 | 南京明德新药研发有限公司 | 嘧啶并环类化合物的盐型、晶型 |
WO2024020419A1 (en) * | 2022-07-18 | 2024-01-25 | Iambic Therapeutics, Inc. | Aza-quinazoline compounds and methods of use |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL220952B1 (pl) | 2002-01-22 | 2016-01-29 | Warner Lambert Co | 2-(Pirydyn-2-yloamino)pirydo[2,3-d]pirymidyn-7-ony |
US8685980B2 (en) | 2008-08-22 | 2014-04-01 | Novartis Ag | Pyrrolopyrimidine compounds and their uses |
CN102231984A (zh) | 2008-10-01 | 2011-11-02 | 北卡罗来纳大学查珀尔希尔分校 | 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗化疗化合物的造血防护 |
PA8852901A1 (es) | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
CA2809836C (en) | 2010-09-01 | 2019-01-15 | Gilead Connecticut, Inc. | Pyridinones/pyrazinones, method of making, and method of use thereof for the treatment of disorders mediated by bruton's tyrosine kinase |
GB201216017D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
CN104470921B (zh) * | 2013-05-17 | 2017-05-03 | 上海恒瑞医药有限公司 | 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用 |
CN109851617B (zh) | 2013-08-23 | 2022-08-16 | 润新生物公司 | 化学实体、组合物和方法 |
EP3052573A4 (en) * | 2013-09-30 | 2017-03-22 | CertainTeed Corporation | Stain repellent and voc eliminating coatings and use thereof |
GB201403536D0 (en) * | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
AU2015296322B2 (en) * | 2014-07-26 | 2019-09-19 | Sunshine Lake Pharma Co., Ltd. | 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as CDK inhibitors and uses thereof |
PL3305785T3 (pl) | 2015-05-29 | 2021-12-27 | Teijin Pharma Limited | Pochodna pirydo[3,4-d]pirymidyny i jej farmaceutycznie dopuszczalna sól |
-
2017
- 2017-11-27 EP EP17874165.8A patent/EP3546458B1/en active Active
- 2017-11-27 WO PCT/JP2017/042443 patent/WO2018097297A1/ja active Application Filing
- 2017-11-27 US US16/463,458 patent/US11084814B2/en active Active
- 2017-11-27 PT PT178741658T patent/PT3546458T/pt unknown
- 2017-11-27 PL PL17874165T patent/PL3546458T3/pl unknown
- 2017-11-27 LT LTEP17874165.8T patent/LT3546458T/lt unknown
- 2017-11-27 ES ES17874165T patent/ES2852123T3/es active Active
- 2017-11-27 JP JP2018553005A patent/JP6785876B2/ja active Active
- 2017-11-27 AU AU2017364807A patent/AU2017364807B2/en active Active
- 2017-11-27 CA CA3043561A patent/CA3043561A1/en active Pending
- 2017-11-27 MX MX2019005803A patent/MX2019005803A/es unknown
- 2017-11-27 MY MYPI2019002624A patent/MY196497A/en unknown
- 2017-11-27 HU HUE17874165A patent/HUE053220T2/hu unknown
- 2017-11-27 SI SI201730612T patent/SI3546458T1/sl unknown
- 2017-11-27 TW TW106141152A patent/TWI799399B/zh active
- 2017-11-27 CN CN201780072637.3A patent/CN110036012B/zh active Active
- 2017-11-27 AR ARP170103290A patent/AR110238A1/es unknown
- 2017-11-27 BR BR112019010674A patent/BR112019010674A2/pt active Search and Examination
- 2017-11-27 KR KR1020197014607A patent/KR102290815B1/ko active IP Right Grant
- 2017-11-27 DK DK17874165.8T patent/DK3546458T3/da active
-
2019
- 2019-04-29 IL IL266312A patent/IL266312B/en unknown
- 2019-05-09 ZA ZA2019/02893A patent/ZA201902893B/en unknown
- 2019-05-20 SA SA519401827A patent/SA519401827B1/ar unknown
- 2019-05-24 CL CL2019001419A patent/CL2019001419A1/es unknown
- 2019-05-27 CO CONC2019/0005514A patent/CO2019005514A2/es unknown
- 2019-05-28 PH PH12019501171A patent/PH12019501171A1/en unknown
-
2021
- 2021-02-10 CY CY20211100119T patent/CY1123850T1/el unknown
- 2021-02-18 HR HRP20210285TT patent/HRP20210285T1/hr unknown
Non-Patent Citations (1)
Title |
---|
None * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9556178B2 (en) | Imidazotriazinecarbonitriles useful as kinase inhibitors | |
AU2019200249B2 (en) | Biheteroaryl compounds and uses thereof | |
JP2022534650A (ja) | Btk阻害薬環誘導体、その調製方法及びその医薬品適用 | |
CA3047212A1 (en) | Tyrosine amide derivatives as rho- kinase inhibitors | |
MX2012009613A (es) | Compuestos de pirrolo-pirimidina como inhibidores de dk4/6. | |
EP3546458B1 (en) | ((pyridin-2-yl)-amino)pyrido[3,4-d]pyrimidine and ((pyridazin-3-yl)-amino)pyrido[3,4-d]pyrimidine derivatives as cdk4/6 inhibitors for treating e.g. rheumatoid arthritis, arteriosclerosis, pulmonary fibrosis, cerebral infarction or cancer | |
EP3674307B1 (en) | Macrocycle containing aminopyrazole and pyrimidine and pharmaceutical composition and use thereof | |
US10961238B2 (en) | Modulators of hedgehog (Hh) signaling pathway | |
JP7417540B2 (ja) | シクロアルカン-1,3-ジアミン誘導体 | |
RU2796400C2 (ru) | Пиридо[3,4-d]пиримидиновое производное и его фармацевтически приемлемая соль | |
US11981658B2 (en) | Substituted aminopyridine compounds as EGFR inhibitors | |
US20240199584A1 (en) | Kras inhibitors | |
KR20240016977A (ko) | 2,8-디아자스피로[4.5]데칸 화합물 | |
TW202225163A (zh) | 芳香雜環類化合物、藥物組合物及其應用 | |
CN115697972A (zh) | 包括哌嗪杂环酰胺脲的受体-相互作用蛋白1抑制剂 | |
CN115557946A (zh) | 杂环内酰胺类化合物,包含其的药物组合物及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190528 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20190911 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 29/00 20060101ALI20190905BHEP Ipc: A61P 9/10 20060101ALI20190905BHEP Ipc: A61K 31/5377 20060101ALI20190905BHEP Ipc: A61K 31/55 20060101ALI20190905BHEP Ipc: C07D 519/00 20060101ALI20190905BHEP Ipc: A61P 43/00 20060101ALI20190905BHEP Ipc: A61P 35/00 20060101ALI20190905BHEP Ipc: A61K 31/541 20060101ALI20190905BHEP Ipc: A61K 31/519 20060101ALI20190905BHEP Ipc: A61P 19/02 20060101ALI20190905BHEP Ipc: A61K 31/551 20060101ALI20190905BHEP Ipc: C07D 471/04 20060101AFI20190905BHEP Ipc: A61P 11/00 20060101ALI20190905BHEP Ipc: A61K 31/553 20060101ALI20190905BHEP |
|
DAV | Request for validation of the european patent (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20200525 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTC | Intention to grant announced (deleted) | ||
INTG | Intention to grant announced |
Effective date: 20201001 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 602017031205 Country of ref document: DE Representative=s name: HOFFMANN - EITLE PATENT- UND RECHTSANWAELTE PA, DE |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1352248 Country of ref document: AT Kind code of ref document: T Effective date: 20210115 Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602017031205 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: TUEP Ref document number: P20210285 Country of ref document: HR |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20210219 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Ref document number: 3546458 Country of ref document: PT Date of ref document: 20210225 Kind code of ref document: T Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20210219 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: BUGNION S.A., CH |
|
REG | Reference to a national code |
Ref country code: EE Ref legal event code: FG4A Ref document number: E020306 Country of ref document: EE Effective date: 20210201 |
|
REG | Reference to a national code |
Ref country code: FI Ref legal event code: FGE Ref country code: RO Ref legal event code: EPE |
|
REG | Reference to a national code |
Ref country code: NO Ref legal event code: T2 Effective date: 20210106 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20210400356 Country of ref document: GR Effective date: 20210316 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: T1PR Ref document number: P20210285 Country of ref document: HR |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: SK Ref legal event code: T3 Ref document number: E 36804 Country of ref document: SK |
|
REG | Reference to a national code |
Ref country code: HU Ref legal event code: AG4A Ref document number: E053220 Country of ref document: HU |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2852123 Country of ref document: ES Kind code of ref document: T3 Effective date: 20210913 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210506 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602017031205 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: UEP Ref document number: 1352248 Country of ref document: AT Kind code of ref document: T Effective date: 20210106 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20211007 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20210285 Country of ref document: HR Payment date: 20211123 Year of fee payment: 5 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210506 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20210285 Country of ref document: HR Payment date: 20221121 Year of fee payment: 6 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230414 |
|
REG | Reference to a national code |
Ref country code: NO Ref legal event code: CHAD Owner name: TEIJIN LIMITED, JP |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20210285 Country of ref document: HR Payment date: 20231116 Year of fee payment: 7 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R081 Ref document number: 602017031205 Country of ref document: DE Owner name: TEIJIN LIMITED, OSAKA-SHI, JP Free format text: FORMER OWNER: TEIJIN PHARMA LIMITED, TOKYO, JP |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20231120 Year of fee payment: 7 Ref country code: LU Payment date: 20231120 Year of fee payment: 7 |
|
REG | Reference to a national code |
Ref country code: LU Ref legal event code: PD Owner name: TEIJIN LIMITED; JP Free format text: FORMER OWNER: TEIJIN PHARMA LIMITED Effective date: 20231214 |
|
REG | Reference to a national code |
Ref country code: EE Ref legal event code: GB1A Ref document number: E020306 Country of ref document: EE |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SK Payment date: 20231121 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20231123 Year of fee payment: 7 Ref country code: GR Payment date: 20231121 Year of fee payment: 7 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: PD Owner name: TEIJIN LIMITED; JP Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT; FORMER OWNER NAME: TEIJIN PHARMA LIMITED Effective date: 20240112 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: TR Payment date: 20231124 Year of fee payment: 7 Ref country code: SI Payment date: 20231116 Year of fee payment: 7 Ref country code: SE Payment date: 20231120 Year of fee payment: 7 Ref country code: RO Payment date: 20231116 Year of fee payment: 7 Ref country code: PT Payment date: 20231116 Year of fee payment: 7 Ref country code: NO Payment date: 20231124 Year of fee payment: 7 Ref country code: MT Payment date: 20231023 Year of fee payment: 7 Ref country code: LV Payment date: 20231115 Year of fee payment: 7 Ref country code: LT Payment date: 20231023 Year of fee payment: 7 Ref country code: IT Payment date: 20231124 Year of fee payment: 7 Ref country code: IE Payment date: 20231121 Year of fee payment: 7 Ref country code: HU Payment date: 20231122 Year of fee payment: 7 Ref country code: HR Payment date: 20231116 Year of fee payment: 7 Ref country code: FR Payment date: 20231120 Year of fee payment: 7 Ref country code: FI Payment date: 20231121 Year of fee payment: 7 Ref country code: EE Payment date: 20231117 Year of fee payment: 7 Ref country code: DK Payment date: 20231124 Year of fee payment: 7 Ref country code: DE Payment date: 20231121 Year of fee payment: 7 Ref country code: CZ Payment date: 20231121 Year of fee payment: 7 Ref country code: CY Payment date: 20231025 Year of fee payment: 7 Ref country code: CH Payment date: 20231201 Year of fee payment: 7 Ref country code: BG Payment date: 20231120 Year of fee payment: 7 Ref country code: AT Payment date: 20231121 Year of fee payment: 7 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: PD Owner name: TEIJIN LIMITED; JP Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT; FORMER OWNER NAME: TEIJIN PHARMA LIMITED Effective date: 20231228 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PL Payment date: 20231116 Year of fee payment: 7 Ref country code: BE Payment date: 20231120 Year of fee payment: 7 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: PPPP Ref document number: P20210285 Country of ref document: HR Owner name: TEIJIN LIMITED, JP |
|
REG | Reference to a national code |
Ref country code: SK Ref legal event code: PC4A Ref document number: E 36804 Country of ref document: SK Owner name: TEIJIN LIMITED, OSAKA, JP Free format text: FORMER OWNER: TEIJIN PHARMA LIMITED, TOKYO, JP Effective date: 20240306 |
|
REG | Reference to a national code |
Ref country code: HU Ref legal event code: GB9C Owner name: TEIJIN LIMITED, JP Free format text: FORMER OWNER(S): TEIJIN PHARMA LIMITED, JP Ref country code: HU Ref legal event code: FH1C Free format text: FORMER REPRESENTATIVE(S): DANUBIA SZABADALMI ES JOGI IRODA KFT., HU Representative=s name: DANUBIA SZABADALMI ES JOGI IRODA KFT., HU |
|
REG | Reference to a national code |
Ref country code: SI Ref legal event code: SP73 Owner name: TEIJIN LIMITED; JP Effective date: 20240131 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: PC Ref document number: 1352248 Country of ref document: AT Kind code of ref document: T Owner name: TEIJIN LIMITED, JP Effective date: 20240226 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20240130 Year of fee payment: 7 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E Free format text: REGISTERED BETWEEN 20240321 AND 20240327 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: PC2A Owner name: TEIJIN LIMITED Effective date: 20240718 |